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1.1 The role of copper in biological systems 
 
Metals play an essential role as trace elements in most of the biochemical processes at 
the basis of Life(1). Current estimates indicate that about a third of all structurally 
characterized proteins contain metal ions either as a structural component or as a catalytic 
co-factor(2).  
The use of metals in living organisms is, indeed, important mainly due to their redox 
properties and to the feasibility of metal ion transfer in different locations or compartments 
of the cell. The metals are implicated in various biological processes such as electron 
transfer reactions, oxygen transport, and in a large number of catalytic processes. 
Many proteins (called metalloproteins) need to bind one or more metal ions to be able 
to perform their function, either because the metal ion is involved in the catalytic 
mechanism or because it stabilizes/determines the protein tertiary or quaternary structure. 
Metal ions are also very important for the structure and function (in the case of RNA) of 
nucleic acids. The intracellular concentration of several metals as well as their distribution 
among the various cell compartments and their incorporation into metalloproteins is tightly 
controlled(2,3,4). A proper balance of the equilibria involved in these control processes is 
necessary for a healthy phenotype. Previously, it was thought that metal enzymes captured 
their essential cofactor by collision processes with free metal ions or metal complexes with 
low-molecular-weight ligands. Recently, several mechanisms how metals are transported 
and inserted into diverse protein location have been identified and this research is an 
emerging field in the scientific world(5,6). Both eukaryotes and prokaryotes have evolved 
several mechanisms that ensure efficient metal homeostasis. From biochemical, inorganic, 
structural, and mechanistic studies a new family of soluble metal receptor, know as 
“metallochaperones”, have been found to interact with metal ions and deliver them to 
several targets in the cell(6). These proteins have the role to guiding and/or inserting a metal 
cofactor into the active site of a target enzyme 
An important metal present as a co-factor in many proteins is copper. Biological 
systems did not utilize copper before the advent of atmospheric oxygen(7). In the prevailing 
reducing conditions before this event, copper was in the water-insoluble Cu(I) state, in the 
form of highly insoluble sulfides, and was not available for biological processes. 
Cyanobacteria are thought to be responsible for the beginning of dioxygen (O2) production 
about 109 years ago. The appearance of a significant O2 concentration in the atmosphere 
required another 200–300 million years because the oxygen produced was initially 
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consumed by the oxidation of ferrous iron in the oceans. The advent of oxygen was a 
catastrophic event for most living organisms and it irreversibly changed life on earth. In 
contrast to the oxidation of iron and its loss of bioavailability as insoluble Fe(III), the 
oxidation of insoluble Cu(I) led to soluble Cu(II). Whereas enzymes involved in anaerobic 
metabolism were designed to operate in the lower portion of the redox spectrum, the 
arrival of dioxygen created the need for a new redox active metal which could attain higher 
redox potentials. Copper, now bioavailable, was ideally suited to exploit the oxidizing 
power of dioxygen. Copper began to be used in energy-capture systems like cytochrome c 
oxidase. The arrival of copper also coincided with the development of multicellular 
organisms which had extracellular cross-linked matrices capable of resisting attacks by 
oxygen free radicals(7). 
In this frame the case of copper represents the most studied example of metal 
homeostasis. Copper is an essential trace element that plays a vital role as a catalytic co-
factor for a variety of metalloenzymes including superoxide dismutase (for protection 
against free radicals), cytochrome c oxidase (mitochondrial electron transport chain), 
tyrosinase (pigmentation), peptidylglycine alpha-amidating mono-oxygenase (PAM) 
(neuropeptide and peptide hormone processing) and lysyl oxidase (collagen 
maturation)(8,9,10). At the same time, copper is toxic to both eukaryotic and prokaryotic 
cells, due to its ability to catalyze the generation of hydroxyl radicals (OH·) via the so 
called  Fenton-type reaction: 
 
Cu+ +  H2O2 ⇔ Cu2+ +  OH- + OH·  (1) 
 
Furthermore, oxidative stress carried out by partially reduced oxygen species (ROS), 
could be amplified by copper reactivity, leading to the impairment of essential molecules 
such as lipids, proteins and DNA(11). Therefore, several genes and their respective gene 
products are dedicated specifically to the transport of copper across cellular membranes, 
the trafficking of copper to cupro-proteins, and the sequestration or elimination of any 
copper excess. Many of these genes and proteins involved in copper metabolism are 
regulated by intracellular copper concentrations, either at the level of transcription, protein 
localization, or stability. Finally, there must exist a responsive form of communication 
between the proteins responsible for copper homeostasis, the organelles in which they 
reside, the external environment and perhaps other cellular processes. At present, several 
of the participants in copper homeostasis have been identified and are in various stages of 
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structural and functional characterization(12). How these proteins are regulated is less well 
understood, and the mechanisms for intracellular communication are not yet clear. It was 
indeed proven that essentially no free copper is available in the cytoplasm of eukaryotic 
cell being the total cytoplasmatic free copper concentration less than 10–18M(6). This 
feature eliminates the possibility that weakly bound copper ions can freely diffuse in the 
cell until a physiologically important active site captures the metal as it was observed in 
vitro where many copper enzymes easily acquire their metal without an auxiliary protein.  
                                       
                                      1.2 Copper and diseases 
 
Keeping in mind the dual aspect of copper (need and toxicity), it is expected that the 
alteration of copper homeostasis leads to errors of metabolism and damage to cells, 
resulting in pathological conditions(13). This is well exemplified by two inherited diseases 
of copper metabolism in humans, Menkes and Wilson syndromes: in both cases, the 
impairment by mutation of two homologous copper transport ATPases (named ATP7A and 
ATP7B, respectively), which are selectively expressed in different tissues, leads either to 
the decrease or to the overload of copper in the cells. 
Menkes disease (MD) is a fatal X-linked copper deficiency disorder due to mutations 
affecting Menkes gene (MNK). Defective export of copper by ATP7A from the intestinal 
cells is responsible for systemic copper deficiency; the copper content is particularly low in 
the brain because mutated ATP7A is also expressed at the blood–brain barrier. Individuals 
affected by Menkes disease usually die in early childhood. Wilson’s disease (WD) is more 
frequent, with a later onset in life and is an autosomal recessive disorder. Mutations of the 
ATP7B exporting copper from the liver to the bile and circulation lead to liver failure as a 
result of the very high concentrations of copper accumulated in this organ. If this disease is 
not treated, death can result from liver failure. Both of the inherited diseases of copper 
homeostasis are accompanied by neurodegeneration. 
Moreover, some very interesting recent findings have linked the imbalance of copper 
homeostasis to some neurodegenerative diseases as Alzheimer’s disease (AD), Creutzfeldt-
Jakob disease, Parkinson’s disease (PD) and Amyotrophic Lateral Sclerosis disease (ALS) 
(15,16). It is probable that aberrant reactivity of copper is a major source of production of 
ROS, which in turn is responsible for the more global oxidative stress parameters observed 
in these diseases.  These disorders may all be classified as “conformational” in that they all 
show, as hallmarks, conformationally altered proteins, which precipitate, form aggregates, 
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and may be responsible of cell damage(17). Direct interaction between copper and the 
proteins that are the pathological hallmark of these diseases has been reported, and thus, 
redox activity of the metal may also be involved in the process of protein misfolding. The 
molecular mechanisms leading to neurodegeneration in all these diseases are still 
unknown. However, metal-mediated oxidative stress could induce a cascade of events, 
including mitochondrial dysfunction that may be responsible for cell death. 
A large body of evidence supports the role of metal accumulation in aged brain as a 
causal or at least ancillary factor in the etiology of neurodegenerative disorders typical of 
late life, namely AD and PD(16,18). For example, amyloid precursor protein (APP) and the 
native Prion Protein which are altered in Alzheimer diseases and in Spongiform 
encephalopathies are both membrane proteins showing conserved copper-binding sites in 
their N-terminal region(19), this, together with other experimental clues, led to the 
suggestion that they may be implicated in copper transport and regulation at the neuron 
plasma membrane and synapses(19, 21). APP binds Cu(II) by two conserved histidines at a 
cysteine-rich region, which shows high structural homology to copper chaperones(19). APP 
seems to be a key modulator of neuronal copper homeostasis, because knockout of the 
protein results in increased copper levels(22), whereas its over-expression results in reduced 
copper levels in the mouse brain(23). Copper bound to APP and β-amyloid can be reduced 
to Cu(I), with ROS generation(24,25). It has to be remembered that copper concentration is 
higher in the neuropil of Alzheimer’s patients and in the core and periphery of plaques(26), 
where β-amyloid also accumulates; thus a powerful source of oxidative stress is operative 
in these regions that show elevated markers of oxidative stress. Recent findings on the 
efficacy of copper-chelating agents in ameliorating behavioral and biochemical changes in 
AD confirm a role for copper in the pathogenesis of that disease and indicate novel 
therapeutic tools for the prevention and treatment of AD(27). 
In PD, it has also been demonstrated that Cu(II) prompts α-synuclein to form self-
oligomers and that the acidic C-terminus of the protein is essential for copper 
interaction(28). Interestingly, fragments of α-synuclein represent the non-β-amyloid 
component of senile plaques in AD, thus reinforcing the role of copper in AD progression. 
In ALS, mutations of the cuproenzyme SOD1 gene have been associated with the 
diseases progression(29). Treatment with copper chelators has been shown to slow the 
progression of the degeneration in both animal and cell culture models of familiar ALS 
(fALS)(30)suggesting a noxious behavior of the metal when not properly bound to the 
protein. 
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Alternatively, in the oligomerization hypothesis, misfolded mutant SOD1 proteins 
oligomerize into increasingly higher molecular weight aggregates that ultimately lead to 
neurodegeneration(30,31). 
Moreover, recently clinical trials have established that Cu privation by diet or by Cu 
chelators diminishes tumor's ability to mount an angiogenic response(9). 
 
                                   1.3 Copper routes in yeast 
 
An accessible model for investigation of eukaryotic copper transport is Saccharomyces 
cerevisiae. It is an extremely attractive eukaryotic model system due to the ease with 
which it can be grown, the facility with which it can be genetically manipulate and 
moreover its complete genome has been completely sequenced. 
Recently, biochemical and structural studies have shed light on copper pathways 
(Fig.1), and the chemical mechanisms for copper shunting, while gene knockout 
experiments in mice have revealed fascinating aspects of the role of copper chaperones in 
mammalian physiology and development. 
 
Fig. 1: Copper transport and distribution in yeast. (Reprinted from Puig S et.al  Curr Opin Chem Biol. 2002 )   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Depending on extracellular copper concentrations, copper is transported inside the cell 
by two high-affinity copper transporters Ctr1 and Ctr3 (Km for copper ~1–5 µM), or by a 
low-affinity Cu/Fe-transporter Fet4 (Km for copper ~35µM)(32). Cu(I) is the substrate for 
the Ctr family members which are relatively small proteins containing three 
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transmembrane domains(33). Prior to the uptake, copper, which is present in the 
extracellular space in the Cu(II) form,  is thought to be reduced to Cu(I) by one or more 
cell-surface Fe(III)/Cu(II) reductases encoded by the FRE1 genes(34). A conserved feature 
of some Ctr importers is an N-terminal segment that contains one or more “Mets” motifs 
(MxxM or MxM), which have been shown by deletion studies in yeast and human cells, to 
be important for survival under copper starvation. These “Mets” motifs are part of the 
extracellular domain and are involved in the acquisition of copper ions to facilitated 
import(35). Unlike some other high affinity metal transporters (such as ATP7A and 
ATP7B), Ctr proteins do not require ATP for copper import(36). Their transport ability is 
stimulated by extracellular K+ and probably facilitated by the extremely low intracellular 
concentration of free copper.  
The delivery of copper to target cuproenzymes depends on an elegant 
metallochaperone system (Fig. 1). Copper is deployed to mitochondrial cytochrome c 
oxidase, via a pathway involving Cox17, Sco1 and Cox11 proteins(37-40), to cytosolic 
copper zinc superoxide dismutase (Cu,Zn SOD), via a pathway involving a copper 
chaperone for Cu,Zn SOD, called CCS(6,41), or to the multicopper oxidase Fet3 in the 
secretory pathway involving the P-type ATPase copper transporter CCC2(42) and the 
copper chaperone ATX1(43,44). In addition, cytosolic concentrations of free copper are 
typically maintained at low levels by metal scavenging systems like metallothioneins (MT) 
and by the Ctr2 protein which is suggested to play a role in the mobilization of intracellular 
pools of copper in the vacuoles(45).  
Homologs of yeast copper proteins have also been discovered in other eukaryotes 
including Arabidopsis thaliana, Caenorhabditis elegans, mice, rats, sheep,  humans and in 
prokaryotes. The latter lack the intracellular compartmentalization that is typical of 
eukaryotes (cyanobacteria being a notable exception); thus organelle-specific carriers of 
metals such as Cox17 may not be essential. In bacteria, for example, Cu,Zn SOD is a 
periplasmic enzyme in contrast with eukaryotes, where it is located mainly in the  cytosol. 
Furthermore, bacteria do not express prokaryotic homologues to CCS and Cox17  but still 
a homologue to ATX1 protein, called CopZ, is present.  
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1.4 Copper delivery to Cytochrome c oxidase 
 
A relevant example of a copper-dependent enzyme is the cytochrome c oxidase (CcO) 
which is the terminal enzyme in the energy transducing respiratory chain.  
CcO is a membrane-bound redox-driven proton pump(46). It is located in the inner 
mitochondrial membrane, where it catalyzes reduction of molecular oxygen to water and 
pumps protons across the membrane(47,48). The energy stored by the proton gradient is 
subsequently utilized for ATP synthesis. The reduction of O2 to H2O in the catalytic center 
of CcO generates energy that is necessary for proton translocation from the mitochondrial 
matrix (a region of low proton concentration and negative electrical potential) to the 
intermembrane space (which is in contact with the cytosol, a region of high proton 
concentration and positive electrical potential). Mammalian CcO consists of 13 polypeptide 
subunits, 3 of which (Cox1-Cox3) are encoded by the mitochondrial genome with the 
remaining 10 subunits encoded by the nuclear genome(49,50). In addition to the subunits, 
over 30 distinct proteins are important for the assembly of CcO(51). A number of these 
accessory proteins are important in the processing and translation of Cox1-Cox3 mRNA 
transcripts, in chaperoning the assembly process, and in the synthesis or delivery of 
cofactors. The cofactors in CcO include two copper sites (CuA and CuB), two heme A 
moieties, a magnesium and a zinc ion (Fig.2 and Fig.3)(52).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a b
Fig. 2: The structure of bovine CcO is shown with the 13 subunits colored differently (a). 
The cofactors are largely obscured by the polypeptide chains. Panel b shows the 
cofactors. 
(Panel a has been reprinted from Carr HS et.al. (2003) Acc Chem Res. May;36(5):309-16)
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Little is known about the delivery of Zn and Mg ions to the mitochondrion or whether 
specific accessory factors are necessary for the insertion of these ions into CcO. More 
information is available concerning copper delivery and insertion. A total of three copper 
ions have to be inserted into two subunits Cox1 and Cox2 which contain the CuB and the 
CuA centers, respectively. The former has one copper ion buried 13 Å below the membrane 
surface (Fig. 3), while the second contains a binuclear copper site located into the inner 
membrane space of the mitochondria in eukaryotes, in the periplasm of Gram-negative 
bacteria, and in the outer leaflet of the cell membrane of Gram-positive bacteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   Cox1
   Cox3
Fig.3 :   Structural representation of the mitochondrial-encoded subunits that make up the catalytic 
core of the  enzyme, Cox1 (yellow), Cox2 (blue) and Cox3 (grey)within their cofactors.           
 -16 ) Carr HS et.al. (2003) Acc Chem Res. May;36(5):309( 
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As both Cox1 and Cox2 are synthesized inside the mitochondria, the three Cu atoms 
must be imported from the cytoplasm or from the mitochondrial matrix. CcO is metallated 
by a pathway that consists of Cox17 and the co-chaperones, Sco1 and Cox11. Cox17 
delivers copper to Cox11 for subsequent insertion into the CuB site in Cox1, and to Sco1 
for insertion into the CuA site of Cox2 (Fig. 4). Initially, the most obvious candidate for 
delivery of copper to the mitochondrion was Cox17 protein which exists indeed in both the 
cytoplasm and mitochondrial inner membrane space (IMS)(53). Moreover it is known that 
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yeast lacking Cox17 (cox17∆ yeast) are respiratory-deficient due to a complete lack of 
CcO activity(54). It can be restored by the addition of 0.4% copper salts to the growth 
medium. This result is consistent with Cox17 functioning in copper delivery to CcO. The 
simple prediction was that Cox17 would shuttle Cu(I) into the IMS to be used in the 
assembly of CcO. This theory was strengthened by the observation that Cox17 is a copper-
binding protein(55). However, Cox17 tethered to the mitochondrial inner membrane by a 
fusion to the transmembrane domain of the inner membrane protein Sco2 was able to 
reverse the respiratory defect of cox17∆ cells and restored normal CcO activity(56). These 
results suggest that the function of Cox17 is confined to the mitochondrial intermembrane 
space(57). 
 
.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4: Scheme of Cu metalation of COX1 and COX2 mediated by Cox11 and Sco1,
respectively. Cox17 is postulated to transfer Cu(I) to Sco1 prior to the transfer to the
CuA site in COX2 and to transfer Cu(I) to Cox11 prior to transfer to the buried CuB site
in COX1. (Reprinted from Cobine PA et.al (2006) Biochim Biophys Acta. Jul;1763(7):759-72
 
 
 
 
In yeast, Cox11 and Sco1 appear to be co-metallochaperones assisting Cox17 in the 
metalation of CcO (Fig. 4). Sco1 and Cox11 proteins are known to be implicated in Cu 
insertion reaction into the CuA site of COX2 and into the CuB site of COX1 subunits, 
respectively. 
 Yeast Sco1 is a 30kDa protein anchored by a single trans-membrane segment of about 
17 aminoacids to the inner mitochondrial membrane. Protein sequence analysis has 
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identified a potential metal binding region, CxxxCP, that is conserved in all mitochondrial 
Sco proteins and their bacterial homologues. Both cysteines in yeast Sco1 are essential for 
its function(58). X-ray absorption spectroscopy, combined with functional studies on yeast 
Sco1 (Sco1p) and human Sco1(HSco1), suggested that the two cysteines present in the 
conserved motif and a conserved histidine in the C-terminal end are involved in copper(I) 
binding(59). However, the X-ray structure of  Sco1p exhibits a thioredoxin-like (Trx-like) 
fold, similar to the one observed  by NMR spectroscopy for a homologue from Bacillus 
subtilis(60). Upon superposition of the core elements defining the Trx-fold, the conserved 
cysteines of the CXXXC motif, found in all Sco homologues are  localized in a position 
analogous to that of the active site CXXC cysteines in Trx and other related 
oxidoreductases. The striking structural similarities between HSco1 and Trx, and especially 
the position of the reactive cysteines, suggested that Hsco1 might have disulfide reductase 
activity. The fact that Sco1 specifically delivers copper to the CuA site in the COX2 
subunit has been proposed on the basis of site specific mutations on the yeast protein(61). 
All these data confirm that HSco1 assists  the copper insertion in the CuA center but leave 
open the possibility that it might be a protein with multiple functions. Some eukaryotic 
genomes contain another protein, highly similar to Sco1, called Sco2, which conserves the 
CXXXCP metal binding motif and whose role remains unresolved. In contrast to Sco1 
mutations, deletion of yeast-Sco2 (Sco2p), an a homologue of Sco1, does not affect 
respiratory growth(62). Like Sco1p, also Sco2p is anchored to the membrane by a single 
transmembrane (TM) domain in the N-terminal part, and presumably possesses the same 
topology as Sco1p(63). Over-expression of Sco2p cannot substitute for the function of 
Sco1p, but can rescue the respiratory deficiency of a cox17∆ mutant, albeit less efficiently 
than over-expression of Sco1p and only in the presence of higher concentrations of 
exogenous copper. The C-terminal part of Sco1p can be replaced by the respective Sco2p 
portion, the resulting chimeric proteins are functional and able to overcome the respiratory 
defect of sco1∆(58).  
Additionally, Sco1 has been shown to interact with COX2 (64). At this moment, it is not 
clear how Hsco1 and Hsco2 cooperate in the copper insertion into CuA. Are they directly 
involved in the copper transfer from Cox17 to Cox2 or do they assist this process via 
reduction of the conserved CXXXC motif of CuA prior to the copper transfer? 
If Sco proteins are primarily important in Cu(I) insertion into COX2, then how is Cu 
provided to COX1? This pathway seems to require another mitochondrial inner membrane 
protein, Cox11 (Fig. 4). Indeed, recently Hiser et al. demonstrated that the CuB site is 
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absent in CcO purified from Rhodobacter sphaeroides lacking Cox11 gene(65). Moreover, 
Tzagoloff et.al.(66) have shown that some Cox11 mutants lack CcO activity; however, RNA 
and protein synthesis of the core subunits I and II are normal, suggesting that Cox11 
functions post-translationally to generate active CcO(66).  
Yeast Cox11 is a 34kDa protein that resembles Sco1, with a single transmembrane 
helix of about 24 aminoacids just downstream of the N-terminal mitochondrial anchored 
targeting sequence. The C-terminal domain protrudes into the inner membrane space and, 
as with the soluble C-terminal domain of Sco1, binds a copper(I) ion. Recently, it has been 
shown that the soluble C-terminal domain of yeast Cox11 forms a dimer(67). The protein 
binds one copper atom per monomer and  in the dimer the two copper(I) ions are in close 
proximity.  
 
1.5 CcO deficiency linked to HSco1/2  pathogenic mutations 
 
Mutations in  HSco1 and HSco2 genes cause severe, tissue-specific COX deficiencies 
owing to a failure in CcO assembly: HSco2 mutations are predominately associated with 
early-onset hypertrophic cardiomyopathy and encephalopathy(68,69,70), whereas  one 
missense mutation (P174L) in HSco1 is founds to be associated with fatal infantile 
hepatoencephalomyopathy(71), a progressive neonatal disorder predominantly affecting the 
liver.  Proline 174 , adjacent to the conserved CXXXC domain of HSco1, is completely 
conserved in eukaryotes. Overexpression of the P174L-Hsco1 mutant in Sco1p∆  yeast 
mutants impaired CcO assembly and induced loss of CcO activity (72). It has been shown 
that the pathogenicity of the mutant does not result from its instability, but rather from an 
impaired function(73).  
In HSco2, the E140K pathogenic mutation (Fig. 5) is adjacent to the postulated 
CXXXC conserved hypothetical copper binding motif. Also S225F pathogenic mutation is 
adjacent to the conserved His224, while the R171W mutation is close to a DXXXD 
conserved motif, which might also be involved in copper binding too. These observations 
suggest that the mutations probably impair the copper binding  on HSco2  and/or the 
copper transfer process. On the other hand, using a policonal antibody against Hsco2, 
severely decreased level of HSco2 in fibroblast and myoblast from patients with different 
Sco2 mutations were observed suggesting an unstable gene product(70).  
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Fi : Amino acid sequence of HSco2 showing the mitochondrial leader sequence 
(u erlined), the copper-binding site (boxed) and  the known missense mutations ( E140K; 
L151P; R171W; S225F) 
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 Both Hsco1 and Hsco2 are ubiquitary expressed and the reason for "tissue specificity" 
in the two disorders is unknown. Remarkably, COX deficiency in cells from patients with 
HSco2 mutations(59,64)  and in bacteria harboring a null mutation in YpmQ (the SCO-like 
homolog in Bacillus subtilis(57), can be rescued by the addition of copper to the growth 
medium, but the mechanism by which this rescue occurs is unknown.  
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1.6 Cu,Zn Superoxide dismutase 
 
 
Superoxide radical anions are physiologically produced in controlled amounts in animals 
and plants from a one-electron reduction of dioxygen occurring in several metabolic 
pathways(75-77). Eukaryotes have evolved with two intracellular superoxide dismutase 
(SOD) enzymes capable to catalyze the disappearance of superoxide(78). One, a manganese 
containing enzyme (SOD2), is located in the mitochondrial matrix(79) in close proximity to 
a primary endogenous source of superoxide, the mitochondrial respiratory chain. The 
other, a copper- and zinc-containing protein (SOD1), is an abundant cytosolic enzyme(80) 
that has also been found in the nucleus, peroxisomes, and lysosomes.  Cu,Zn superoxide 
dismutase (Cu,Zn SOD) (known earlier as erythrocuprein) has long been known as the 
major copper containing protein in erythrocytes(81), but its enzymatic function was not 
discovered until 1969, when McCord and Fridovich found that ‘erythrocuprein’ dismutes 
superoxide(82). SOD1 catalyzes a disproportionation reaction turning two molecules of 
superoxide into one molecule of O2 and one of H2O2:  
 
              Cu2+ + O2- ↔ Cu+ + O2  
Cu+ + 2H+ + O2-↔ Cu2++ H2O2 
 
generating a cycling  ‘ping-pong’ mechanism: 
 
 
 
 
 
 
 Cu,Zn SOD is found in almost all eukaryotic cells and in very few prokaryotes. Structural 
studies reveal that all eukaryotic SOD1s are homodimeric proteins that contain one copper, 
one zinc, and one intrasubunit disulfide bond per monomer. A considerable sequence 
homology is present among Cu,Zn SOD proteins from various species so far examined, 
within the mammalian species, human, rat, pig, and horse the homology is around 80%. 
The X-ray structure of the oxidized form of SOD1 has been available since 1982 for the 
bovine enzyme(83,84). Nowadays several other structures are available(85,86). The solution 
structure of monomeric ad dimeric Cu,Zn,SOD were solved  in our laboratory(87,88) (Fig.6).  
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             Cu,Zn SOD properties: 
 
-Dimeric protein  
 
-Two metal ions per subunit: 
 
Cu ligands: H46, H48, H63, H120  
 
Zn ligands: H63, H71, H80, D83 
 
A conserved and stable SS bond:(C57-
C146) 
Fig. 6: Tube representation of the family of 30 conformers of human reduced native SOD.
Elements of secondary structure are highlighted (blue: β structure, orange: α structure). The Cu 
ion is shown in cyan, the Zn ion in yellow. (Reprinted from Lucia Banci, Ivano Bertini, Fiorenza Cramaro, 
Rebecca Del Conte and Maria Silvia Viezzoli, Eur J Biochem. 2002 ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The human Cu,Zn SOD is constituted by of two identical subunits bearing the same 
amino acidic sequence of about 150 residues. Within each subunit the polypeptide chain is 
folded in a characteristic eight stranded β-barrel. The latter is formed by two four-stranded 
antiparallel β-sheets which are connected by turns and loops in a Greek key β-barrel motif 
(Fig. 7). The eight β-strands forming the walls of the β-barrel display an overall right 
handed twist. The first sheet is formed by strands 1, 2, 3 and 6 and the second by strands 4, 
5, 7 and 8. The loops connecting the secondary structure elements can be divided in two 
groups: the odd loops are located on the opposite side of the barrel with respect to regions 
involved in the subunit-subunit interface, while the even loops are in part located at the 
subunit-subunit interface. Inspection of the SOD1 structure reveals that loop IV, 
containing, Cys57, which forms the disulfide bridge with residue Cys146 in strand β8, can 
influence the conformation of the catalytically important residue, Arg143, through a 
hydrogen-bonding network(89). Portions of this loop also contribute to the dimer 
interface(90), leading to the possibility that the disulfide bond influences the protein 
dimerization and thereby the SOD1 quaternary structure. This disulfide bond is conserved 
among all the structurally determined Cu,Zn SOD1. Crystallographic studies of SOD1 
suggest a structural role for the disulfide in guiding the substrate into the active site(91). 
Furthermore, the effect of the disulfide on dismutase activity and quaternary structure is 
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not clear, even though altered or aggregated forms of the protein are thought to be at the 
center of a familial form of amyotrophic lateral sclerosis (fALS)(92). 
 
 
 
 
 
       
 
 
 
 
 
 
.  
 
 
 
  
Fig. 7 :  Schematic view  of the Q133M2SOD structure displaying the secondary structure elements 
numbered by Getzoff et al. Proteins. 1989;5(4):322-36. The side - chains of the residues homologous 
 to those involved in the subunit- -subunit interface in the WT dimer are  as yellow sticks.shown  
The mutated residues E50, E51, Q133 are shown as red sticks. 
Orange, Yellow and gray spheres of arbitrary radius represent copper and zinc ions. 
i l(Reprinted from  Ferraroni et.al Journal of Molecular Biology1999) 
The two monomers of SOD1 are held together by hydrophobic interactions. The 
contact surface between the monomers comprises the N terminus, strand β1, the C 
terminus, strand β8, the two loop regions:loop IV and loop VI. The extension of the 
contact region explains the high stability of the dimer to thermal and chemical 
denaturation. SOD1 is one of the most thermally stable enzymes known in mesophilic 
organisms. Dismutase activity declines at 80 °C with a corresponding melting temperature, 
Tm, above 90 °C(93). The protein is stable in the presence of strong denaturants, and the 
activity is observed in 4% SDS or 10 M urea(94).  
Mutations of residues in the interface region can lead to disruption of the quaternary 
structure, resulting in the formation of stable SOD1 monomers. Monomeric forms of the 
enzyme have been obtained by substituting hydrophobic residues at the subunit–subunit 
interface with hydrophilic residues. In particular, Phe50 and Gly51 have been substituted 
by two Glu residues, yielding a soluble single subunit. This mutant displays an activity of 
about 10% respect to the wild–type human Cu,ZnSOD(95). Therefore, to partially restore 
the activity, Glu133 has been neutralized by substituting it with Gln(96). This particular 
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monomeric CuZnSOD is referred as F50E/G51E/E133Q monomeric triple mutant or 
CuZnQ133M2SOD mutant.  
Each SOD1 monomer contains one Cu and one Zn ion. The Zn ion is tetrahedrally 
coordinated to three histidyl imidazoles (His63, His71, His80) and to an aspartyl 
carboxylate group (Asp83). The Cu ion, in the oxidized enzyme, is coordinated by four 
histidines (His46, His48, His63, His120) and, weakly, by a water molecule in a distorted 
square planar pyramid. The water molecule occupies the apical position toward the 
opening of the cavity. The two metal ions are bridged, in the oxidized enzyme, by His63 
that keeps them apart of about 6 Å. His63 binds Zn ion and Cu ion through the Nδ1 and 
Nε2 atoms, respectively. In the reduced Cu(I) form, a trigonal planar arrangement is 
obtained through the migration of the copper ion of about 1 Å which is accompanied by 
protonation of the histidine ligand that is no more linked to the Cu ion (Fig. 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8: Overall view of the metal coordination in the active site in Cu,Zn SOD1. The 
zinc ion is in magenta and the copper(I) ion is in orange and cadmiun (mimicking the
Cu(II) site) is in yellow.  (Reprinted from Ferraroni et.al Journal of Molecular Biology1999) 
 
 In SOD1, the zinc is completely buried in the protein and its role appears to be 
primarily structural(83). Removal of the Zn ion indeed, results in a diminished thermal 
stability, i.e., the zinc-depleted protein denaturates at a lower temperature(97). However, in 
conditions where the copper ion remains bound to the copper site, the removal of Zn ion 
does not significantly reduce SOD1 activity. The Cu ion instead has a solvent-exposed 
surface of 5.2 Å2 and lies at the bottom of a narrow channel that is large enough to admit 
only water, small anions and similarly small ligands (Fig. 9). Its role in the enzyme appears 
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to be mainly catalytic. The redox properties of copper ion  permit the disproportionation of 
superoxide anion to hydrogen peroxide and dioxygen.  
The insertion of copper into Cu,,Zn SOD requires a copper metallochaperone called 
CCS (copper chaperone for superoxide dismutase)(41,45,98). Yeast mutants lacking CCS 
express a form of SOD protein that is essentially copper depleted(98) but contains a single 
atom of zinc per subunit(41,99). Mice with disruptions in CCS exhibit marked reductions in 
SOD activity, stressing the conserved requirement for CCS in activation of eukaryotic 
Cu,Zn SOD(100).  
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Fig. 9: Schematic diagram of a cross section of the active site channel in Cu,,Zn SOD1
 
CCS is the largest copper metallochaperone identified to date. Whereas other copper 
chaperones as ATX1 and COX17 represent single domain proteins, CCS folds into three 
functionally distinct protein domains(100-102). The N-terminal domain I of CCS bears 
striking homology to ATX1, including a MXCXXC copper-binding motif. Surprisingly, a 
CCS molecule lacking this domain can still insert copper into superoxide dismutase in 
vivo(101). It has been therefore proposed that this ATX1-like domain is only needed to 
maximize CCS function under extreme copper-limiting conditions(5). The central domain of 
CCS (domain II) is homologous to Cu,ZnSOD(100,102). This domain physically interacts 
with SOD(103) and it was suggested to secure the enzyme during copper insertion. The C-
terminal domain III of CCS is quite small (30 amino acids), yet is extremely crucial for 
activating SOD in vivo. This domain is highly conserved among CCS molecules from 
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diverse species and includes an invariant CXC motif that can bind copper(101). Domain III 
is disordered in the crystal structure; however, it is predicted to lie in the vicinity of the N-
terminal domain I. Models have been proposed in which domain III, perhaps in concert 
with the N-terminal domain I, directly inserts copper into the active site of SOD(104). The 
mechanism of copper movement from an all-sulfur coordination environment (in CCS) to 
the all-nitrogen site in SOD remains an open issue. On the contrary, domain II of CCS is 
proposed to participate in target recognition rather than in direct transfer of copper.  
.  
1.7 SOD1 and amyotrophic lateral sclerosis disease 
 
Amyotrophic lateral sclerosis (ALS) is a devastating, fatal neurodegenerative disease 
that specifically targets the motor neurons in the spinal cord, brain stem, and cortex(105). It 
typically has an adult onset, starting first with weakness in arms or legs and proceeding 
relentlessly to total paralysis and death. With a lifetime risk of approximately 1 in 2000, it 
is the most common motor neuron disease(106). Unfortunately, there is no known cure or 
effective treatment for ALS at present. Since the disease is selective for motor neurons, 
intellect is usually not affected. Patients generally die of respiratory failure within two to 
five years for first appearance of the diseases symptoms.  Most instances (90%–95%) of 
ALS have no  apparent genetic link and are termed sporadic ALS (sALS). In the remaining 
5%–10% of cases there is a family history of the disease, and the disease is termed familial 
ALS (fALS).  
To date, at least 105 different mutations in the sod1 gene have been linked to fALS(92).  
The majority of these mutations cause single  amino acid substitutions at one of at least 64 
different locations but, some cause frameshifts, truncations, deletions, or insertions(92). 
(http://www.alsod.org) Mutations are scattered throughout the sequence of the protein 
(Fig. 10).  The vast majority of the mutations are genetically dominant.  
The autosomal dominant nature of SOD1-associated fALS suggests a toxic gain of 
function for mutant SOD1, and pioneering fALS transgenic mouse studies provided strong 
support for this hypothesis(107). 
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Fig. 10: Secondary structural representation of SOD1 showing the locations of fALS-associated 
mutations (left) and a monomer of SOD1 (right) colored to match the drawing on the left. 
Copper ligands are shown in green and zinc ligands shown in red. Copper and zinc ions are
shown as green and grey spheres, respectively, and the intrasubunit disulfide bond is shown in
red. Point mutation, deletions, and insertions are indicated with a line, whereas mutations that 
cause C-terminal truncations are shown as scissor cuts at the point of the stop codon. ( Reprinted 
from Valentine JS et al (2005) Annual Review of Biochemistry) 
 
Two hypothesis can explain the toxicity of ALS mutant Cu,,Zn SOD proteins: the 
oxidative damage hypothesis and the oligomerization hypothesis(92,108). The first one 
maintains that fALS mutants acquire one or more toxic properties, catalysing reactions 
with oxidants such as peroxynitrite(98) and possibly hydrogen peroxide(109). These reactive 
nitrogen and oxygen species cause toxicity spoiling proteins, nucleic acids and lipids. The 
oxidative damage hypothesis seems to require copper (or some other redox active metal 
ion) bound to the fALS mutant Cu,,Zn SOD protein to promote the oxidative reaction. This 
former hypothesis has been recently abandoned as the second is supported by the finding 
of proteinaceous inclusions rich in mutant SOD1 in tissues from ALS patients, ALS-SOD1 
transgenic mice, and in cell culture model systems(106). These finding led many 
investigators to think that SOD1-associated fALS is a protein conformational disorder, 
similar to Alzheimer's disease, Parkinson's disease, Huntington's disease, transmittable 
spongiform encephalopathies, and other neurodegenerative diseases in which protein 
aggregates are found(30,110). The visible inclusions in SOD1-linked fALS contain 
neurofilament proteins, ubiquitin, and a variety of other components in addition to SOD1, 
but it is not known if copper, zinc, or any other metal ions are present in the inclusions or 
are involved in their formation. It is also not known if the SOD1 polypeptide has been 
fragmented or otherwise covalently modified in the processes leading to aggregate 
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formation. The most likely explanation is that inclusions, and other visible protein 
aggregates, common to all of these the neudogenerative diseases, represent an end stage of 
a molecular cascade of several steps, and that earlier steps in the cascade may be more 
directly tied to pathogenesis than the inclusions themselves (Fig. 11). 
The relatively large fibrils or insoluble inclusions observed in ALS may instead be the 
result of a protective mechanism that forms inclusions when the burden of misfolded or 
damaged proteins exceeds the capacity of the protein degradation machinery to eliminate 
them(111). High-molecular-weight oligomerized species of SOD1, which may be more 
closely related to the toxic form, are found in the spinal cords of mice expressing mutant 
SOD1 well before disease onset(112). This clearly indicates that the pathogenic SOD1 
proteins must have some feature distinct from the wild-type protein that facilitates their 
self-association. 
Currently many structural and biochemical data  about metallated and apo WT-SOD1 
and mutants are known. However all the efforts performed in order to correlate the 
biophysical properties with the survival data or with any other of the biological properties 
failed. It is not clear at this stage which factors represent the driving force for 
oligomerization of SOD1 and why ALS affect selectively only the motor neurons.  
Moreover, at the moment, there is no valid  model able to explain a  common mechanism 
for both familiar and sporadic ALS. 
 
Toxic?
Toxic?
Toxic?
Protective?
DISEASE  PROTEINS
ABNORMAL CONFORMATION
GLOBULAR INTERMEDIATE
PROTOFIBRILS
FIBERS
INCLUSIONS
Fig. 11: Hypothetical common pathway of 
protein aggregation in neudegenerative 
diseases. An initiating event in aggregation 
may be covalent modification of the 
disease protein, for example by cleavage or 
phosphorylation, facilitating conversion of 
the protein to an abnormal conformation. 
Oligomeric (globular) intermediates may 
form, and then protofibrillar structures are 
assembled. Amyloid fibers can then form, 
possibly through association of 
protofibrillar intermediates, resulting in 
aggregates or inclusions visible in the light 
microscope. The intermediate species are 
hypothesized to be more toxic than either 
the precursor protein or the aggresomes and 
inclusions. (Reprinted from Ross CA et.al Nat 
Med. 2004 Jul;10 Suppl:S10-7.) 
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1.8 Aims and topics of the research 
 
During the three years of PhD my research was focused on the investigation of the 
mechanisms that ensure the copper homeostasis in both eukaryotes and prokaryotes. My 
attention was devoted to proteins belonging to two different copper trafficking pathways in 
cells, i.e. copper delivery to cytosolic superoxide dismutase and to cytochrome c oxidase. 
Molecular mechanisms of copper insertion into these two enzymes, essential for cells life, 
still remain a puzzling issue. 
Copper incorporation in Cox1 and Cox2 subunits of CcO is an essential step during 
the enzyme maturation for proper assembly of the complex. The recent identification of 
accessory proteins involved in this process, Cox17, Cox11 and HSco1/2 provides an 
exciting chance to elucidate the mechanism of assembly of this complex. Therefore, the 
aim of our research was the investigation and integrate comparison of all genetic, structural 
and biochemical data (including red-ox, structural and metal binding properties) in order to 
clarify the respective functional and molecular roles of these proteins within the assembly 
CcO mechanism. In the absence of direct experimental data, some clues on the properties 
of Cox11, Sco and related proteins, and on their involvement in copper delivery to CcO, 
have been initially gained from their genomic context, including operon structures and 
conserved domain fusions in prokaryotes.(114). Therefore, we have performed a genome-
wide search in prokaryotic organisms for sequences sharing similarity with human Cox17, 
Sco1/2, and Cox11, and we extended the analysis to genes close to the found proteins. 
Afterwards, wild-type human Sco1 and Sco2, and P174L-HSco1 pathogenic mutant were 
cloned and expressed and their solution and/or crystal structures determined for the first 
time. The copper acquisition mechanism of HSco1 and its pathogenic P174L mutant from 
the mithocondrial chaperone Cox17, was finally investigated in order to understand how 
copper transfer occurs and how the mutation can affect it. 
The eukaryotic copper,zinc superoxide dismutases are remarkably stable dimeric 
proteins that maintain an intrasubunit disulfide bond in the reducing environment of the 
cytosol and are active under a variety of stringent denaturing conditions. The structural 
interplay of conserved disulfide bond and metal-site occupancy in human copper,zinc 
superoxide dismutase (Cu,Zn SOD1) is of increasing interest as these post-translational 
modifications are known to dramatically alter the catalytic chemistry, the subcellular 
localization, and the susceptibility of the protein to aggregation. The structural 
destabilization and/or an increase in mobility of superoxide dismutase mutants is suggested 
 23
to play a role in the pathology of amyotrophic lateral sclerosis disease (ALS) which is may 
be classified as an “conformational” disorder. These class of disordes generally, through an 
abnormal folding pathway, result in protein aggregation and high-molecular weight protein 
complexes formation. Therefore, at the beginning, the stability of the quaternary structure 
of WT-SOD1 in relation to its metallation and oxidation states was analyzed. The results of 
this first set of studies showed that reduction of the C57–C146 disulfide bond and the 
metallation are critical for the integrity of the dimer interface and shifts the equilibrium 
toward marginally stable monomers. It has been proposed that protein monomerization 
plays a role in formation of SOD1 misfolded intermediates, leading to protein aggregation 
in ALS. Therefore, the propensity for oligomerization of mature, i.e., disulfide-intact, WT 
human SOD1 under the relatively mild conditions likely to be encountered in the protein 
“in vivo” and the roles of metallation in hindering or promoting such oligomerization were 
then investigated.  
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  2.1 Structural and Functional Genomics approach 
 
The genome sequencing projects developed in the last few years have made available 
the primary sequence of an enormous number of new genes. The draft sequence of the 
human genome(1,2) is now available together with the complete genomes of many other 
organisms (Web site: www.ncbi.nlm.nih.gov). This wealth of genomic data can be fully 
exploited only through elucidation of the three-dimensional structures of the corresponding 
proteins. The final objective of the “classic” Stuctural Genomics is the structure-based 
drug design for the care of diseases.  
The European perception of Structural Genomics is extended to the study of the protein 
function. This can be achieved by the identification, production and characterization of 
partner proteins and by protein-protein interaction studies. The various Structural 
Genomics initiatives commencing worldwide differ in the choice of protein targets in an 
effort to provide a complete coverage of protein structures and relative associated function.  
So, there are actually two different possible philosophies that distinguish the various 
research consortia. 
 
-The “classic” Structural Genomics approach: It is High-Throughput approach 
whose goal is to provide a complete repertoire of protein folding by determining a 
representative structure. In this case the effort for the target selection is limited.  
Entire genomes or very large protein families (like for example: soluble human 
proteins under 100 residues) are selected, cloned, expressed in parallel using 
automatic systems. The  great advantage of this approach is that a huge number of 
genes can be screened for protein expression and solubility. However, a common 
cloning and expression protocol has to be used for all the genes limiting in this way, 
the rate of success (usually 20-30%) for each target.  
 
- The Functional Genomics approach: this approach focuses the effort on a 
limited number of proteins that belong specific families linked into diseases or 
involved in some specific metabolic pathways. Large bibliographic and 
bioinformatics research is at the basis of the target selection. A limited number of 
targets are cloned but, in order to maximize the rate of success, many simultaneous 
cloning and expression strategies have to be performed. 
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For both strategies a multidisciplinary approach is necessary; a large number of steps, 
regarding different scientific fields like bioinformatics, biochemistry and molecular 
biology have to cooperate in order to proceed to the target selection, protein expression, 
structural and functional characterization. The general strategy of the research consists of 
the following phases:  target selection performing genome browsing in bacteria and 
eukaryotes; domain definition; gene cloning and protein expression; structural 
determination by NMR and/or X-ray; modeling; protein-protein interaction studies. 
 
                                        2.2 Genome browsing 
 
One of the challenges faced by the molecular biology community today is to make 
sense of the wealth of data that have been produced by the genome sequencing projects. In 
the past decade, bioinformatics has become an integral part of research and development in 
biomedical sciences. Bioinformatics has nowadays an essential role both in deciphering 
genomic, transcriptomic and proteomic data, generated by high-throughput experimental 
technologies, and in organizing information gathered from traditional biology. It is an 
interdisciplinary research area at the interface between the biological and computational 
science. The ultimate goal of bioinformatics is to uncover the biological information 
hidden in the wide collection of data and to obtain a better insight into the fundamental 
biology of organisms. A number of data banks with databases and programs have been 
created with the aim of providing the scientific community with tools for searching gene 
banks, for the analysis of protein sequences and for the prediction of a variety of protein 
properties. 
In this research we have focused our attention on finding new metalloproteins. In the 
initial stage of the search a number of metalloprotein sequences were selected on the basis 
of previously genetic and biochemical studies. Several different bioinformatic approaches 
are possible in relation to which kind of target we are interested in searching. One possible 
strategy is performing a BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) search in order to 
explore all of the available sequence databases (NCBI at http://www.ncbi.nlm.nih.gov/) 
searching for an unknown protein that contain a conserved consensus motifs for the metal 
binding, For example, HSco1 and HSco2 show the same CXXXC hypothetical copper 
binding motif, conserved in the CuA centre of CcO, while Atx1 presents the same 
MXCXXC motif found also in CCC2. The consensus sequence gives a unique perspective 
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to structural genomics of metalloproteins based on genome browsing, as an intriguing and 
broad variety of functions and metal binding properties are found in proteins sharing the 
same fold and the same consensus sequence. Performing a  ClustalW 
(http://www.ebi.ac.uk/clustalw/) alignment and a Seqspace 
(http://industry.ebi.ac.uk/SeqSpace/) run of the obtained sequences from the genome 
browsing, we selected an identified macro-group of genes characterized by common 
features. In some cases, it is possible to observe the occurrence of distinctive domains and 
the repetition of metal consensus sequences within the same gene. The collected sequences 
can be further divided in subfamily on the basis of their domain organization. Phylogenetic 
comparative analysis, and a gene-context analysis (STRING at http://string.embl.de/), for 
the genes having prokaryotic homologues, could be useful to divide the genes of the 
macro-families into classes. 
When a protein of particular interest is identified, it becomes the subject of further 
bioinformatics investigations in order to predict features like stability, solubility, 
hydrophobicity, secondary and tertiary structures. 
 
2.3 Domain definition 
 
From each class of proteins, several domains are selected for expression. Multiple 
sequence alignment provides a number of homologous genes from different organisms; the 
gene cloning could be carried out on various sequences. Several preliminary analysis are 
thus necessary to select the protein construct with the highest probability of giving rise to a 
soluble and folded protein.  
In our laboratory the domain definition is performed taking in consideration the 
following aspects: 
 
- The presence of  transmembrane regions. It is very important to know if we are 
dealing with a completely soluble protein, with an integral transmembrane 
protein or with a protein with a short peptide inserted into the phospholipidic 
bilayer, that is for the most part soluble. While in the first case the full length 
chain represent probably the best construct, in the latter one it is possible to 
attempt the expression of a recombinant protein without the transmembrane 
tail. In this case, in order to maximize the successful rate several possible 
constructs of the soluble part(s) are designed. 
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- The presence of N-terminal signal peptide (Predicted by SignalP at 
www.cbs.dtu.dk/services/SignalP/)  sequence that enable the expression of the 
protein in the periplasmic or mithocondrial  area. 
- The N-terminal part with designed  in respect to the N-end rules(3).  This rule 
suggest a relation between the metabolic stability of a protein and the identity 
of its N-terminal residue.  
- The presence in the sequence of intrinsically unstructured/disordered regions 
(Predicted by IUPred at http://iupred.enzim.hu/) 
- The presence in the DNA coding sequences of codons that are “rare” to the host 
selected for the expression of the recombinant protein. (for E.coli expression 
system are predicted  at  http://nihserver.mbi.ucla.edu/RACC/) 
- The domain is usually cut  in correspondence to regions that show in  ClustalW 
alignment (www.ebi.ac.uk/clustalw/), a low degree of similarity to the protein 
family they belong to, and where no stable secondary structural elements are 
localized . (Predicted at http://npsa-pbil.ibcp.fr/). 
 
In the current work this approach was used to design the HSco1 domains. Hsco1 
contains a N-terminal signal peptide, in the regions 1-31 and a transmembrane region from 
94 to 110. ClustalW alignment with all other Sco1 homologues shows the presence, in 
HSco1, of a highly charged 14aa sequence localized between the TM region and the 
CXXXC conserved copper binding motif, that is not present in prokaryotic Sco1 
homologues. Two different domains were designed, one with and the other without this 
charged region. As it can be read in chapter 3.2  both the two domain result in soluble 
expression but the short one is monomer while the long is dimer. 
 
2.4 Gene cloning 
 
In the Functional genomic approach, which currently represent our philosophy, the 
strategy for cloning the target protein has to be carefully designed since it will influence 
the behaviour of the protein, e.g. yield, solubility, folding, etc. Although protein expression 
is no longer considered a major limiting step and protein purification techniques have 
improved dramatically in the past decade, the problem of producing soluble proteins for 
purification has continued to be a major bottleneck in the field. Unfortunately many 
proteins belonging to interesting families, especially the human proteins, are extremely 
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difficult to be produce as soluble proteins in E.coli as they are often accumulated as 
inclusion bodies. Even if in the recent years, the increasing knowledge of additives can 
assist the “in vitro” refolding process, and  numerous proteins have been refolded into their 
active forms, yet the successful rate of this strategy is very low. Considerable efforts are 
currently underway to make alternative hosts more accessible and affordable, and 
eukaryotic systems including mammalian, yeast and insect cell expression are becoming 
easier and less expensive to be used(4,5). Cell-free protein synthesis has also great potential 
for overcoming some of the problems of soluble and membrane proteins expression, but it 
still remains a work in progress for the time being(6). However especially for NMR 
purpose, which requires the production of high yield of labelled 15N and 13C samples, the 
E.coli expression system is nowadays, the most widely used.  
Many efforts are currently focused on the optimization of the E.coli expression 
system. Factors such as reduced temperature(7), changes in the E.coli expression strain(8), 
different promoters or induction conditions(9) and co-expression of molecular chaperones 
and folding modulators(10) have all been examined and,  in some specific cases, they lead to 
enhancements of soluble protein production. Many years ago it was discovered that some 
affinity tags are able to enhance the solubility of some of the partner proteins to which they 
are attached(11); even if the number of fusion partners is increasing progressively during the 
years none of these tags work universally with each partner protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12:  Schematic representation of the
pathway from protein expression to
purification using solubility tags. Four
arbitrary tagged versions of the protein of interest
are generated in E. coli.  
 
(a) After expression, some fusions will remain in
the  insoluble fraction and be lost from the pathway. 
(b) Soluble fusions are purified by IMAC using the
attached His6 tag. A protease is then used to cleave
the fusion tag from the partner protein.  
(c) Some fusions will not cleave efficiently, and
will leave behind a mixture of cleaved and
uncleaved proteins that cannot be easily separated.  
(d) Other fusions will cleave efficiently, but when
separated from the solubility tag the partner protein
will become insoluble and precipitate.  
(e) However, a well-behaved fusion will remain in
solution and can be purified by a second IMAC step
to remove the His6-tagged solubility tag and
protease, leaving only the target protein in the flow
through (IMAC FT). 
 
IMAC=immobilized metal affinity chromatography.
(Reprinted from Esposito D et.al (2006) Current
Opinion in Biotechnology 17, I 353-358) 
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The best way to maximize the probability of obtaining a soluble and correctly folded 
target protein is to proceed with a parallel cloning and expression of it with a high number 
of fusion partner (Fig.12)   
Anyway, the experience shows that in some cases the classic approach, that is to 
express the native protein without any tag results the only successful one. While classical 
approaches do not require further sub cloning, fusion partners’ impact on protein solubility 
leads to sub cloning the gene of interest in a library of expression vectors that becomes 
laborious when handling a large number of genes. Recently, Landy and co-workers(12) have 
described a cloning method (Gateway technology) that enables rapid cloning of one or 
more genes into virtually any expression vector using site-specific and conservative 
recombination (LR reaction) eliminating the requirement to work with restriction enzymes 
and ligase (Fig.13). 
 
    DNA  
 
     PCR     PCR  
 
 
R1 R2 
 
 Topo cloning reaction Enzimatic 
restriction  
* GST  MBP
* * * * 
NusA GB1
 Trx
 * LR reaction 
  Ligase 
 Fig.13: Schematic comparison between the Classic and  the
Gateway cloning technology. Theoretically parallel cloning is
possible in both the cases but the Gateway system resulted faster
due to the higher reaction efficiency and less sequencing demand
since only the starting pENTR should be sequence verified.  
 
 
 
 
On the basis of the former considerations, in our laboratory, we select at list two 
different domains for each new target. These are cloned with the classic methods to 
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express the protein in the native form, and with Gateway system (Invitrogen) in order to 
express it with five different N-Terminal fusion tag (GST, MBP,NusA,Trx,GB1).  
Human Sco1 and human Cox17 were cloned according to the general procedure 
described above.                     
 
                                               2.5 Protein expression 
 
 At first, expression and solubility screening, in small scale culture (1-10ml LB) is 
performed generally using at list 3 different E.coli strains (BL21Gold (DE3), Rosetta(DE3) 
and Origami(DE3 ) and inducing the protein expression at two different temperature (37°C 
and 25°C). The result of this first test is analysed and on the basis of these data it is 
decided whether or not proceeding to the scale-up and testing the expression in minimum 
media. A second screening is sometimes performed in order to refine expression conditions 
or, in the case in which  all the test are negative, to redefine the strategy.  
 
1) If no expression is observed we can take into consideration the following choice: 
- Redefine the domain. 
- Use an expression vector containing an inducible promoter different from T7(for 
example ARA or Cold inducible promoters)(9) 
- Test other E.coli strains. In some cases, using promoters different from T7, as 
for instance LacIq , better results were obtained with E.coli strain lacking the 
DE3 episome. 
- Consider the possibility to move to an eukaryotic expression system. 
 
2) If all the proteins are expressed in the insoluble fraction as inclusion bodies the 
choice are: 
- Change the expression condition (temperature, induction time, medium ecc) 
- Redefine the domain. 
- Proceed with an “ in vitro” refolding screening 
-      Clone again the domain in a “classic vector” codifying for the same fusion 
partners but lacking the His-tag.  In some case it was observed that the presence 
of an N-or C-terminal His-tag(13) and/or the sequences corresponding at the 
Gateway recombination cassette, has a noticeable negative affect on protein 
solubility. 
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-       Consider the possibility to move to an eukaryotic expression system. 
        
 3) If from the expression screening we obtain positive results we select the more 
promising conditions and move to the scale-up, which is performed according to the 
following scheme: 
 
1 liter Culture in LB
(in shaking flask)
Purification  
Tag-removal  
(using a proteases) 
Protein yield 
estimations
Good expression
in LB!!
Clone selection 
(based on small screening data)  
1 liter culture in 
Minimun media  
Yield optimization 
 in Fermenters 
(i h ki fl k)
Fusion-Target 
Purification 
Low expression in M9  
Good expression
in M9!! 
   
If the protein has a good folding and it is stable during
concentration, we start the production 15N and 15N, 13C 
labbelled samples for structural characterization   
Fig.14: Typical scale-up optimization process. Expression, purification, tag-removal by proteases 
are optimized on the unlabelled samples from the LB culture. In parallel, simulation of culture in 
minimal media(M9) are performed to optimize the labelling procedure. Fermentors are used only
for M9 when low yields are obtained  from shaking-flask.
Centrifugation and 
cell lysis
 
 
 
 
 
   
 
 
 
 
 
 
Low expression 
in LB!!
          !! NOT LABELLED PURE PROTEIN!! 
 
        Preliminary folding analysis: 
- 1H-NMR 
- Circular dichroism 
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The set-up of a new expression protocol generally requires the optimization of 
different steps. In Fig.14, it is also shown, the frequent situation in which it is necessary to 
return to the cloning selection and restart from the beginning if the optimisation of some 
intermediate step fail.  
 
For HSco1 proteins expression, competent E.coli BL21-Gold(DE3) cells were used. 
The 15N-labeled 15N 13C-labeled proteins were obtained by growing cells in minimal 
medium (M9) containing  3g/l  13C-Glucose and 1g/l  15N-(NH4)2SO4  whereas LB medium 
was used for the non-labelled protein. For the latter form, the cells were grown in shaking 
flaks at 37°C until OD=0.7 and then induced with 0,7mM IPTG for 1h a 37°C and 16h at 
30°C. A longer induction at 37°C results in expression of Hsco1 in the insoluble fraction. 
The same procedure repeated in minimal medium results in a dramatic loss of protein 
expression level. A good yield (>40mg/l of the GST-Hsco1 fused proteins) was recovered, 
optimizing the growth and expression condition in 1.8 liter Minifors fermenter (Infors HT). 
For Cox17 protein expression, competent E.coli Origami(DE3)plyss cells were used. 
The 15N-labeled 15N 13C-labeled proteins were obtained by growing cells in M9 containing  
3g/l  13C-Glucose and 1g/l  15N-(NH4)2SO4  whereas LB medium was used for the non-
labelled protein. For the latter form, the cells were grown in shaking flask at 37°C until 
OD=0.7; protein expression was induced with 0,7mM IPTG at 25°C over night. For Cox17 
the shaking flask culture in minimal medium provide a  really good yield (>70mg/l of the 
GST-Cox17 fused proteins), and the optimization with fermenters was not necessary.   
 
                                              2.6 Protein purification 
 
The strategy of purification depends mainly upon the location of the expressed 
protein within the host, indeed, the protein can be transported in the periplasmic space or 
expressed like a soluble or insoluble (inclusion bodies) protein within the cytoplasm. In 
each cases, the isolation was performed in a different way. All the purifications involve 
several chromatographic steps performed adjusting the parameters according to the 
different physical chemical and biological characteristics of the proteins. Ion exchange and 
size exclusion chromatography are commonly used to purify proteins expressed in their 
native states. Some tags, like MBP or GST, are specific affinity tag, which not only 
facilitate soluble expression but also increase the efficiency of protein purification. In some 
cases, other solubility tags have been combined with a simple His-tag, allowing the fusion 
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partner to maintain its solubilizing functionality and also simultaneously as an affinity tag. 
Immobilized metal ion affinity chromatography (IMAC) is currently the most used affinity 
technique, it exploits the interaction between chelated transition metal ions (generally Zn2+ 
or Ni2+) and side-chains of specific amino acids (mainly histidine) on the protein (Fig. 15) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NATIVE CONDITIONS 
 
                            IMAC Chromatografy procedure                         
    Fig.15:General purification procedure of a typical His-tagged proteins 
   ( Reprinted from Qiagen handbook for expression and purification of His-tagged proteins) 
 
 
 
 
                       Elution buffer        
                    Tris 20mM Ph=8 
                   Nacl 0,5M 
                   Imidazole 300mM  Pure Fusion Protein 
     Elution buffer    
                  + 
       Urea6M or Gn-
 
 
 
 
           Wash buffer           
           Tris 20mM Ph=8 
           Nacl 0,5M 
           Imidazole 60mM 
 
 
 
 
 
 
 
 
 
 
 
 
                   Wash buffer  
                             + 
          Urea6M or Gn-Hcl 6M        
 
 
 
 
 
 
 
 
        Binding buffer 
                    + 
  Urea6M or Gn-Hcl 6M  
 
         Binding buffer 
       Tris 20mM Ph=8 
        Nacl 0,5M 
        Imidazole 10mM 
 
     DENATURING CONDITIONS
 
In IMAC chromatography, the target protein is usually washed from the impurities and 
then eluted using increasing concentration of imidazole, which acts like a competitive 
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agent. As an alternatives to imidazole elution, histidine-tagged proteins can be eluted from 
the coloumn by several other methods or combinations of methods: 
 
– for example a lowering of pH within the range of 2.5–7.5 can be used,. At 
pH values below 4, metal ions will be stripped off the medium. 
– EDTA in the elution buffer strips the metal ions from the column. 
 
Enzymatic digestion using a specific protease is then necessary to remove the fusion 
partner from the target protein and a second IMAC purification is generally performed in 
order to separate the two proteins. TEV, Fatt.Xa, Thrombin, Prescission Protease, 
recombinant Enterokinase are some example of proteases that are normally used for the 
cleavage of fusion proteins. The protease specific recognition site is selected and cloned in 
the vector codifying for the protein sequence at the cloning step. For each protease/fusion 
protein pilot experiments should be done to find out suitable conditions. 
 
For both HSco1 and HCox17, the first purification step was performed using IMAC 
by His-trap column charged with Zn2+. Both  proteins were eluted in Tris 20mM, NaCl 
0.5M and imidazol 300mM  pH=8. After concentration the samples were loaded on a PD-
10 desalting column in order to exchange the buffer in Tris 50mM, EDTA 0.5mM DTT 
1mM. His-GST tag was cleaved with 2ul of Ac-TEV protease/1mg of fusion protein 
(Invitrogen, Carlsbad, CA) under over night incubation at room temperature. For Hsco1 a 
second IMAC purification was necessary. At this point, the HSco1, lacking the fusion part 
containing the his-tag do not bind the column, while, the His-GST tag is eluted at 300mM 
of imidazole. On the contrary the cut HCox17, in the second IMAC purification, in not 
eluted in the unbound fraction. It remains bound and it is eluted in the same fraction with 
of His-GST tag. Exploiting the high difference in molecular weight between HCox17 and 
GST, this problem is overcome performing a size exclusion chromatography using a 
20mM Tris, 1mM DTT, 5mM EDTA, 300mM NaCl buffer, in order to minimize possible 
protein-protein interaction.   
 
 
 
 
 
 40
                                           2.7 Samples preparation 
 
Copper and zinc metalloproteins, which in many cases bind metal atoms through Cys 
residues are not easy to handle. Establishing a good  “in vitro” metallation protocol, could 
is a huge effort. Disulfide status is important and can affect sample metallation and 
stability. Disulfide reduction prior to metallation have to be performed. Unfortunately, the 
most commonly used reducing agents, like Dithiothreitol DTT, are characterized by a short 
life time and by a high affinity for metals. Therefore, after disulfide reduction and prior to 
metallation , the reducing agents have to be removed almost completely from the samples. 
The re-oxidation of the cysteine residues can induce no specific intra-molecular disulfide 
bonds formation followed by to  protein aggregation and precipitation. Many different 
trials were done before founding the metallation protocol for Hsco1. Protein reduction and 
metallation were carried out under nitrogen atmosphere in an anaerobic chamber to prevent 
oxidation of the cysteine residues. (DTT) was added to the protein in a 10mM 
concentration to reduce the cysteine residues in the CXXXC motif prior to metal 
reconstitution. The buffer was than exchanged into 50 mM phosphate (Pi) buffer at pH 7.2 
to remove the excess of DTT using PD-10 desalting column.  In order to obtain Cu(I), 
Cu(II), Ni(II) metallated protein,  progressive titration, monitored by UV-vis or 15N-HSQC 
experiment were performed, using the metals respectively in the  [Cu(I)(CH3CN)4]PF6, 
Cu2SO4 and NiCl2 forms. The titration was performed using a maximum protein 
concentration  of 0.2mM. Intensive precipitation was observed in all the tests performed 
with higher protein concentrations. The excess of metals was removed through a PD-10 
desalting column. All the NMR samples were prepared in Pi 50mM pH=7.2 buffer. Similar 
protocol for Cu(I) titration was developed also for the metallation of HCox17.  
Polyethylene glycol (PEG)6000/pH, (NH)4SO4/pH screening using a vapour 
diffusion methods were performed in order to obtain a Ni(II)-HSco1 crystal suitable for X-
Ray diffraction. Different protein concentration (from 30mg/ml to 5 mg/ml) were screened. 
Crystals of Ni(II)-HSco1 were grew at 20°C from a 0.1 M Tris·HCl/30%PEG6000 solution 
at pH 8.5. Higher pH, show intensive formation of Ni(OH)2 crystals. 
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2.8 Preliminary protein  characterization 
 
Once obtained a pure protein several studies can be done in order to characterize it. 
First of all, mass spectroscopy analysis is performed in order to verify the protein identity 
and understand if the sequence has the N-terminal methionine. Solubility and stability of 
the protein at high concentration generally represent an indication of a good folding. 
Anyway before proceeding to the preparation of labelled samples the degree of 
“foldedness” is estimated by 1H-NMR and circular dichroism spectroscopy. The latter 
technique could be suitable also to evaluate the thermal stability. Size exclusion 
chromatography coupled with multiangle light scattering is performed in order to 
determine the aggregation state of the protein in solution. The metal content is analyzed by 
atomic absorption measurements. Disulfide status could be checked by SDS−PAGE after 
modification with AMS, or more accurately, by mass spectroscopy after modification with 
iodoacetamide. 
 
2.9 Biophysical characterizations 
 
 
- UV fluorescence: 
 
Eukaryotic and prokaryotic cells contain a number of compounds that are fluorescent 
under UV light excitation. Proteins and peptides, with aromatic amino acids are 
“intrinsically” fluorescent when excited by UV light. Many enzymatic cofactors, such as 
FMN, FAD, NAD and porphyrins, which are also intrinsically fluorescent, add to the 
protein fluorescence. These moieties have a common trait in that they all contain aromatic 
ring structures that are excited by the UV light. There are also special proteins such as 
Green Fluorescent Protein, which has an internal serine-tyrosine-glycine sequence that is 
modified post-translationally and is fluorescent in the visible light region.  
The three amino acid residues that are primarily responsible for the inherent 
fluorescence of proteins are tryptophan, tyrosine and phenylalanine. These residues have 
distinct absorption and emission wavelengths and differ in the quantum yields (Table.1).  
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Tryptophan is much more fluorescent than either tyrosine or phenylalanine. 
However, the fluorescent properties of tryptophan are solvent dependent. As the polarity of 
the solvent decreases, the spectrum shifts to shorter wavelengths and increases in intensity. 
For this reason, tryptophan residues buried in hydrophobic domains of folded proteins 
exhibit a spectral shift of 10 to 20 nm. Tyrosine can be excited at wavelengths similar to 
that of tryptophan, but emits at a distinctly different wavelength (303nm). While tyrosine is 
less fluorescent than tryptophan(14), it can provide significant signal, as it is often present in 
large numbers in many proteins. Tyrosine fluorescence has been observed to be quenched 
by the presence of nearby tryptophan moieties via resonance energy transfer, as well as by 
ionization of its aromatic hydroxyl group. Phenylalanine is very weakly fluorescent(14) and 
can only be observed in the absence of both tryptophan and tyrosine. Protein fluorescence 
is generally excited at 280 nm or at longer wavelengths, usually at 295 nm. In the first 
case, we obtain the excitation of  both tryptophan and tyrosine residues but, due to 
tryptophan’s greater absorptivity, the fluorescence spectrum usually resembles that of 
tryptophan. In the second case,  using an excitation wavelength of 295 nm  we can obtain a 
selective excitation of the tryptophan. 
The fluorescence of the aromatic residues varies in a somewhat unpredictable manner 
in various proteins. The quantum yield may be either increased or decreased by the folding. 
Accordingly, a folded protein can have either greater or less fluorescence than the unfolded 
form. The intensity of fluorescence is not very informative in itself. The magnitude of 
intensity, however, can be used as a probe of the perturbation of the folded state.  
The fact that protein conformal transitions, corresponding at the transition between 
different states, like folded and unfolded, oxidated and reduced, are generally characterized 
by different fluorescence intensities(15) was exploit in order to determine the relative 
stability of this states under different conditions. Progressive protein unfolding in urea(16), 
or a disulfide bond red-ox potential(17) are some examples of interesting protein properties 
that can be monitored in this way.  
In the present work, the red-ox potential of WT-HSco1 and P174L-HSco1 mutant 
was investigated by fluorescence spectroscopy (see Cap.5) in order to verify if the 
pathogenic mutation affects the red-ox properties of HSco1.  
Moreover, proteins can be covalently labeled with various fluorophores, thus 
producing fluorescent protein conjugates. The emission from these attached tags is called 
“extrinsic” fluorescence. Tagging a protein with fluorescent labels is an important and 
valuable tool for protein characterization. 
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 In the present work using three different fluoroprobes we performed the following 
assays: 
 
1) Thermal-Shift assay (Thermofluor): The conceptual basis of this method is that 
folded and unfolded proteins can be distinguished through exposure to a hydrophobic 
fluoroprobe, Sypro Orange. This probe has low quantum yield in aqueous solution 
but is highly fluorescent in non polar environments with low dielectric constants such 
as hydrophobic sites in proteins. When a protein starts to unfold or melt, the dye 
binds to exposed hydrophobic parts of the protein, resulting in a significant increase 
in fluorescence emission (Fig. 16). The fluorescence intensity reaches a maximum 
and then starts to decrease, probably due to precipitation of the complex of the 
fluorescent probe and the denatured protein. Thermally induced unfolding is an 
irreversible unfolding process following a typical two-state model with a sharp 
transition between the folded and unfolded states, where Tm is defined as the 
midpoint of temperature of the protein-unfolding transition(18). For several proteins, 
melting temperatures, obtained with the thermofluor method  have been shown to 
correlate well with values determined by other biophysical methods such as circular 
dichroism (CD), turbidity measurements, and differential scanning calorimetry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Folded 
protein
Hydrophobi
fluoro  probe -
+ 
Probe (Sypro Orange)  
Higly fluorescent in 
low dielectric media 
Unfolded 
protein 
Fig. 16: Typical Thermal shift assay results. (Reprinted from Ericsson UB et.al. Analytical 
Biochemistry Volume 357, Issue 2 , 15 October 2006, Pages 289-298)
 
In this work the use of Thermofluor was limited to the Tm measurement of WT-Hsco1 
and P174L pathogenic mutant in order to compare their  thermal stability (see capther n°5). 
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2)ThioflavinT (ThT) fluorescence: It a commonly used method to monitor fibril 
formation. This method is particularly attractive since ThT fluoresces only when 
bound to fibrils. The reaction between the protein and ThT is completed within 1 
minute and ThT does not interfere with aggregation. Free ThT has excitation and 
emission maxima at 350 nm and 450 nm, respectively.  However, upon binding to 
fibrils the excitation and emission change to 450 nm and 485 nm, respectively(21). 
This fluorometric technique is really important in the studies of neurodegenerative 
diseases because it allows the kinetic elucidation of the fibril assembly process. In 
this work we used ThT probes, coupled with size esclusion chromatography, in order 
to investigate the tendency of the apo, copper depleted and fully metallated, human 
SOD1 to form fibrillar aggregates under incubation in condition close to the 
physiological ones (100uM and 37°C). 
3)Free-thiols quantification: Estimation of free thiols during aggregation was 
performed by 4-acetamido 4' maleimidylstilbene-2,2'-disulfonic acid (AMS) 
modification. This iodoacetamide derivate has high water solubility and is readily 
conjugated to thiols. 
AMS is a stilbene derivate, and  shows a typical UV absorption at around 328 
nm  and emission maximum at 408 nm. Fluorescence measurements were performed 
in order to monitor the variation of free thiols during the incubation at 37°C of the 
protein samples. The methods require a preliminary calibration curve for the free 
cysteine quantification. In our case, this calibration curve, was determined using 
freshly prepared apo SOD1 WT at different concentrations as a standard.  MALDI 
analysis proved that there is a maximum of two free cysteines per apo SOD1 
monomer. 
 
 
 
 
 
 
 
 
 
 
 45
                                             2.10 Structural characterization 
 
X-ray crystallography and NMR spectroscopy are the two main techniques that 
can provide structures of macromolecules at atomic resolution. Both techniques are well 
established and play a key role in structural biology as a basis for a detailed 
understanding of molecular functions. Their respective different advantages and 
disadvantages in terms of sample preparation and data collection and analysis make them 
complementary in Structual proteomics. X-ray studies usually requires substantial 
investment of time in order to optimize the crystallization conditions and obtain a crystal 
with a good diffraction properties This process can take weeks or months, but once a 
well-diffracting (<2.5Å) crystal is obtained, the structure determination can proceed quite 
quickly. Whereas X-ray crystallography requires single crystals, NMR measurements are 
carried out in solution under conditions that can be as close as possible to the 
physiological state. Some times even if crystal structures are available, additional data in 
solution would be needed to determine the potential biological function of the protein. 
NMR is not only capable of solving protein structures to atomic resolution but also has 
the unique ability to accurately measure the dynamic properties of proteins and can  also 
supply information on protein folding and on intra-, as well as, intermolecular 
interactions. Furthermore, the analysis through NMR spectroscopy easily allows the 
characterization under several, different experimental conditions, such as different ionic 
strength and pH. Generally, a promising protein sample characterized by a good circular 
dichroism spectra, 1H-NMR or better from a good 1H-15N HSQC spectra and stable on 
time (in the mM range) have high probability to be suitable for NMR structural 
characterization. However, the two majors bottlenecks limiting the NMR in structural 
biology are represented to the long time request for the data analysis and the drawback  
size limit of protein. The current is around 35KDa but recent advances in both hardware 
and experimental design promise to allow the study of much larger proteins(19) . 
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2.10.1 Structure Determination of Proteins with NMR Spectroscopy 
 
NMR spectra of biological macromolecules contain hundreds or even thousands of 
resonance lines which cannot be resolved in a conventional one-dimensional spectra (1D). 
Further, the interpretation of NMR data requires correlations between different nuclei, 
which are implicitly contained in 1D spectra but often difficult to extract. 
Multidimensional NMR spectra provide both, increased resolution and correlations which 
are easy to analyse. 
The crucial step in increasing the dimensionality of NMR experiments lies in the extension 
from one to two dimensions. A higher dimensional NMR experiment consists of a 
combination of two-dimensional (2D) experiments. All 2D NMR experiments use the same 
basic scheme which consists of the four following, consecutive time periods 
 
excitation - evolution - mixing – detection 
 
During the excitation period the spins are prepared in the desired state from which the 
chemical shifts of the individual nuclei are observed during the evolution period t1. In the 
mixing period the spins are correlated with each other and the information on the chemical 
shift of one nucleus ends up on an other nucleus of which the frequency is measured during 
the detection period t2. A resonance in the 2D spectrum, such as a cross peak, represents a 
pair of nuclei that suitably interact during the mixing time. 
The extension from a 2D to a n-dimensional (nD) NMR experiment consists in the 
combination of (n-1) two-dimensional experiments which contains only one excitation and 
one detection period but repeats the evolution and mixing times (n-1) times. A typical nD 
NMR experiment thus follows the scheme:  
 
excitation - (evolution - mixing)n–1 – detection 
 
where the bracket repeats (n–1) times. Only during the detection period the signal is 
physically measured and this period is often referred to as the direct dimension in contrast 
to the evolution periods which are referred to as indirect dimensions. 
The NMR multidimensional measurements almost always use protons (1H) and 
depending on the isotope labelling, 13C and/or 15N nuclei. A 3D spectrum can for example 
be obtained by correlating the amide groups with the α-carbon nuclei attached to 15N. The 
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chemical shifts of these carbon nuclei are used to spread the resonances from the 2D plane 
into a third dimension. The sensitivity obtainable with these types of nuclei greatly varies 
even if the sample is fully isotope labelled with 13C or 15N. The proton offers the best 
sensitivity and for this reason constitutes the preferred nucleus for detection of the NMR 
signal. The other nuclei are usually measured during evolution periods of multidimensional 
NMR experiments and their information is transferred to protons for detection. 
For small proteins (less than 10kDa), it is not required to label the sample with 13C or 15N. 
In this case the assignment strategy makes use of a combination of 2D homonuclear 1H 
NMR experiments such as COSY/TOCSY, and NOESY/ROESY spectra.  
COSY- and TOCSY-type experiments, where COSY stands for COrrelation 
SpectroscopY and TOCSY for Total Correlation Spectroscopy, correlate different nuclei 
via J coupling(20,21). In proteins which are isotope labelled with 15N and 13C J couplings 
between 1H, 15N and 13C allow through-bond correlations across the peptide bond. 
Through-space correlations are instead measured via the nuclear Overhauser effect 
(NOE) and provide the basis for geometric information required to determine the structure 
of a macromolecule(22). The NMR method for protein structure determination relies on a 
dense network of distance constraints derived from NOEs between nearby hydrogen atoms 
in the protein(22). NOEs connect pairs of hydrogen atoms separated by less than about 5 Å. 
In contrast to COSY-type experiments the nuclei involved in the NOE correlation can 
belong to amino acid residues that may be far apart along the protein sequence but close in 
space. For molecules with a molecular weight of more than 5 kDa the intensity of an NOE 
is approximately proportional to r-6 and to the molecular weight, where r is the distance 
between the two interacting spins. NMR experiments which measure the NOE are often 
referred to as NOESY experiments where NOESY stands for NOE SpectroscopY (23). 
 
Sequence Resonance Assignment 
 
For a detailed analysis of the information content of NMR spectra nearly complete 
assignments of signals in the spectra to individual atoms in the molecule are a requirement. 
The application of multidimensional NMR spectroscopy allowed the development of 
general strategies for the assignment of signals in proteins. All procedures use the known 
protein sequence to connect nuclei of amino acid residues which are neighbours in the 
sequence. As mentioned before, for unlabelled proteins smaller than 10 kDa the 
combination of the [1H,1H]-COSY or TOCSY, used for the sequential assignment, with the 
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[1H, 1H]-NOESY spectrum allows the assignment of most proton NMR signals to 
individual protons(23). 
For larger proteins extensive signal overlap prevents complete assignments of all 
1H signals in proton spectra. This barrier can be overcome with 3D NMR technique and 
uniformly 13C and 15N labelled proteins. The resonance assignment of single (15N or 13C) 
labelled proteins using 3D experiments is basically an extension of Wüthrich’s strategy 
which exclusively relies on homonuclear 1H NMR experiments. With these methods, 
systems with molecular weights up to approximately 30 kDa can be studied. 
In 13C, 15N-labeled proteins a sequential assignment strategy is based on through-bond 
correlations across the peptide-bond between sequential amino acids. This procedure 
circumvents the use of NOESY spectra already in the assignment step. Most of these 
correlation experiments use the three types of nuclei 1H, 15N, 13C and are referred to as 
triple resonance experiments. 
The 3D triple resonance experiments exclusively correlate the resonances of the peptide 
backbone (HN(i), N(i), Cα(i), Hα(i), Cα(i-1), CO(i) and CO(i-1)). Fig. 17 shows the spin 
system of the peptide backbone and indicates the size of the coupling constants used for 
magnetization transfer in double 13C-, 15N-labelled proteins.  
 
 
 
 
 
 
 
 
 
Fig. 17: Spin system of the peptide
backbone and the size of the 1J and 2J
coupling constants that are used for
magnetization transfer in 13C-, 15N-
labelled proteins. 
The 3D experiments used to identify the backbone resonances are, usually, HNCA or 
HNCACB, HN(CO)CA or HN(CO)CACB, HNCO, HN(CA)CO and HNHA(24). The 
HNCACB for example, correlates each H-15N group with both the intra- and the 
neighbouring inter-residue Cα and Cβ. These four types of connectivities are discriminated 
using the HN(CO)CACB experiment, in which only the inter-residue HN-Cα and Cβ 
couplings are observed. 
Similar strategy can be used to assign the other resonances in the other triple 
resonance spectra.  
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  In the case of proteins with a molecular weight larger than 30 kDa the use of 
TROSY-type experiments(25) is necessarily. TROSY experiment can reduce the signal loss, 
which is the direct consequence of the slower correlation tumbling of large molecules 
which results in faster relaxation and consequently broader lines in the NMR spectrum. 
TROSY uses constructive interference between different relaxation mechanisms and works 
best at the highest available magnetic field strengths in the range of 700 to 900 MHz 
proton resonance frequency. With TROSY the molecular size of proteins accessible for 
detailed NMR investigations has been extended several fold. The TROSY technique 
benefits a variety of triple resonance NMR experiments as the 3D HNCA and HNCOCA 
(26) and the TROSY-based NOESY experiments for the collection of structural constraints 
are also available (27).  
Since the Hα and Cα/β chemical shifts have been assigned, 3D H(C)CH-TOCSY and 
(H)CCH-TOCSY (28) experiments are then used to link the side chain spin systems to the 
backbone assignments. These two experiments provide information for the assignment of 
the side chain protons and of the side chain carbons, respectively. 
A complete set of backbone chemical shifts for all Hα, Cα, Cβ and CO resonances 
can be used to predict the secondary structure of the protein(29). One technique in 
particular, the Chemical Shift Index (CSI)(30), has been widely used for the quantitative 
identification and location of secondary structure in proteins.  
The method relies on the fact that the chemical shifts of the different nuclei in the protein 
backbone are related both to the type of amino acid and to the nature of the secondary 
structure they are located in. By comparing the actual chemical shift for a nucleus in a 
specific amino acid with a reference value, it is possible to predict in what secondary 
structure element the nucleus resides. The reference value that you compare with is the 
random coil chemical shift for that same nucleus in the same amino acid.  
 
Collection of conformational constraints 
 
In structure calculation, geometric conformational information in the form of distances 
and/or torsion angles has to be derived from the NMR data. The latter have to be 
supplemented by information about the covalent structure of the protein, such as the amino 
acid sequence, bond lengths, bond angles, chiralities, and planar groups, as well as by 
steric repulsion between non-bonded atom pairs. 
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Although a variety of NMR parameters contain structural information, the crucial 
information comes from NOE measurements which provide distance information between 
pairs of protons. Supplementary constraints can be derived from through bond correlations 
in the form of dihedral angles(23). Furthermore, CSI data, provides, as before mentioned, 
information on the type of secondary structure. Such information can be included in a 
structure calculation by restricting the local conformation of a residue to the α−helical or 
β-sheet region of the Ramachandran plot through torsion angle restraints.  Hydrogen bonds 
can also be experimentally detected via through-bond interactions(31) and they can be 
useful during structure calculations of larger proteins when not enough NOE data are 
available yet. Finally one other class of conformational restraints  originate from residual 
dipolar couplings in partially aligned or paramagnetic molecules and gives information on 
angles between covalent bonds and globally defined axes in the molecule, namely those of 
the magnetic susceptibility tensor (32,33). 
With sufficient structural constraint, a folded conformation can be determined at 
atomic resolution. The result of NMR structure determination is not one model, but a set of 
similar models, all of which fit the experimentally the structural constraints. The RMSD 
(root mean square deviation) between these models is used to assess how well the structure 
calculations have converged. The best structures have backbone RMSD values of less than 
1 Å. A final structure is obtained by averaging the models, and then finding the 
conformation of minimum energy that lies nearest to this average conformation. 
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During the three years of the PhD course, I mainly focused my work on genome 
browsing, gene cloning, protein expression and purification, preliminary biophysical 
characterization on copper proteins and NMR sample preparation. Specifically: 
A PSI-BLAST search was performed in order to find putative Cox17, Sco1/2, and 
Cox11 homologs in prokaryotic genomes. Multiple sequence alignments showing sequence 
similarity within these protein families were then obtained through ClustalW program. The 
search for sequences similar to Sco1/2 located 102 putative sequences from 69 bacterial 
and archaeal genomes. All Sco-like sequences have a CxxxC consensus motif. A DxxxD 
motif is also conserved together with a histidine residue. Multiple Sco-like sequences (up 
to five) can be found in a single organism. The genomic-context analysis for Sco1 genes 
supports the role of Sco proteins in copper homeostasis. However, at variance with Cox11, 
which, when present, is close to genes encoding COX subunits, a dramatic variability is 
observed in the localization of Sco genes suggesting a multifunctional role of this protein 
family. 
Human Cox17 and two different truncated forms of the human Sco1 gene, both lacking 
the N-terminal mitochondrial targeting sequence and the single-transmembrane, were 
cloned. The P174L-HSco1 pathogenic mutant was successfully produced using 
QuikChange mutagenesis kit. A protocol for expression and purification of unlabelled and 
labelled (15N and 13C/15N) samples for each of these proteins was developed. 
The degree of folding and thermal stability of the above proteins were evaluate by 
circular dichroism and thermofloor analysis. Size-exclusion chromatography coupled with 
multiangle light scattering was performed to verify the aggregation states of the different 
HSco1 truncated forms. We have succeeded in preparing Cu(I) or Ni(II) derivatives of 
WT-HSco1, P174L-HSco1 mutant and human Cox17 suitable for NMR structure 
determination. Cu(II) and Ni(II)HSco1 derivates have been obtained and crystals were 
produced in the latter case. The metal binding properties, for each of these proteins, were 
studied using NMR, EPR and UV/VIS spectroscopy. The red-ox potentials of WT-HSco1 
and P174L-HSco1 were also measured through fluorescence spectroscopy. 
Human SOD1, in which the non-conserved cysteine residues, Cys6 and Cys111, were 
mutated to Ala and  Ser respectively (AS form), were expressed and purified. A protocol 
for the preparation of fully reduced and demetallated SOD1 forms was also developed. 15N 
labelled apo and metallated SOD1 samples were prepared for NMR analysis. Size-
exclusion chromatography was performed to verify the aggregation states of the SOD1 
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protein under different oxidation and metallation states. Cicular dichroism measuraments 
were performed to estimate the secondary structure content of the different forms of SOD1. 
WT-human SOD1, containing the non-conserved cysteine residues, Cys6 and Cys111 
were also expressed and purified. To determine the propensity for oligomerization of the 
mature, i.e., disulfide-intact, WT human SOD1 under the relatively mild conditions likely 
to be encountered by the protein in vivo, 100uM samples of apo, partially and fully 
metallated SOD1 were incubated at 37°C. These sample allowed also to investigate the 
roles of metallation in hindering or promoting the oligomerization. Changes in secondary 
structure were monitored by CD spectroscopy, and changes in the aggregation state were 
followed by gel filtration chromatography and ThT  binding fluorescence. Variation of free 
thiols during the incubation, in order to investigate the possible formation of an 
intermolecular disulfide bonds during the aggregation process, was monitored by 4-
acetamido 4' maleimidylstilbene-2,2'-disulfonic acid (AMS). The covalent nature of protein 
aggregates was confirmed analyzing the persistence of the oligomeric species in presence a 
chaotropic agents as guanidinium hydrochloride, which disrupts hydrogen bond networks 
in the secondary and tertiary structure, but not the possible disulfide. 
The results and findings related to the above-mentioned proteins are reported in the 
following articles. 
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Cytochrome c oxidase (COX) is a multi-subunit enzyme of the mitochondrial respiratory chain. Delivery
of metal cofactors to COX is essential for assembly, which represents a long-standing puzzle. The
proteins Cox17, Sco1/2, and Cox11 are necessary for copper insertion into CuA and CuB redox centers
of COX in eukaryotes. A genome-wide search in all prokaryotic genomes combined with genomic context
reveals that only Sco and Cox11 have orthologs in prokaryotes. However, while Cox11 function is
confined to COX assembly, Sco acts as a multifunctional linker connecting a variety of biological
processes. Multifunctionality is achieved by gene duplication and paralogs. Neighbor genes of Sco
paralogs often encode cuproenzymes and cytochrome c domains and, in some cases, Sco is fused to
cytochrome c. This led us to suggest that cytochrome c might be relevant to Sco function and the two
proteins might jointly be involved in COX assembly. Sco is also related, in terms of gene neighborhood
and phylogenetic occurrence, to a newly detected protein involved in copper trafficking in bacteria
and archaea, but with no sequence similarity to the mitochondrial copper chaperone Cox17. By linking
the assembly system to the copper uptake system, Sco allows COX to face alternative copper trafficking
pathways.
Keywords: cytochrome c oxidase ¥ enzyme assembly ¥ copper trafficking ¥ genomic-context ¥ paralogs ¥ origin of
mitochondria
Introduction
Cytochrome c oxidase (COX) is an enzyme (EC 1.9.3.1) which
reduces oxygen to water and generates the proton gradient that
drives ATP synthesis. COX is a multi-subunit complex1,2 which
requires a large protein machinery for its assembly.3 It also
contains several metal cofactors, whose insertion and binding
in the proper subunit is required to produce the final, active
enzyme.4 It has been shown that the mammalian enzyme is
present in a dimeric form.2
Mitochondrial COX (aa3-type), present in all the eukaryotic
organisms characterized so far, contains two copper centers,
designated CuA and CuB. CuA, present in subunit II of COX
(Cox2), is formed by two copper ions bound to two His and
two bridging Cys residues of the consensus motif HxnCxExCGx2-
Hx2M. CuB, present in subunit I of COX (Cox1), is formed by a
copper ion, with a binding motif Hx3Yx44HH, coupled to heme
a3, thus forming a binuclear iron/copper center.2 The CuA
center receives the electron from cytochrome c (cyt c) and
transfers it to heme a and finally to the heme a3-CuB center.5
Three subunits (Cox1, Cox2 and Cox3) are encoded by the
mitochondrial genome and the remaining subunits are en-
coded by the nuclear genome, therefore subunits synthesized
in two compartments must be coordinately recruited to as-
semble in mitochondria.3
Many bacteria and archaea contain an aa3-type COX com-
plex with an arrangement similar to that of the mitochondrial
enzymes.6 The prokaryotic aa3-type COX contains identical
redox centers and homologous core polypeptides (subunits I
and II) to the mitochondrial COX.1 In some bacterial aa3-type
COX, a cyt c is fused to the C-terminus of Cox2 (caa3-type COX).
In bacterial species, it is often found in addition to, or instead
of aa3-type, a cbb3-type COX which, however, lacks the CuA
center.7
It is now well-established that free metal ions are not present
in the cytoplasm while they are always bound to proteins, called
metallochaperones, which transfer them to the requiring target
proteins.8 In several cases, metal trafficking occurs through a
cascade of transfers which involves a series of proteins. Among
them there are soluble metal transporters and membrane
proteins, like ATPases and permeases, which allow transfer of
the metal across membranes, thus controlling metal import/
efflux in the cell or its transfer from one cellular compartment
to another.9 While these pathways start to be unraveled for
some processes, like copper insertion into multicopper oxidases
and superoxide dismutase, little is known on the metal inser-
tion in the COX subunits.
In eukaryotes, it has been found that three proteins, Cox17,
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Sco1, and Cox11 are required for copper delivery to COX
(reviewed in ref 4). Cox17 is a soluble protein of 70 amino
acids involved in providing copper ions for formation of both
CuA and CuB sites in mitochondria. Cells lacking Cox17 are
respiratory deficient, but this defect is complemented by
addition of exogenous copper to cells.10 In Cox17, three out of
six conserved cysteines are present in a CCxC sequence motif,
essential for Cu(I) binding.11 Sco1 and Cox11 are involved,
together with Cox17, in copper delivery to CuA and CuB,
respectively.12,13 Both Sco1 and Cox11 contain a single trans-
membrane helix in the N-terminal segment which anchor them
to the inner mitochondrial membrane. The specific function
of both proteins is not clear. It has been shown that while the
lack of Cox17 can be compensated by exogenous copper
supply,10 the lack of Sco1 cannot be and Sco1 deficient cells
are not able to form a functionally active COX enzyme.12 Some
eukaryotes contain another protein, highly similar to Sco1,
called Sco2, whose role in copper insertion into CuA is also not
yet fully elucidated.12 Sco2 is able to restore respiration in
Cox17, but not in Sco1 mutants, indicating that Sco1 and Sco2
have overlapping but not identical functions. While the precise
role of each of these proteins in copper incorporation remains
unclear, recent studies have revealed that inherited mutations
in these proteins can result in severe pathology in human
infants in association with cytochrome c oxidase deficiency.14,15
Correlating data on mitochondrial proteins with information
about their evolutionary histories might yield insights into the
nature and function of eukaryotic cells,16 aimed at ultimately
understanding the molecular bases of mitochondrial disorders,
which represent some of the most common metabolic genetic
diseases.17 Given the similarity between mitochondrial and
prokaryotic oxygen respiratory chain it is very likely that some
of the proteins required for copper delivery to the respiratory
complexes are conserved. Indeed, proteins homologous to the
eukaryotic COX accessory proteins have been located in some
bacterial species even if scattered pieces of information are
available. Combining genomic-context analysis (conserved
neighborhood, gene fusions, phylogenetic occurrence) with
homology-based methods (genome search, structure modeling,
correlated mutation analysis) one might be able to predict both
the pathway in which a protein operates and its molecular
function.18 Therefore, to have a comprehensive description of
proteins involved in copper delivery to COX, we have per-
formed a genome-wide search in prokaryotic organisms for
sequences sharing similarity with human Cox17, Sco1/2, and
Cox11, and we extended the analysis to genes close to the found
proteins. The results shed a new light on the COX assembly
system and are discussed in connection with the changing
redox and copper metabolisms of the cellular compartment
where the soluble COX assembly components are carried or
located (i.e., the periplasm in Gram-negative bacteria and the
intermembrane space in mitochondria). The evolutionary
history of this metalloenzyme is linked to the endosymbiotic
origin of mitochondria.
Procedures
Sequence Search and Genomic-Context Analysis. We per-
formed a PSI-BLAST search (E < 0.01)19 in order to find putative
Cox17, Sco1/2, and Cox11 homologs in genomic databanks,
using the consensus motif to refine the search.20 Multiple
sequence alignments were obtained with the program CLUST-
ALW.21 The genomic-context analysis for the selected proteins
was performed on fully sequenced genomes and fragments
containing gene clusters, which were available at December
2003 in the GenBank (http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?db)Genome). A genomic-context network was built
with the program STRING (http://www.bork.embl-heidelberg.de/
STRING), which integrates the three types of genomic context
(conserved neighborhood, gene fusion and co-occurrence) into
a single score function.22 Assignment of functional categories
of genes was derived from the Clusters of Orthologous Groups
(COGs) database23 and automatically made by STRING. When
genes could not be assigned to COGs they are referred to as
nonsupervised orthologous groups (NOGs). The presence of
functional modules24 was deduced from the network.
3D Structural Models. Structural models of various Sco
orthologs and paralogs as well as of some cyt c domains were
generated using the program Modeller-6v2.25 The input align-
ments for Modeller were obtained with CLUSTALW.21 Models
of Sco paralogs were created using as template the only
experimentally determined structure of a member of this class,
Sco from Bacillus subtilis.26 For cyt c domains every model was
created using as template the structure deposited in the Protein
Data Bank with the closest sequence to the target protein. The
program MOLMOL27 was used to analyze the structural models
in terms of per-residue solvent accessibility and surface
properties (shape, electrostatics).
Correlated Mutation Analysis. To obtain the ‘interaction
index’ between two selected proteins (A and B),28 their se-
quence alignments were reduced to the set of organisms
common to the two proteins, and a virtual concatenated
alignment was generated by attaching the sequence of protein
A to the sequence of protein B from the same organism. A
‘correlation value’ was calculated with the program PlotCorr29
for every pair of positions in the concatenated alignment. The
pairs were divided into three sets: two for the intraprotein pairs
(CAA and CBB; pairs of positions within protein A and within
protein B) and one for the interprotein pairs (CAB; one position
from protein A and one from protein B) and the ‘interaction
index’ was calculated by comparing the distribution of inter-
protein correlation values with the two distributions of intra-
protein correlation values. Interaction indexes > 2.0 correspond
mostly to true interactions. This method is called in silico two-
hybrid system.28 Interprotein pairs were used to predict inter-
protein contacts as previously described.30 For this analysis, we
considered only correlated residue pairs with the highest
correlation values (>0.75) and, for each protein, only those
residues involved in at least three predicted contacts with the
other protein.
Results
Sequence Search. A search in prokaryotic genomes for
sequences similar to human Cox17 produced no results. In
contrast, the search for Cox11-like sequences located 36
sequences, all containing a CFCF consensus motif, from 36
genomes of Gram-negative bacteria. Cox11-like sequences were
found in 21 out of 89 fully sequenced genomes of Gram-
negative bacteria, Cox11 is not found in Gram-positive bacteria
and archaea, even if these organisms do contain a Cox1 subunit
with a classical CuB center. The search for sequences similar
to Sco1/2 located 102 putative sequences from 69 bacterial and
archaeal genomes. Sco-like sequences were found in 38 out of
the 131 fully sequenced bacterial genomes, and in 2 out of the
17 fully sequenced archaeal genomes. For 12 prokaryotic
complete genomes, which contain an aa3-type COX with a CuA
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center, no Sco homologue is present. All Sco-like sequences
contain a CxxxC consensus motif. A DxxxD motif is also
conserved together with a histidine residue. Sco1-like se-
quences from Gram-positive bacteria also contain a MxxxM
motif, located two residues downstream from CxxxC. Instead,
all the eukaryotic Sco1-like sequences share the motif Cxxx-
CxxxxE(D)K(R), i.e., with two adjacent oppositely charged
residues after CxxxC. Pairwise residue identities of 20 ( 7% and
37 ( 5% are found over all Sco-like and all Cox11-like
sequences, respectively, indicating that Cox11-like sequences
are more conserved than Sco-like (see Table 1S and 2S of
Supporting Information).
Genomic-Context Analysis. We performed a genomic-
context analysis in order to predict possible functional associa-
tions of Sco and Cox11 homologues with other proteins, based
on their coding gene position, phylogenetic occurrence and
gene fusions.31,32 Generally, in prokaryotes, genes which encode
the various COX subunits are close each other and are all
present or absent together. The conservation of relative gene
position derives from the organization of prokaryotic genes into
operons which encode proteins involved in the same overall
process. This might be then used to extrapolate the findings
to species with little or no operon structure, such as eukaryotes,
to predict functional relations among genes also for these
organisms.33
Context of Cox11 and Sco Genes. The results on gene
neighborhood are summarized in Figure 1 (see Figure 1S of
Supporting Information for an extended version). Analyzing the
COX operon we found that the Cox11 gene, when present, is
close to genes encoding COX subunits. The only exception is
represented by Pseudomonas syringae, where Cox11 is far from
Cox1 and Cox2 genes but it is found adjacent to Sco (see Figure
1). In this peculiar case, Cox2 lacks the ligands of the CuA
center.
At variance with Cox11, a dramatic variability is observed in
the localization of Sco genes. Multiple Sco-like sequences (up
to five) can be found in a single organism in different genomic
contexts. When five Sco homologues are present (i.e., in
Pseudomonas putida and Pseudomonas fluorescens) one gene
is close to caa3-type COX genes, one is close to a protein of
unknown function (Hyp1 hereafter, COG2847), one is close to
a multicopper oxidase and it is fused to a cyt c, and the last
Figure 1. Gene neighborhood analysis of cytochrome c oxidase accessory proteins. Operon and divergon structures of genes encoding
Sco and Cox11 domains and their neighbors are shown. Genes are represented as arrows. The color code is illustrated in the inset.
Unrelated genes are shown as gray arrows. For all Sco and most Hyp1 genes is given the numbers they have in the genomes. Gram-
negative bacteria are indicated in blue; Gram-positive bacteria are indicated in orange, and Archaea in green. The correspondence of
the full species names to the ones used in the figures is as follows: PP: Pseudomonas putida KT2440; Bcep: Burkholderia fungorum;
Rs: Ralstonia solanacearum; Aq: Aquifex aeolicus; Pspto: Pseudomonas syringae pv. tomato str. DC3000; XCC: Xanthomonas
campestris pv. campestris str. ATCC 33913; NMA: Neisseria meningitidis serogroup A strain Z2491; NMB: Neisseria meningitidis
serogroup B strain MC58; Blr: Bradyrhizobium japonicum; BME: Brucella melitensis; CV: Chromobacterium violaceum ATCC 12472;
SynW: Synechococcus sp. WH8102; Slr: Synechocystis sp. PCC 6803; PMT: Prochlorococcus marinus MIT9313; DR: Deinococcus
radiodurans; LA: Leptospira interrogans serovar lai str. 56601 chromosome I; Sco: Streptomyces coelicolor A3(2); SAV: Streptomyces
avermitilis MA-4680; BH: Bacillus halodurans; BA: Bacillus anthracis A2012; Bsu: Bacillus subtilis; BC: Bacillus cereus ATCC
14579;OB: Oceanobacillus iheyensis HTE83; NCgl: Corynebacterium glutamicum ATCC 13032; CE: Corynebacterium efficiens YS-314;
Dip: Corynebacterium diphtheriae; PAE: Pyrobaculum aerophilum; APE: Aeropyrum pernix.
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two are adjacent each other and close to another multicopper
oxidase. When less than five Sco homologues are present, they
can be either close to one of the above-mentioned proteins or
to other copper-dependent enzymes, i.e., nitrite reductase or
cbb3-type COX. Sco-like sequences of the same organisms can
be as different as to have only 15% residue identity.
Occurrence of Cytochrome c Domains. A Sco gene is found
close to COX genes only when a cyt c domain is attached to
the C-terminus Cox2 (caa3-type COX). This occurs in ten Gram-
negative bacteria. Cyts c fused to Cox2 are also found in Gram-
positive bacteria but, in these organisms, Sco is not close to
COX genes. In the case of Sco genes close to multicopper
oxidases (i.e., in Pseudomonas and Ralstonia), a cyt c domain
with a single CxxCH heme binding motif is present in the same
operon, either fused to the periplasmic component of an ABC-
type amino acid transporter (and the fused gene is designated
MofC,34 NOG13183) or, remarkably, to Sco itself. In some
genomes Sco is found in the vicinity of a gene encoding a
copper nitrite reductase (NirK, COG2132), which catalyzes the
reduction of nitrite to nitric oxide, a key step in the anaerobic
denitrification process, and NirK also contains a cyt c fused at
its C-terminus. In Ralstonia, a Sco gene is found in the cbb3-
type COX operon, adjacent to a subunit (FixP, COG2010)
containing a c-type heme. Also in Pseudomonas stutzeri, a Sco
homolog, designated ScoP, is close to the operon encoding a
cbb3-type COX and it is located downstream of the FnrA gene,
which encodes a regulator of the cbb3-type COX gene expres-
sion.35
New Potential Copper Transporter. Some Sco genes are
close to a protein of yet unknown function that we call Hyp1
(COG2847). This close neighborhood occurs in a large number
of organisms, even when aa3-type COX genes are missing. For
instance, Hyp1 is present together with a Sco gene in the
pathogens Neisseria gonorrheae and Neisseria meningitidis,
which only have a cbb3-type COX, thus lacking the CuA center.36
We therefore analyzed the sequence and the genomic context
of this unknown protein to find possible relationships with
known genes.
Hyp1 is a soluble protein mostly occurring in Gram-negative
bacteria, and consisting of about 150 amino acids. A Hyp1 gene
is also found in a few Gram-positive bacteria where it is
characterized by the presence of a single transmembrane
segment. No homologues of Hyp1 are found in eukaryotes. All
Hyp1 sequences share a conserved H(M)x10Mx21HxM consen-
sus motif (Banci L., Bertini I., Ciofi-Baffoni, S., Katsari E.,
Kubicek K., manuscript in preparation) similar to the Cu(I)
binding motif of CopC (COG2372), a well-characterized peri-
plasmic protein involved in copper resistance.37 CopC is able
to selectively bind Cu(I) and Cu(II) at different sites: Cu(II) is
bound by two histidines, an aspartate and a glutamate, whereas
Cu(I) is bound by a histidine and three methionines. A shift in
the redox state causes the copper ion to migrate between the
two sites. Thus, CopC acts as a molecular switch that facilitates
Cu(II) import to the cytoplasm via the inner membrane protein
CopD (COG1276) or Cu(I) export via the outer membrane
protein CopB.37 In several organisms, we found a Hyp1 gene
close to a gene encoding CopC fused to CopD (see Figure 1).
Up to three Hyp1 genes can be found in a single organism
in different genomic contexts. Hyp1 can be found either close
to a Sco gene or to a copper-transporting outer membrane
channel protein (NosA or OprC, COG1629)38 of the family of
TonB receptors, which are mostly involved in siderophore-iron
uptake.39 NosA is known to be involved in the copper delivery
pathway for the CuA site of the nitrous oxide reductase,40 which
is the terminal oxidoreductase of a respiratory process that
generates N2 from NO3-. The observed regulatory responses
indicate that the outer membrane protein, NosA, functions in
anaerobic metabolism, and since it is repressed by Cu, its role
seems to be limited to conditions in which the Cu supply is
low.40 In some organisms, a Hyp1 gene is fused to a membrane
protein of unknown function (Hyp3 hereafter, COG4549), while
in other organisms Hyp1 and Hyp3 are encoded by two
separated genes which form a cluster with the fusion gene
encoding CopCD (COG2372 and COG1276) (see Figure 1). In
this case, CopC lacks the Cu(I) binding motif due to internal
sequence deletion of the Met-rich region, but maintains all four
Cu(II) ligands. It is therefore not unlikely that, in a hypothetical
interaction between CopC and Hyp1, a shift in the redox state
may cause the copper ion to migrate between the Cu(II)
binding site of CopC to the Met-rich region of Hyp1.
The genomic-context analysis strongly suggests a role of
Hyp1 in copper trafficking in prokaryotes.
Genomic-Context Network. A genomic-context network was
obtained with the program STRING,22 which integrates infor-
mation on conserved neighborhood, gene fusion and co-
occurrence (Figure 2). The network shows that the orthologous
group of Cox11 (COG3175) is densely linked to the subcluster
(or functional module) of proteins involved in (c)aa3-type COX
assembly, and it appears to have a univocal function in this
process. Cox11 is linked, among others, to Surf1 (COG3346).
This latter protein is conserved in eukaryotes and mutations
in its gene are observed in patients with Leigh syndrome and
COX deficiency.41 Surf1 and Cox11 are both linked to a protein
of unknown function (Hyp2, NOG10163), which is found in the
COX operon (Figure 1). Similarly to Sco, Hyp2 proteins have a
conserved CxxxC motif and a thioredoxin-fold, as predicted by
threading methods, but lack the DxxxD motif and the histidine
(sequence identity to Sco ) 7(3%). Surf1 is also linked to Cox10
and Cox15, which are involved in the synthesis of heme a
before its insertion into Cox1.15,42
Within a genomic-context network orthologous groups that
connect separate subclusters tend to be multifunctional and/
or to play a role in different processes.24 The multifunctionality
does not necessarily reside in the individual proteins of the
orthologous group, but can be achieved by gene duplication,
leading to different functional associations and assignment to
multiple subclusters.24 This is the case of Sco (COG1999), Hyp1
(COG2847), and cyt c (COG2010), which act as linkers con-
necting different functional modules. In particular, the sub-
clusters of (c)aa3-type and cbb3-type COXs are connected
through a single linker, i.e., cyt c (COG2010), while (c)aa3-type
COX and the copper uptake subclusters are linked through a
two-linker-connection involving the orthologous groups of Sco
and Hyp1. Importantly, the linker proteins are more conserved
than those in nonlinkers and mutations in their sequences have
a significantly higher effect on biological processes.43
3D Structural Models. Structural models were built for all
five Sco paralogs of Pseudomonas putida and for the neighbor
cyt c domains, the models of yeast and human Sco1 and Sco226
and of human mitochondrial cyt c44 being available as well as
the experimental structure of cyt c from yeast.45 All the three
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cyt c domains present in the genome of Bacillus subtilis were
also modeled, including the cyt c attached to the C-terminus
of Cox2. The electrostatic potential surfaces of Sco paralogs
and cyt c domains of four different organisms, i.e., two
eukaryotes, a Gram-negative and a Gram-positive bacterium,
are compared in Figure 3. The CxxxC motif is exposed to the
solvent in all Sco models but the electrostatic surface in the
proximity of the motif is variable. In the human and yeast
proteins, as well as in Sco from Bacillus subtilis, the region
around the CxxxC motif is largely negative and surrounded by
a ring of positive charges. On the contrary, among the five Sco
paralogs from Pseudomonas putida, a large negative patch is
present only in the Sco paralog fused to cyt c and close to a
multicopper oxidase, while in the other Sco paralogs this
negative region is reduced, at various extent, due to the
presence of scattered neutral or positively charged residues.
In particular, the electrostatic potential surface of Sco paralogs
encoded by two adjacent genes in Pseudomonas putida are
remarkably different.
Human and yeast mitochondrial cyt c show surface comple-
mentarity with both Sco1 and Sco2 from the corresponding
organisms in proximity of the exposed heme edge, where a
number of lysine and arginine residues form a positive patch.
The cyt c domain attached to the C-terminus of Cox2 in Bacillus
subtilis also shows a positive region surrounded by a ring of
negative charges on the side of the exposed heme edge. Also
in this system the electrostatic surface of cyt c is complemen-
tary to that of Sco, around the CxxxC motif. In contrast, in the
other two cyt c domains of Bacillus subtilis the face corre-
sponding to the exposed heme edge is largely neutral. Elec-
trostatic surface complementarity is also present between some
Sco paralogs and neighbor cyt c domains of Pseudomonas
putida. This is more evident in the case of fused Sco and cyt c
(see Figure 3).
Figure 2. Functional modules in a genomic-context network obtained with the program STRING.22 Shown are the orthologous groups
linked via genomic context to COG1999 (Sco) either directly or via another COG (network depth ) 2). For each COG the gene name is
indicated. Color coding of genes is the same as that reported in Figure 1. The three types of context evidence (gene order, gene fusion
and co-occurrence) are indicated by separate lines in the network (full lines correspond to a combined association score > 0.4 and
dashed lines to a score <0.4 and >0.3). The three subclusters ((c) aa3-COX, cbb3-COX and copper uptake) are connected to each other
through either one orthologous group (COG2010) or one link (between COG1999 and COG2847).
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Correlated Mutation Analysis. Correlated mutation pattern
can be defined as the tendency of residues to be conserved or
to mutate in tandem between (sets of) sequences. Correlated
mutations have been suggested to be related to protein-protein
interactions.30 Therefore, we analyzed them to predict potential
interactions of Sco. For this analysis we selected all Sco
sequences close to caa3-type COX genes or close to Hyp1 genes.
As mentioned above, in caa3-type COX a cyt c domain is
attached to the C-terminus of the Cox2 subunit, whose N-
terminal domain contains the CuA center. We analyzed the
correlated mutation pattern of the following protein/domain
pairs: Sco/cyt c, CuA/cyt c, Sco/CuA (Figure 2S of Supporting
Information) and Sco/Hyp1 (Figure 3S of Supporting Informa-
tion). On the basis of interaction indexes calculated from
correlated mutations (see Methods), one might speculate a
possible interaction for the pairs Sco/cyt c and Sco1/Hyp1. The
values of interaction indexes are 4.2 and 3.9 for the pairs Sco/
cyt c and Sco/Hyp1, respectively, which are equal or even larger
than those found for the CuA/cyt c and Sco/CuA pairs (2.8 and
3.8, respectively), for which experimental evidence of interac-
tion was reported.46,47
The information from correlated mutation analysis might
also suggests an evolutionary compensation between pairs of
positions which are possibly in physical proximity. Therefore,
it might also highlight potential interaction sites.30 For the Sco/
cyt c pair, correlated mutations were mapped on the structure
of Sco from Bacillus subtilis and of the cyt c domain attached
to the caa3-type COX from the same organism (see inset of
Figure 3). Remarkably, correlated residues are clustered around
the CxxxC motif of Sco and around the exposed heme edge of
cyt c. These are the two regions which also show complemen-
tary electrostatic surfaces in the structural models of Sco
paralogs and cyt c domains. For the Sco/Hyp1 pair the mapping
of correlated mutations on the protein structure of Sco
indicates that correlated residues are again clustered around
the CxxxC motif, whereas in Hyp1 they are close to methionines
of the consensus motif, and indicate that this region could be
part of the surface interacting with Sco.
For the CuA/cyt c and Sco/CuA pairs a direct interaction has
been experimentally proved.46 Our correlated mutation analysis
indicates that correlated residues are close to the electron-
transfer sites of CuA and cyt c and to the conserved CxxxC motif
of Sco.
Discussion
Possible Roles of Cox11 and Sco. In the absence of direct
experimental data, some clues on the properties of Cox11, Sco
and related proteins, and their involvement in copper delivery
to COX, can be gained from their genomic context, including
operon structures and conserved domain fusions in prokary-
otes.32
Cox11 has been shown to be involved in the insertion of CuB
in Rhodobacter sphaeroides13 and, indeed, we found Cox11
genes in the aa3-type COX operon in a large number of Gram-
negative bacteria. No Cox11 genes were found in the proximity
of quinol oxidases, which contain only the CuB site and use
the lipid-soluble quinol as electron carrier. This indicates that
the role of Cox11 is confined to a function in copper delivery
to CuB in aa3-type COX, whereas alternative copper transport
systems could be involved in copper delivery to quinol oxidases.
The absence of Cox11 in Gram-positive bacteria and archaea
also suggests a different mechanism of copper incorporation
in CuB in these organisms as well as in some Gram-negative
bacteria. For example, it is known that a copper transporting
P-type ATPase, called FixI, is involved in copper delivery to the
CuB site of cbb3-type COX in Rhizobia.48
The function of Sco is more complex and less univocal.
Multiple Sco-like sequences can be found in a single organism.
These might be all derived from a gene duplication event and
can be considered paralog proteins. In support of this, in some
bacteria two Sco genes are found in adjacent positions and in
eukaryotes two paralog proteins, Sco1 and Sco2, exist. The
variety in number and localization of Sco genes suggests that
Sco paralogs can be involved in other functions besides copper
insertion into CuA. Indeed, some Sco genes are neighbors to
copper-dependent enzymes others than COX. Furthermore, the
variability of the electrostatic surface features of the 3D
structural models of Sco paralogs (Figure 3) may suggest their
involvement in different partnerships.
Connection between Redox and Copper Homeostasis. In
this analysis, a correlation emerges between Sco and cyt c. Cyt
c, which acts as an electron donor for the CuA center in Cox2
and for other copper-dependent enzymes. The structure of Sco
has a thioredoxin fold and a thiol-disulfide oxidoreductase
function has been proposed for this protein.26 Therefore, Sco
might be involved, in addition to its well documented role in
copper transfer to CuA,4 in the reduction of disulfide bonds of
CuA prior to copper insertion. Also, the two cysteines of the
CxxxC motif of Sco should remain in a reduced state, despite
Figure 3. Electrostatic surface potential of structural models of
Sco1 paralogs and cyt c domains of four different organisms.
The positively, negatively charged and neutral amino acids are
represented in blue, red and white, respectively. The genomic
context is indicated with arrows above each protein. Color coding
of genes is the same as that reported in Figure 1. The inset in
the bottom right shows the mapping of correlated mutations (see
text for details) on the surfaces of Sco1 and cyt c from Bacillus
subtilis. Correlated residues are shown in magenta. A yellow
surface indicates no correlations. A ribbon representation of the
two proteins is also shown. The cysteines of the CxxxC motif of
Sco1 and of the CxxC motif of cyt c are shown in yellow, the
heme cofactor of cyt c and the conserved His of Sco1 are shown
in green. The orientation of all Sco1 and cyt c structures is chosen
to allow to see the face where lie the CxxxC motif of Sco1 and
the exposed heme edge of cyt c, respectively.
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the oxidizing environment, where it is located. Thioredoxins
are usually associated to transmembrane electron transporters
involved in a disulfide bond reduction cascade which carries
electrons (reducing equivalents) from the cytoplasm to the
periplasm, which is a strongly oxidizing environment.49 As we
did not find any correlation between Sco and transmembrane
electron transporters, a candidate molecule for reducing the
disulfide of the CxxxC motif might be cyt c. In eukaryotes, cyt
c is required not only for electron transfer but also for COX
assembly through a still unknown mechanism. Indeed, in
mitochondria lacking the folded and mature (heme-containing)
form of cyt c, the COX subunits are not properly assembled.50,51
It is therefore likely that cyt c and Sco are jointly involved in
enzyme assembly.
Some Sco paralogs in bacteria and archaea are related, both
in terms of gene neighborhood and phylogenetic occurrence,
to Hyp1 (COG2847), a conserved bacterial protein which
possesses a Met-rich motif potentially involved in copper
binding. Several periplasmic proteins involved in copper ho-
meostasis have been identified so far (e.g., CopC and CueO),
which adopt a Cu(I)-thioether coordination chemistry involving
Met-rich motifs.9 The periplasm is the cell compartment of
Gram-negative bacteria where COX and other copper enzymes
acquire their metal cofactors. Under normal conditions, the
copper concentration in the periplasm is not limiting.9 How-
ever, under conditions of low copper supply, a more efficient
copper uptake mechanism might be activated. Hyp1 might be
expressed only in oxygen and copper limiting conditions, as it
has been demonstrated for one of its neighbor genes, NosA,
which encodes an outer membrane channel responsible for
copper uptake in the periplasm.38,40 As there are no prokaryotic
homologues of the mitochondrial copper chaperone Cox17, is
proposed that Hyp1 takes the role of Cox17 in bacteria and
archaea, probably trafficking Cu(I) ions only in copper starving
conditions and/or anaerobiosis. Hyp1 has been expressed and
structurally characterized in our lab and its metal binding
properties have been determined, demonstrating that Hyp1 is
indeed a Cu(I) binding protein (Banci L., Bertini I., Ciofi-
Baffoni, S., Katsari E., Kubicek K., manuscript in preparation).
In the genomic-context network, we identified Sco and Hyp1
as linkers, which are responsible for networking two functional
modules: one involved in (c)aa3-type COX assembly and one
in copper uptake (see Figure 2). Therefore, the association
between Sco and Hyp1 may represent the event at the origin
of copper insertion into subunit II of COX.
A potential interaction of Sco with Hyp1 and cyt c is
consistent with the values of the interaction index calculated
from correlated mutations. In addition, 3D structural models
of Sco paralogs and neighbor cyt c domains from different
organisms highlight an electrostatic surface complementarity
between the two proteins around their active sites, that are the
regions where correlated mutations are also clustered (Figure
3).
From the present analysis of protein sequences and of their
genomic context, we can summarize that Sco could play a role
in delivering copper to a variety of different enzymes whose
activity depends on copper, and/or to play a role as a
thioreductase, keeping the residues that coordinate copper in
those enzymes in a reduced state for copper delivery.
Thanks to its dual nature and the paralogs, in response to
variations in oxygen levels and copper availability occurred
during the evolution,52 Sco may have led to the incorporation
of a copper cofactor into subunit II of COX, possibly being
recruited among thioredoxins responsible for heme incorpora-
tion into apocytochromes.53 In support of this, a possible
evolutionary relationship exist between subunit II of caa3-type
COX and the dihaemic subunit (called FixP) of cbb3-type COX.7
This is based on the observation that the cyt c domain fused
at the C-terminus of Cox2 is quite similar to the second cyt c
domain of FixP. Furthermore, the binding site of the first c-type
heme of FixP seems to be part of the binding site of CuA: the
axial ligands of the heme, the histidine and the methionine,
are ligands of the copper center.7
Conclusions
From Bacteria to Mitochondria. It is well established that
mitochondria originated from ancient invasion of Gram-
negative R-proteobacteria (endosymbiont) into an archaea-type
or an eukaryotic host. In losing their autonomy, endosymbionts
elaborated mechanisms for organelle biogenesis and metabolite
exchange, thus acquiring many host-derived properties.54 A
fundamental step in this process was the adaptation to the
metal uptake mechanisms of the host. As a consequence the
functional link between Sco and the potential copper trans-
porter Hyp1 was lost and a new link was established between
Sco and the mitochondrial copper chaperone Cox17, this latter
protein being only present in eukaryotes, including the protists
Plasmodium falciparum and Chlamidomonas reinhardtii. On
the other hand, Hyp1 is conserved among the R-proteobacteria
(see Figure 1S of Supporting Information) and occurs in many
other prokaryotes, including the Neisseria and Vibrio pathogens,
but it lacks a homologue among the eukaryotes. Therefore
Hyp1 represents a potential drug target.
In the lifestyle transition from free-living versus obligate
intracellular, the adaptation to the copper transport and
metabolism of the host was possible thanks to the pivotal role
of the multifunctional protein Sco, while keeping unvaried the
core components of the COX assembly module inherited from
Gram-negative R-proteobacteria (see Figure 2). This fits with
the observation that most of the ancestral bacterial genes
present in the mitochondrial genome are involved in bioen-
ergetic and translational processes, while novel genes recruited
from the host nuclear genome are primarily involved in
transport and regulatory functions.55,56
Gene duplications are regarded as an efficient engine that
enables rapid responses to alterations in the environmental
conditions.57 After gene duplication, multiple partnerships of
a single ancestral gene may become separately allocated among
paralogs by acquisition of functional specialization. The pres-
ence of two Sco paralogs in eukaryotes (i.e., Sco1 and Sco2)
can be rationalized in the light of the genomic-context analysis
of prokaryotic paralogs: one Sco gene may preferentially
interact with subunit II of COX thus favoring COX assembly,
while the second gene may assist the metallochaperone Cox17
which is responsible for copper recruitment in the inter
membrane space of mitochondria. In this scenario, it is possible
that the two eukaryotic Sco paralogs interact to promote copper
insertion into CuA. Similar conclusions for human Sco genes
were reached using an experimental approach.58
To conclude, we found that Cox11 is highly networked within
the COX assembly module and likely fulfills a univocal function
in COX assembly, while Sco represents a multifunctional linker
or adaptor which allows the COX enzyme to interface with
alternative redox and copper metabolisms.
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The solution structures of apo, Cu(I), and Ni(II) human Sco1 have
been determined. The protein passes from an open and confor-
mationally mobile state to a closed and rigid conformation upon
metal binding as shown by electrospray ionization MS and NMR
data. The metal ligands of Cu(I) are two Cys residues of the CPXXCP
motif and a His residue. The latter is suitably located to coordinate
the metal anchored by the two Cys residues. The coordination
sphere of Ni(II) in solution is completed by another ligand, possibly
Asp. Crystals of the Ni(II) derivative were also obtained with the
Ni(II) ion bound to the same His residue and to the two oxidized Cys
residues of the CPXXCP motif. We propose that the various struc-
tures solved here represent the various states of the protein in its
functional cycle and that the metal can be bound to the oxidized
protein at a certain stage. Although it now seems reasonable that
Sco1, which is characterized by a thioredoxin fold, has evolved to
bind a metal atom via the di-Cys motif to act as a copper chaperone,
the oxidized form of the nickel-bound protein suggests that it may
also maintain the thioredoxin function.
cytochrome c oxidase  NMR  x-ray  assembly factor
Sco is a family of proteins ubiquitous to all kingdoms of life.Ortholog and paralog genome browsing has shown that one or
more representative of this class are present in most bacterial and
eukaryotic genomes (1, 2). In the bacterial operons, Sco proteins
often are associated with copper enzymes, suggesting that they are
involved in the maturation or functioning of such enzymes (1).
Eukaryotic genomes contain two paralogs, Sco1 and Sco2 (3, 4),
both involved in copper-dependent assembly of cytochrome c
oxidase (CcO) (5).CcOcontains two functional copper ions located
in the binuclearCuA site and one located in the binuclearCuB-heme
a3 site (6). CcO is a multimeric enzyme complex embedded in the
inner mitochondrial membrane of all eukaryotes and in the plasma
membrane of prokaryotes, and it functions as terminal enzyme of
the respiratory chain (7). Sco1 was first suggested to be involved in
copper ion delivery to the CcO complex based on the observation
that, in the presence of high copper concentrations, overexpression
of either Sco1 or the homologous Sco2 can restore the CcO activity
of Saccharomyces cerevisiae strains lacking the gene of the mito-
chondrial copper chaperone Cox17 (8). Yeast strains lacking Sco1
also are respiratory deficient, and an excess of copper andor
overexpression of either Cox17 or Sco2 cannot compensate for the
Sco1-associated CcO deficiency (8). The absolute requirement of
Sco1 in the activation of CcO indicates that Sco1 functions down-
stream fromCox17 in the delivery of copper toCcO. Indeed, in vitro
Sco1 can receive copper from the copper chaperone Cox17 (9).
Human Sco1 (HSco1) is a 301-residue polypeptide anchored
through a single helix to the inner mitochondrial membrane of
eukaryotes (10). The functional part of the Sco1 protein is com-
posed of a single soluble domain, located in C-terminal region,
whereas the N terminus contains a mitochondrial-targeting se-
quence followed by a transmembrane helix (11). The structure of
the soluble domain was first resolved by NMR for apoSco1 from
Bacillus subtilis (12). The structure revealed a potential metal
binding site constituted by two Cys residues present in a conserved
motif CPXXCP and a fully conserved His residue, in agreement
with earlier extended x-ray absorption fine structure investigations
of yeast Cu(I)Sco1 (13). Besides extended x-ray absorption fine
structure data many other spectroscopic data on the human, yeast,
and B. subtilis Sco proteins have confirmed that the protein binds
Cu(I), Cu(II), and other metal ions (14–17). The fold of apoSco1
protein, which contains four -helices and seven -strands orga-
nized in two -sheets (12), is atypical for a metal chaperone given
that it resembles the fold of thioredoxins, which are enzymes
specialized for the reduction of protein disulfides (18). Also, the
x-ray structures of the apo forms of the B. subtilis Sco1 and HSco1
proteins have been determined (16, 19). Some crystals of B. subtilis
apoSco1 contained Sco1 with SOS bonds, thus supporting a role of
the protein in redox processes. In addition, it has been recently
suggested on the basis of the extreme sensitivity of the yeast
sco1-null mutant to hydrogen peroxide that HSco1 might function
as a mitochondrial redox signaling molecule (19). Thus, the specific
role of Sco1 in maturation of CcO, either as a copper chaperone or
connected with redox processes, is still elusive.
To date there are no structures available for anymetallated forms
of Sco1 proteins. The structure of the metal adducts is, however,
crucial for understanding the mechanism of Sco-mediated copper
insertion into CcO. We have succeeded in preparing a human
Cu(I)Sco1 derivative [hereafter referred to as Cu(I)HSco1] in vitro
and have determined its solution structure through NMR. We also
have investigated the structure of the Ni(II) derivative of HSco1 as
a model for the binding of bipositive metal ions like Cu(II). We
would like to stress that NMR solution structure determination of
metalloproteins is a difficult challenge as far as the protein metal-
binding mode is concerned because NMR does not provide direct
information on protein–metal interaction. In contrast, it is also
common that the crystallization procedures might provide deriva-
tives different than the physiological ones. Still, these derivatives
may be significant as models of transient species and for the
mechanism of action. Indeed, the x-ray structure of human
Ni(II)Sco1 [hereafter referred to as Ni(II)HSco1], also reported
here, displays a completely different metal binding with respect to
the solution structure, being the metal bound to the SOS bond of
the oxidized HSco1. Structural information for different conform-
ers of the same protein is extremely valuable because individual
structures often mimic transient species, which enable elucidation
of the mechanism of protein action.
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Here, we propose that the Cu(I)HSco1 species act as chap-
erones for copper ion delivery and that the specific oxidation of
metal-ligating thiolates of HSco1 could have a role in the transfer
of copper ions to CcO.
Results
Two truncated forms of the HSco1 gene have been engineered,
both lacking the N-terminal mitochondrial targeting sequence
and the single-transmembrane helix (Fig. 1). The two truncated
forms differ by a 14-aa segment at the N-terminal side. This
14-aa segment is rich in positively and negatively charged
residues and is predicted to be unstructured. Size-exclusion
chromatography equipped with multiangle light scattering shows
that the shorter apoHSco1 construct eluted in fractions corre-
sponding to a monomeric state for the protein, whereas the
longer construct eluted as a dimer (see Fig. 6, which is published
as supporting information on the PNAS web site). This obser-
vation suggests that the residues separating the transmembrane
helix from the folded domain are essential to promote dimer-
ization. In vivo studies also have shown that this N-terminal
region is crucial for yeast Sco1 function and cannot be replaced,
even by its Sco2 counterpart (20).
For the structural and electrospray ionization (ESI)-MS char-
acterization, the short construct of 170 aa (corresponding to
residue segment 132–301) of the HSco1 gene was used. Addi-
tionally, this construct contains an additional 4-aa segment
(GSFT), corresponding to the tobacco etch virus protease
recognition site at the N terminus (Fig. 1), thus producing a final
construct of 174 aa whose identity was confirmed by ESI-MS
analysis. The ESI-MS spectrum of the oxidized apoWT-HSco1
showed two main peaks corresponding to 9 and 10 ions, and
the deconvolution of the spectrum gave the expected molecular
mass of 19,741.3 Da. Incubation of oxidized HSco1 with 1 mM
DTT increased molecular mass by 2.3 Da (molecular mass 
19,743.9 Da), which indicates that the disulfide bridge in HSco1
could be reduced easily by 1 mM DTT.
Reconstitution of Fully Reduced HSco1 with Metal Ions.We are able
to prepare HSco1 containing Cu(I) ions at 1:1, a ratio suitable
for structural studies. Mass spectra of fully reduced HSco1
reconstituted at pH 7.5 with increasing concentrations of Cu(I)
ions, are presented in Fig. 7, which is published as supporting
information on the PNAS web site. Addition of one equivalent
of Cu(I) ions to reduced HSco1 generates a new peak in MS
spectrum, which corresponds to Cu1HSco1 (Fig. 7). Addition of
further equivalents of Cu(I) ions leads to a slight additional
increase of the Cu1HSco1 peak but does not induce metal-
loforms with higher metal stoichiometry (Fig. 7). We also
showed that oxidized HSco1 does not form complex with Cu(II)
ions in an ESI-MS experiment (Fig. 7), which indicates that such
a complex, even if present in solution, is weak and dissociates
during the ESI process. Accordingly, addition of Ni(II)Cl2 to
oxidized 15N HSco1 does not affect the 1H–15N heteronuclear
single quantum correlation (HSQC) spectrum. However, we
have prepared the Cu(II) and Ni(II)HSco1 derivatives of re-
ducedHSco1 in a 1:1 metalprotein ratio. The ultravioletvisible
(UVVIS) and EPR spectra of Cu(II)HSco1 are identical to
those recently reported (15). Similar UVVIS spectra also were
reported for bacterial Sco homologues (12, 14, 17) and Cu(II)
nitrosocyanin (21, 22). In addition, the UVVIS spectrum of
Ni(II)HSco1 (Fig. 8, which is published as supporting informa-
tion on the PNAS web site) is similar to that reported for the B.
subtilis and Rhodobacter sphaeroides homologues (14, 17), with
two weak bands at 380 and 540 nm, respectively, correlating with
the two low-energy bands of the Cu(II)HSco1 spectrum al-
though shifted to lower energy (Fig. 8). The intense thiolate-
Ni(II) charge transfer band (23) is also red-shifted at 304 nmwith
respect to the Cu(II)HSco1 spectrum (Fig. 8).
The aggregation state and the conformational properties of
the Cu(I) and Ni(II)HSco1 forms have been investigated by
multiple techniques, including size-exclusion chromatography,
ESI-MS, and NMR. In NMR, 15N relaxation rates are modulated
by the correlation time for the protein tumbling (m), which is
directly related to the molecular weight of the protein, thus
monitoring its aggregation state (24). The correlation times of
Cu(I)HSco1 and Ni(II)HSco1 proteins (at millimolar concen-
trations) are 14.5  1.1 ns and 15.6  1.2, respectively, as
expected for a protein of this size in a monomeric state. These
values also are similar to the m of apoHSco1 (13.8  1.6 ns),
which reorients in solution as a monomeric protein as shown by
size-exclusion chromatography and multiangle light scattering
experiments. ESI-MS experiments conducted at a 1.8 M con-
centration of protein did not detect any higher aggregates for
apoHSco1 or Cu1HSco1. ESI-MS spectra and, especially, the
charge-state distribution of ions also can yield information about
the conformational states of proteins under a variety of condi-
tions (25). Upon the binding of Cu(I), the charge state distri-
bution of Cu1HSco1 species shifted toward ions with lower
charges (9 and 8), which indicates that binding of metal
induces a conformation change of the protein to a more compact
state (Fig. 7).
Cu(I), Ni(II), and apoHSco1 Solution Structures. The solution struc-
tures of Cu(I)HSco1 and Ni(II)HSco1 (Fig. 2) were determined
by using distance and angle restraints as obtained from 2D and
3D heteronuclear NMR experiments (Table 1, which is pub-
lished as supporting information on the PNAS web site). The
overall fold of Cu(I)HSco1 and Ni(II)HSco1 structures is the
same as that of the crystal structure of apoHSco1 (19) and
contains four -helices and nine -strands organized into the
thioredoxin fold. The solution structure of apoHSco1 also
displays the same global thioredoxin fold. However, the -hair-
pin present in the extended, solvent-exposed loop-8 region does
not form anymore (Fig. 2).
Cu(I) is coordinated by the two Cys residues of the CPXXCP
conserved motif, shared by the third loop and helix 1, and by
the conserved His-260 (Fig. 2), located in the seventh -strand,
as shown by 2JNH coupling-based 1H–15N HSQC experiments
Fig. 1. Diagram of the protein sequence and cloned constructs of HSco1. The positions of the mitochondrial target sequence (MTS), transmembrane helix (TM),
and the soluble fragment of HSco1 are orange, blue, and yellow, respectively. The N terminus of HSco1 protruding into the mitochondrial matrix is green. The
soluble fragments used in the present study are named long and short truncated constructs. The truncates lack only the mitochondrial target sequence and
transmembrane helix. The essential CPXXCP motif, the tobacco etch virus protease recognition site (GSFT), and the 14-aa segment (red dotted box) at the N
terminus side are indicated in bold. The positively and negatively charged amino acids are represented in blue and red, respectively.
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(Fig. 9, which is published as supporting information on the
PNAS web site). From these experiments, it appears that, in
Cu(I)HSco1, His-260 acquires a preferential conformation
where N1 is protonated and N2 is coordinated to the metal ion.
The involvement in the metal binding of residues from two
different regions of the protein produces a compact state of
protein with respect to the apo form, in agreement with obser-
vations in ESI-MS experiments. Backbone NH resonances of
three regions comprising residues 166–180, 202–204, and 244–
264 are indeed not detected in the 1H–15N HSQC spectrum
of apoHSco1, although they are present in both Cu(I) and
Ni(II)HSco1 spectra. These three regions comprise the
CPXXCP metal-binding motif and the surrounding loops 5 and
8, the latter containing the third ligand, His-260. The inability to
detect the backbone NH signals listed above is because of their
fast exchange with the bulk solvent or because of the presence
of multiple backbone conformations in the metal-binding area of
apoHSco1, whereas the metal binding is able to ‘‘freeze’’ these
regions in a more rigid conformation. In particular, the large
conformational variability of the long loop 8 observed in the
apoHSco1 solution structure (no long-range nuclear Overhauser
effects are detected in loop 8) indicates that backbone structural
changes are necessary to locate the metal ligand His-260 in the
vicinity of the other two ligands, Cys-169 and Cys-173 (Fig. 2).
Analysis of backbone dynamics (Fig. 10, which is published as
supporting information on the PNAS web site) also is in agree-
ment with the latter picture and demonstrates that both metal-
lated forms of HSco1 do not display extensive motions on both
milli- to microsecond andor nano- to picosecond time scales,
with the exception of the C and N termini.
When reduced, HSco1 binds a divalent cation, as Ni(II), and
the metal is still bound by the two Cys residues of the CPXXCP
motif and by His-260 through the N2 atom (Fig. 2), as confirmed
by 2J 1H–15N HSQC NMR experiments. Because Ni(II) is
expected to be at least four-coordinated, it is feasible that a forth
ligand is completing its coordination sphere. This ligand could be
a water molecule or a residue donated by the protein. The
solution structure of Ni(II)HSco1 shows that two acidic groups
(Asp-171 and Asp-259) could complete the Ni(II) coordination
sphere, but our data do not allow discrimination between these
two possibilities.
Ni(II)HSco1 Crystal Structure. Crystals of the Ni(II)HSco1 deriva-
tive also were obtained in aerobic conditions. The overall
structure of the Ni(II)HSco1 complex is essentially superimpos-
able with that of apoHSco1 [Protein Data Bank (PDB) ID code
1WP0] (19), which was used as the model in the molecular
replacement. The main exception is the solvent exposed a region
involving residues 240–260 (loop 8 and the -hairpin), ending
with the metal-binding His-260. This loop indeed acquires a
more ordered conformation as a consequence of the metal
binding, according to the behavior in solution; this greater
stability is confirmed by the good quality of the electron density
map in that region for both molecules in the asymmetric unit,
which is indeed better than that observed in the apoHSco1
crystal structure (19). A further confirmation is the significantly
lower temperature factors of the atoms belonging to the above-
mentioned loop in the structure of Ni(II)HSco1 with respect to
those of the crystal structure of apoHSco1 (19).
The coordination sphere of Ni(II) in the crystal structure of
Ni(II)HSco1 is quite odd and unexpected. In this structure, the
Fig. 3. The distorted square planar coordination of nickel as present in the
x-ray structure of oxidized Ni(II)HSco1. Bonding distances between nickel and
the coordinating moieties are shown in green along with the distance be-
tween the two Cys residues. The distance between the nickel ion and the OH
oxygen of Tyr-163 is also shown in magenta, and it is too large to be considered
a bonding interaction.
Fig. 2. Solution structures of human Cu(I), Ni(II), and apoSco1. (Left) The
superimposition of 20 structures of Cu(I), Ni(II) and apoHSco1 are shown.
-helices and -strands are colored in red and cyan, respectively. (Right) The
average structures of the lowest energy ensemble are shown. The metal-
binding residues Cys-169, Cys-173, and His-260 are shown in yellow and blue,
respectively. Cu(I) and Ni(II) ions are depicted as orange and pink spheres,
respectively.
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two metal-binding Cys residues are oxidized and form a disulfide
bond (Fig. 3; see also Fig. 11, which is published as supporting
information on the PNAS web site) and therefore not capable of
binding the Ni(II) ion as thiolates. Still, the metal ion remains in
contact with the SOS bridge with a NiOS distance of 2.0–2.2 Å,
suggesting the formation of bonds with the available lone pairs
of sulfur atoms (Fig. 3). The coordination sphere of Ni(II) is
completed by His-260 (N2ONi, 2.03–2.45 Å), in agreement with
the solution structure of Ni(II)HSco1, and a water molecule or
more likely an anion such as Cl arranged in a distorted square
planar geometry.
We have been able to trace one case only in the PDB of a
nickel ion coordinated to Cys residues (PDB ID code 1FRF) that
are at bonding distance; in this case, the metal-binding site is
dinuclear (iron and nickel) and is made of four Cys residues
pointing toward two metal ions that are at a distance of 3.2 Å
from each other. Cys-75 and Cys-546 are at interaction distance
(2.4 Å), whereas Cys-72 and Cys-543 are farther apart (3.0 Å)
(26). The distances between nickel and the four sulfur atoms are
as follows: Cys-72–Ni, 2.15 Å; Cys-543–Ni, 2.11 Å; Cys-75–Ni,
1.61 Å; and Cys-546–Ni, 2.44 Å.
Discussion
The solution and crystal structures of the metal derivatives of
HSco1 are completely superimposable along the entire amino acid
sequence (Fig. 4) (backbone rms deviation to the new structure
within 0.8 Å). These structures also are very similar to the solution
structure of apoHSco1 with the exception of loop 8, which displays
a different backbone conformation in apoHSco1, positioning the
imidazole ring of His-260 at 10 Å from the sulfur atoms of the
metal binding Cys residues (Fig. 4). In addition, helix 2, which
encompasses the CPXXCP metal-binding site at its N terminus, is
tilted in the apo solution structure with respect to the structure of
themetallatedHSco1 (Fig. 4). From theNMRstructures, it appears
that the apo form is highly disordered around themetal binding site,
sampling more open conformations than in the metallated forms
(Fig. 2). This observation also agrees with the results of confor-
mation analysis byESI-MS. In the x-ray structure of apoHSco1 (19),
however, the protein is frozen in a specific conformation that does
not reflect the real condition in solution. Therefore, metal binding
is accompanied by a relatively large, albeit localized, effect on the
protein structure, mainly involving loop 8: From an open confor-
mation with local disorder, the structure converts into a well
defined, compact state in which a metal ion is bound. In particular,
the presence of the His ligand, suitably located in loop 8 to
coordinate both divalent and monovalent metal ions, is important
to modulate the order and disorder state of loop 8 observed in the
metallated and apo forms, respectively. Also taking into account
that disordered regions in protein structure often are engaged in
protein–protein interactions (27), one may speculate that loop 8
modulates association–dissociation of HSco1 with its partner, the
Cu(I) chaperone Cox17. For example, it is possible that, once
Cu(I)Cox17 interacts transiently with apoHSco1 and donates its
copper cargo to HSco1, loop 8 structurally rearranges and allows
His binding and concomitant formation of the compact Cu(I)H-
Sco1 structure, which might not exchange copper with Cox17. The
formation of the stable, compact Cu(I)HSco1 state could thus
constitute the important driving force of the copper transfer from
Cox17 to HSco1.
Biological Context. The debate on whether HSco1 is a metal-
loprotein or a thioredoxin can significantly be advanced in light
of the structural results presented here. HSco1 forms 1:1 com-
plexes with the Cu(I) and Ni(II) ions by exploiting the same
metal binding ligands, which confirms that HSco1 is suitable for
binding both monovalent and divalent metal ions (15). Reduced
HSco1 also can bind one equivalent of Cu(II); however, the
reconstituted Cu(II)HSco1 complex shows two different coor-
dination environments with different populations (15). Similar
results on Cu(II)Sco1 complexes also were obtained for the B.
subtilis and yeast proteins (12, 15). It is therefore reasonable to
assign a copper chaperone role to HSco1, the metal ion being
coordinated by two Cys residues and one His residue. A similar
metal-binding site also is found in another copper chaperone,
i.e., the ATX1 from Synecocystis (28). Similarly to the latter
system, themetal-donating and themetal-receiving coordination
sites are different, thus overcoming the condition that ‘‘donor’’
and ‘‘recipient’’ protein partners in metal transfer processes need
metal-binding sites similar in structure, as recently suggested
(29). The presence of three ligands, one of each being a
‘‘f lexible’’ His residue, also makes the site suitable for the
binding of divalent metal ions. Indeed, Cu(II), Ni(II), and,
presumably, Zn(II) (14) can bind at the same site of HSco1. In
the case of a divalent metals, the coordination can be completed
by an additional exogenous ligand, e.g., H2O, or by a protein
carboxylate. The latter hypothesis is supported by the observa-
tion that the affinity of HSco1 for the Cu(II) ion is reduced if
Asp-259 is mutated (15).
The fold of HSco1 is similar to that of redox-active proteins
like thioredoxins and peroxiredoxins, with themetal-binding Cys
residues located at the same positions as the conserved catalytic
Cys residues in thioredoxins. This feature became apparent when
the first structure of a Sco1 homolog was solved (12). Therefore,
a thioredoxin fold has evolved as a metal chaperone to bind the
metal atom via the di-Cys motif, and one may speculate that the
thioredoxin function is still maintained. Indeed, apoHSco1 can
be easily oxidized to form SOS bonds. In this research, we also
have shown that, in the oxidized form, the protein has low
affinity for metal ions because their addition did not affect the
1H–15N HSQC spectrum of oxidized apoHSco1, and no metal
adduct has been detected by ESI-MS experiments. In the PDB,
only one example of a metal ion bound to an oxidized SOS bond
is reported (26). Therefore, it is feasible that the present crystal
structure of the nickel derivative of oxidized HSco1 represents
the transient copper-delivery complex, which might exist just
before the copper is transferred to the CuA site of the COXII
subunit. Indeed, biochemical and genetic studies on yeast Sco1
Fig. 4. Overlay of the backbone of apo (blue), Cu(I) (green), and Ni(II) (red)
HSco1 solution structures and of Ni(II) (black) HSco1 x-ray structure.
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demonstrated its ability for direct interaction with the COXII
subunit (30, 31). Because numerous proteins in the mitochon-
drial intermembrane space have disulfide bonds (32–34), the two
Cys residues of the CuA site of COXII may also require reduction
before metal transfer. The same requirement applies to the
bacteria in which the COXII subunit is exposed to oxidizing
periplasmatic or extracelluar environments. Therefore, it may be
argued that Sco1 participates, along with metal transfer, in the
reduction of the CuA site of COXII and its metal-transfer
mechanism might include the following steps: (i) CuHSco1
interacts with the oxidized COXII and reduces the Cys residues
of the CuA site as a thioredoxin, and (ii) the oxidized HSco1
protein transfers Cu to the reduced CuA site (Fig. 5). The
oxidized apoHSco1 could be reduced before the next metal
transfer and its reduction can be performed by another thiore-
doxin-like protein, such as HSco2, which is known to play a key
role in CuA formation (35), or by cytochrome c, an electron-
transfer protein that is found in the same operon of Sco1
homologs in some bacteria or is fused to some Sco1 paralog
proteins (1). The copper delivery process therefore seems to
involve several proteins in a complex molecular mechanism that
requires further investigation. Interestingly, a dual functional
role in the assembly mechanism of the copper enzyme super-
oxide dismutase has been similarly proposed for its copper
chaperone CCS, which is, along with the copper donation,
involved in the formation of an intramolecular disulfide essential
for superoxide dismutase activity (36).
Concluding Remarks. We have succeeded in preparing Cu(I) and
Ni(II) derivatives of HSco1 and determined their solution
structures. The solution structure of apoHSco1 also has been
determined. The structures confirm that the metal ions are
bound by two Cys residues and one His residue, and they show
the transition from a locally disordered apo protein to a compact
metallated form, as confirmed by ESI-MS studies. We also
obtained crystals of Ni(II)HSco1, which suggest the binding of
the metal ion to the oxidized form of HSco1. This species may
represent a transition state of the copper transfer from HSco1
to the CuA site of COXII. This transient species may present a
missing link that integrates the metal transfer and thioredoxin
functions already proposed for this fascinating protein. A similar
mechanism of copper transfer also has been previously suggested
for the bacterial Sco1 homologue PrrC from Rhodobacter spha-
eroides (17).
Methods
Protein Preparation and Characterization. Long and short soluble
domains of HSco1 (lacking the first 351 and 393 bp, respectively,
corresponding to residues 1–117 and 1–131) were amplified by
PCR, cloned into the Gateway Entry vector pENTRtobacco etch
virusD-TOPO (Invitrogen), and subcloned into pETG-30A (Eu-
ropean Molecular Biology Laboratory Protein Expression and
Purification Facility) by Gateway LR reaction to generate N-
terminal, His-GST fused proteins. The proteins were expressed in
Escherichia coli BL21-Gold(DE3) cells (Stratagene), which were
grown in LB and minimal medium [(15NH4)2SO4 andor [13C]-
glucose] for the production of labeled samples. Purification was
performed by using a HiTrap chelating HP column (Amersham
Pharmacia Biosciences) charged with Zn(II). His-GST tag was
cleaved with AcTEV, and separated from the C-terminal domain
with a second purification step. After this purification, the protein
preparations showed a single component by SDSPAGEwith5%
of copper bound to the protein, as checked through ESI-MS
spectrometry. DTT was added to the apoprotein in a 10 mM
concentration to reduce the Cys residues of the CPXXCP motif
before metal reconstitution. The Cu(I), Cu(II), Ni(II) metallated
forms were obtained by addition of stoichiometric amounts of the
metal ions {as [Cu(I)(CH3CN)4]PF6, CuSO4, and NiCl2} to diluted
protein solutions in 50 mMphosphate buffer at pH 7.2, followed by
protein concentration under nitrogen atmosphere. The metal con-
tent was finally determined by inductively coupled plasma MS.
Electronic spectra on the metal derivatives were recorded
on a Cary 50 spectrophotometer (Varian). EPR spectra on
Cu(II)HSco1 were recorded at 180 K on an Elexsys E500
spectrometer (Bruker) equipped with a X-band microwave
bridge (microwave frequency, 9.45 GHz) and an ER 4131 VT
unit for temperature control. To investigate the aggregation
state of HSco1, 0.5–1 mM protein samples were run on a
Superdex75 HR-1030 size-exclusion column on an AKTA-
FPLC system (Amersham Pharmacia Biosciences) connected
with a multiangle light scattering (DAWN-EOS, Wyatt Tech-
nologies, Santa Barbara, CA) coupled with quasielastic light-
scattering detectors.
Before ESI-MS experiments, purified apoHSco1 protein was
brought into 50 mM ammonium acetate buffer (pH 7.5) by using
a HiPrep2610 desalting column (Amersham Pharmacia Bio-
sciences). In MS experiments, 1.8 M protein samples were
infused by a syringe pump at 15 lmin into an Ettan API
ESI-TOF mass spectrometer (Amersham Pharmacia Bio-
sciences). Mass spectra were recorded during 2–3 min at a
capillary exit voltage of 150 V. apoHSco1 was reduced by
addition of 0.5 or 1.0 mM DTT at 25°C. Reconstitution of
apoHSco1 with copper was conducted as follows. First, Cu(II)
acetate was dissolved at 150 M concentration in argon-
saturated 50 mM ammonium acetate, pH 7.5, and Cu(II) was
reduced to Cu(I) by addition of 0.5 mM DTT. Different equiv-
alents of freshly prepared Cu(I)DTT complex were added to the
apoHSco1 samples (protein concentration, 1.8 M), the mixture
was incubated for 1 min at 25°C, and ESI-MS spectra were
recorded as described above.
Solution Structures Determination. NMR spectral assignment and
structure determination were obtained through the experiments
listed in Table 1, which also indicates the magnetic fields at which
they were collected. Overall, the resonances of 95% of carbon
atoms, 97% of nitrogen atoms, and 90%of protons were assigned
in Cu(I)HSco1 and Ni(II)HSco1 (deposited in the Protein Data
Bank database). In the case of apo form, the resonances of 85%
of carbon atoms, 80% of nitrogen atoms, and 80% of proton
Fig. 5. Proposed mechanism for copper transfer from HSco1 to the COXII
subunit of CcO. This model implies that HSco1 may form a transient species
characterized by an oxidized SOS moiety still able to interact with a copper
ion. This state might exist just before the copper is transferred to the CuA site
of CcO. In the metal transfer mechanism, HSco1 also can work as a thioredoxin
in the reduction of the Cys residues in the CuA site of COXII. At this stage, the
oxidization state of copper during the metal transfer cannot be assessed. The
CuA site of the COXII subunit can indeed accept both Cu(I) and Cu(II) ions from
HSco1. Broken lines indicate the metal coordination bonds.
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atoms were assigned. The 1H, 13C, and 15N resonance assign-
ments of the apo, Cu(I), and Ni(II)HSco1 forms are reported,
respectively, in Tables 2–4, which are published as supporting
information on the PNAS web site. The His ring protons were
assigned through a 1H–15N HSQC experiment tailored to the
detection of 2J 1H–15N couplings and from the analysis of
the 13C-NOESY-HSQC spectra. For all His residues, all of the
nonexchangeable protons were assigned in Cu(I)HSco1 and
Ni(II)HSco1. The exchangeable proton of the metal-binding
ligand, His-260, also was detected in both metallated forms. R1
and R2 15N relaxation rates and 1H–15N nuclear Overhauser
effects (with and without 1H saturation) (Table 1) were mea-
sured at 298K on Avance 500 and 600 MHz Bruker spectrom-
eters and then analyzed by using a standard procedure (37).
After conversion of the NMR data in structural constraints
[3,035, 2,776 and 2,066 meaningful proton–proton distances,
together with 85  and 83  angle constraints for Cu(I)HSco1,
Ni(II)HSco1, and apoHSco1, respectively], the structures were
calculated using the program DYANA (38). The best 30 structures
of the DYANA family were then subjected to restrained energy
minimization with AMBER 8.0 (39). The force-field parameters for
the metal ions were adapted from similar systems (40, 41). The
statistical analysis of the restrained energy minimization family
of apoHSco1, Cu(I)HSco1, and Ni(II)HSco1 structures are
reported, respectively, in Tables 5, 6, and 7, which are published
as supporting information on the PNAS web site. The programs
PROCHECK and PROCHECK-NMR (42, 43) were used in the eval-
uation of the quality of the structures.More than 90% of residues
were located in the allowed regions of the Ramachandran plot.
Crystallization, Data Collection, and Structure Solution. Crystals of
Ni(II)HSco1 grew at 20°C from a 0.1 M TrisHCl30% polyeth-
ylene glycol 6000 solution at pH 8.5 by the vapor diffusion
technique. The final protein concentration was10 mgml. The
data set was collected by using synchrotron radiation at beamline
ID-29 (European Synchrotron Radiation Facility, Grenoble,
France) at 100 K, with the crystal cryocooled, in the presence of
10–15% of ethylen glycol. The Ni(II)HSco1 crystal diffracted up
to 2.5-Å resolution and belongs to space group P212121 (a 
51.46 Å, b  52.44 Å, c  136.41 Å) with two molecules in the
asymmetric unit, a solvent content of 47.1%, and a mosaicity of
0.7°. The structure was solved by using the molecular replace-
ment technique, with the structure of the apoHSco1 (PDB ID
code 1WP0) as starting model.
The Ramachandran plot of the refined model shows that
97.5% of residues are in allowed regions of the plot, 2.5% of
residues are in generously allowed, and no residues are in
disallowed regions. Table 8, which is published as supporting
information on the PNAS web site, reports the data collection
and refinement statistics.
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Fig. 6 Aggregation state of HSco1 domains monitored by size exclusion chromatography coupled 
with multi angle light scattering.
Long and short truncated constructs of HSco1 eluted  mainly as a single peak with a  molecular weight (MW) corresponding 
to a dimeric (black) and monomeric (blue) state, respectively. 
Measured MW : 43680 (±0.4%)
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Fig. 7 Binding of copper ions to HSco1.
ESI-TOF mass spectra of HSco1 (1.8 µM) reconstituted with Cu(II)acetate or Cu(I)DTT complex in 50 mM ammonium acetate, pH 7.5. 
A - HSco1; B - HSco1 + 1 equivalent of Cu(II)acetate; C - HSco1 + 1 equivalent of Cu(I) in the presence of 0.5 mM DTT;
D - HSco1 + 2 equivalents of Cu(I) in in the presence of 0.5 mM DTT. Charge state +9 and +10 ions are presented 
and numbers on the peaks denote the metal stoichiometry of the complex. 
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Fig. 8 Electronic absorption spectra of Cu(II) (black) and Ni(II) (blu) HSco1.
The spectra were obtained at 298K in 50 mM phosphate (pH = 7.2). Both spectra were baseline corrected by 
subtracting the spectrum of apoHSco1.
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Fig. 9 1H-15N HSQC spectra optimized for the detection of 2J NH of histidine rings, recorded on Cu(I)HSco1.
The spectra were collected at 298 K and pH 7.2 on a spectrometer equipped with cryo-probe and operating at 500 MHz. The tautomeric
species of His ring of copper(I) bound form is also depicted. 
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Fig. 10 Spectral density functions J(ωH), J(ωN) and J(0) versus the residue numbers as obtained from the 15N 
relaxation data measured at 500 MHz and 600 MHz for Cu(I) (A) and Ni(II)HSco1 (B), respectively.
A B
Fig. 11 Stereo view of the electron density map (2Fo-Fc contoured at 1 sigma level) around the residues involved 
in nickel binding.
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The pathogenic mutant (P174L) of human Sco1 produces respira-
tory chain deficiency associated with cytochrome c oxidase (CcO)
assembly defects. The solution structure of the mutant in its Cu(I)
form shows that Leu-174 prevents the formation of a well packed
hydrophobic region around the metal-binding site and causes a
reduction of the affinity of copper(I) for the protein. KD values for
Cu(I)WT-HSco1 and Cu(I)P174L-HSco1 are 1017 and 1013, re-
spectively. The reduction potentials of the two apo proteins are
similar, but slower reduction/oxidation rates are found for the
mutant with respect to the WT. The mitochondrial metal-
lochaperone in the partially oxidized Cu1(I)Cox172S-S form, at
variance with the fully reduced Cu4(I)Cox17, interacts transiently
with both WT-HSco1 and the mutant, forming the Cox17/Cu(I)/
HSco1 complex, but copper is efficiently transferred only in the
case of WT protein. Cu1(I)Cox172S-S indeed has an affinity for
copper(I) (KD 1015) higher than that of the P174L-HSco1 mutant
but lower than that of WT-HSco1. We propose that HSco1 muta-
tion, altering the structure around the metal-binding site, affects
both copper(I) binding and redox properties of the protein, thus
impairing the efficiency of copper transfer to CcO. The pathogenic
mutation therefore could (i) lessen the Sco1 affinity for copper(I)
and hence copper supply for CcO or (ii) decrease the efficiency of
reduction of CcO thiols involved in copper binding, or both effects
could be produced by the mutation.
cytochrome c oxidase  mass spectrometry  NMR  copper chaperone 
respiratory chain deficiency
Cytochrome c oxidase (CcO) is the terminal enzyme of therespiratory chain, embedded in the inner mitochondrial
membrane of all eukaryotes and in the plasma membrane of
many prokaryotes. In eukaryotes, a large number of nuclear
genes are required for the proper assembly and function of the
CcO complex, among which at least six proteins (Cox17, Cox23,
Cox19, Sco1, Sco2, and Cox11) are involved in the delivery and
insertion of copper into the binuclear CuA and CuB-heme a3 sites
of CcO (1–3). Sco1 and Sco2, which are anchored to the inner
mitochondrial membrane through a single transmembrane helix,
are specifically implicated in the assembly of the CuA site of CcO
(4–7). Sco1 and Sco2 are both metal-binding proteins capable to
bind either copper(I) or copper(II) in the same metal-binding
site (8, 9); mutations of the ligands that abrogate their copper-
binding ability drastically compromise CcO activity (9, 10). The
mitochondrial copper chaperone Cox17 is capable of donating
copper(I) to Sco1 (11), implying that it might transfer copper to
Sco1, which, in turn, inserts it into the CuA site. According to this
mechanism, Sco1 was shown to interact with the CuA-containing
COXII subunit of CcO (6).
Important insights on the function of this class of proteins also
recently were obtained from a genome-wide search for all
available prokaryotic genomes (12). This search showed the
presence of several Sco paralogs adjacent to copper and/or redox
proteins, thus suggesting that Sco proteins can have multifunc-
tional properties involved in different physiological processes.
The structure of Sco proteins is characterized by a thioredoxin
fold (13–15), and, from the first structural characterization (13),
it was suggested that the protein also may fulfill a redox function.
Recently, we have solved the solution structures of the demet-
allated, the copper(I), and the nickel(II) derivatives of human
Sco1 (HSco1 hereafter) as well as the crystal structure of a
nickel(II) derivative (16). The structural analysis showed that
Cu(I) is coordinated by ligands located in two distant protein
regions: Cys-169 and Cys-173 of the CXXXC conserved motif in
loop 3 and His-260 in loop 8. In the structure of the apo protein,
the latter loop is highly disordered and mobile in solution (16),
suggesting that the metal binding is able to ‘‘freeze’’ this loop in
a more rigid conformation, thus representing an important step
in the metal-binding process of HSco1. In the crystal structure
of oxidized Ni(II)HSco1, the two metal-binding cysteines are
oxidized and form a disulfide bond, still with the metal ion
interacting with the S-S moiety. This metal environment showed
that the protein can have a peculiar mode of interaction with a
metal ion, suggesting that cysteine oxidation of HSco1 also might
play a role in the metal release to CuA site of CcO (16). These
structural data further support our initial suggestion that Sco1
can act both as a copper chaperone and a thioredoxin (13).
Human SCO1 and SCO2 genes can experience pathogenic
mutations that produce respiratory chain deficiency associated
with CcO assembly defects (17). The missense mutation in
human Sco1 gene of a proline into a leucine, P174L, is associated
with a fatal neonatal hepatopathy when the second allele also is
nonfunctional (18). This finding implies that the pathology is
caused by a loss of normal Sco1 function rather than gain of some
aberrant action of the mutant protein. This proline, adjacent to
the conserved CXXXC domain of HSco1, is completely con-
served in eukaryotes. Introduction of the P174Lmutant chimeric
HSco1 protein in Sco1-null yeast mutants impaired CcO assem-
bly and induced loss of CcO activity (19). WT protein and P174L
mutant chimera are present in comparable concentrations in
mitochondrial extracts, thus indicating that the pathogenicity of
the mutant does not result from its instability but rather from an
impaired function (19). During the preparation of our work, a
paper on the same P174L-HSco1 mutant came out indicating
that the mutation compromises Cox17-dependent metalation
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without impairing copper binding (20). In the present research,
we have explored at the molecular level the effect of the
mutation on the Sco1 function by solving the solution structure
of the P174L-HSco1 mutant, characterizing the metal-binding
and redox properties of the P174L-HSco1 mutant with respect
to WT HSco1 (WT-HSco1 hereafter), and investigating the role
of Cox17 in the copper transfer to both WT and mutant HSco1
proteins. Our work demonstrates that the P174L mutation alters
hydrophobic interactions around the metal-binding site, thus
affecting both the copper-binding and the redox properties of
HSco1 and, therefore, determining a reduction of the copper
transfer efficiency from Cox17 to HSco1. We also learned that
the partially oxidized Cu1(I)Cox172S-S and not the fully reduced
Cu4(I)Cox17 are the preferential species delivering copper to
HSco1.
Results
Structural Properties of the Pathogenic Mutant P174L-HSco1.
ApoP174L-HSco1 at millimolar concentration is a well folded
protein as it appears from the 1H-15N heteronuclear single
quantum correlation (HSQC) spectrum [see supporting infor-
mation (SI) Fig. 5], which also is similar to that of apoWT-
HSco1. Accordingly, the mutant maintains the same fold of
WT-HSco1, featuring indeed the same content of -strands
(21%) and -helices (26%) as derived from circular dichroism
spectra. Fluorimetric thermal unfolding assay (SI Fig. 5) shows
that the thermal stability of apoP174L-HSco1 also is the same as
that of apoWT-HSco1, both having a melting temperature of
54°C. These data show that the pathogenic nature of the
mutation does not originate from fold and/or stability differ-
ences of apoP174L-HSco1 with respect to the WT protein. This
conclusion also is consistent with in vivo results, which showed
that comparable concentrations of either WT or P174L mutant
protein are present in mitochondrial extracts (19).
ApoP174L-HSco1, as apoWT-HSco1, is able to bind Cu(I)
ions, when the latter is provided as Cu(I) acetonitrile complex.
The metalation of both proteins, followed through 1H-15N
HSQC spectra in the presence of 1 mM DTT (SI Fig. 6),
however, shows meaningful differences. Indeed, although 1 eq of
Cu(I) fully metallates WT-HSco1, complete metalation of
P174L-HSco1 is not achieved even when 3 eq of Cu(I) are added,
as 20% of P174L-HSco1 is still in the apo form (SI Fig. 6). In
the latter experiment, Cu(I) thus competes between the mutant
and the DTT chelator, allowing us to determine the dissociation
constant (KD) of the Cu(I)P174L-HSco1 complex. Following the
relative ratio of apo and copper(I) forms, as obtained from the
1H-15N HSQC spectra of the mixture during the titration steps
[the interaction between the protein and Cu(I)DTT complex is
slow on the chemical-shift time scale], KD of the Cu(I)P174L-
HSco1 complex is estimated to be 3.2  0.6  1013 M. This
value is much higher than the KD 1017 of theWT protein (see
Transfer of Copper from Cox17 to HSco1). When copper(I) is
added in the absence of DTT, 1.5 eq are enough to fully
metallate the mutant.
Copper binding to WT-HSco1 induces major conformational
changes to the protein, which passes from an open state in the
apo form to a closed, compact one upon copper binding (16).
This change clearly is evident from the solution structures of
these two states of WT-HSco1 and also can readily be assessed
from the charge state analysis of electrospray ionization
(ESI)-MS spectra. Conformational analysis by ESI-MS is based
on observation that, during the ESI, tightly compact proteins
acquire only a narrow range of low-charge values, whereas open
conformations produce a more heterogeneous and highly
charged population (21). Charge-state distribution of
Cu(I)P174L-HSco1 (Int9/Int10  1.6; Fig. 1) is similar to that
of apoP174L-HSco1 (Int9/Int10  1.7) and apoWT-HSco1
(Int9/Int10 1.4), indicating that all these systems have a more
open conformation than Cu(I)WT-HSco1, in which the lower
9 state was more populated (Int9/Int10  3.8; Fig. 1). These
data therefore show that Cu(I) binding to apoP174L-HSco1 is
unable to induce the compact conformation as it occurs in the
WT protein.
In the 1H-15N HSQC spectrum of the fully metallated P174L-
HSco1 (Cu1(I)P174L-HSco1), 34 residues show a splitting in two
or, in a few cases, three NH cross-peaks, indicating the occur-
rence of structural heterogeneity, which is absent in Cu1(I)WT-
HSco1. The twomajor species are present in a ratio of 60:40. The
relative intensity of the resonances of the two species is
temperature-dependent, indicating that there is an equilibrium
between the two. The solution structure of Cu1(I)P174L-HSco1
(determined from the more abundant species) shows the same
thioredoxin-like fold of the WT protein (Fig. 2) with an average
backbone rmsd of 1.30 Å. The only significant structural differ-
ence is in loop 8, which contains the His copper ligand. In the
mutant, this loop does not have the short -hairpin (Fig. 2),
similarly to what occurs in the apoWT-HSco1 solution structure
but at variance with the Cu1(I)WT-HSco1 structure (16). Be-
cause no apo form of the mutant is present in the NMR sample
(see Methods), the latter less defined secondary structure could
be the consequence of the structural heterogeneity in this region,
which in turn could induce a weaker copper-affinity in the
mutant. Several residues with double conformations are located
in helix 2, which is in contact with the metal-binding CXXXC
Fig. 1. Binding of copper ions to human Sco1 and mutant P174LSco1. ESI-TOF
mass spectra of WT-HSco1 (0.8 M) and P174L-HSco1 (1.2 M) reconstituted
with Cu(I)DTT complex in 50 mM ammonium acetate, pH 7.5. (A) apoWT-
HSco1. (B) WT-HSco1  1 eq of Cu(I) in the presence of 1.0 mM DTT. (C)
apoP174L-HSco1. (D) P174L-HSco1  1 eq of Cu(I) in the presence of 1.0 mM
DTT. (E) P174L-HSco1 1 eq of Cu(I) 3 eq of Cox172S-S in the presence of 1.0
mM DTT. Charge state 8, 9, and 10 ions are presented and numbers on
the peaks denote the metal stoichiometry of the complex.
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region through hydrophobic interactions involving Leu-174 or
Pro-174 and Leu-177 (helix 1), and Tyr-216 and Phe-220 (helix
2). Although Pro-174 has extensive hydrophobic contacts with
both Tyr-216 and Phe-220 in Cu1(I)WT-HSco1, thus forming a
compact hydrophobic patch, in the mutant, the bulkier Leu side
chain prevents the optimal packing with the two aromatic side
chains (Fig. 2), which indeed display double conformation.
Leu-174 essentially interacts only with Phe-220 (Fig. 2) and is
more solvent-exposed (25%) than Pro-174 is (12%). The lack of
a well organized hydrophobic core on this side of the metal-
binding region also causes the presence of a double conforma-
tion for His-260, located in loop 8. Two patterns for the aromatic
ring of this His are observed in the 2JNH coupling-based 1H-15N
HSQC spectra (SI Fig. 7). One pattern, belonging to the minor
species, fully matches the shifts of His-260 in Cu1(I)WT-HSco1,
whereas the other has different shifts but still is indicative of
copper(I) coordination through N2 as in theWT protein. In the
major species, His-260 lacks NOEs contacts with the CXXXC
metal-binding region that are present in the WT form. A
decreased number of NOEs with respect to WT protein also is
observed in the metal-binding loop 3 and in the surrounding
loops 5, 7, and 8, likely reflecting the effect of the observed
conformational disorder. From this structural investigation, we
thus can conclude that the mutation (i) perturbs the hydrophobic
interactions and (ii) induces conformational heterogeneity
around the copper-binding site, with both effects overall reduc-
ing the affinity of the protein for copper(I).
Redox Properties of the Pathogenic Mutant P174L-HSco1. Based on
its thioredoxin fold, it has been suggested that the two Cys
residues of the CXXXC conserved motif in Sco protein family
can be involved in redox reactions (13–15), perhaps in the
reduction of the oxidized cysteines in CuA site of CcO (16).
Oxidized and reduced forms of apoHSco1 are characterized by
different fluorescence spectra (Fig. 3). Trp-159 and, to a lesser
extent, Tyr-163 are the residues principally contributing to the
difference of florescence intensity upon change of the oxidation
state of the protein (see SI Text for details), as assessed by
comparing the fluorescence spectra of W159F, W159F/Y163F,
and Y216F mutants with that of WT-HSco1 (SI Fig. 8). Tyr-163
is close to the CXXXC motif, whereas Trp-159 is far but still
belonging to the same -strand of Tyr-163. From the difference
in fluorescence of the two redox states of the protein, the
reduction potential of the two cysteines for WT- and P174L-
HSco1 in their apo forms can be determined. The measured
reduction potentials at pH 7.2 are 0.277  0.030 V and
0.275  0.028 V for WT-HSco1 and P174L-HSco1, respec-
tively (Fig. 3), falling in the standard state redox potentials range
of the thioredoxin family of thiol-disulfide oxidoreductases
(124 to 270 mV) (22), consistently with a possible function
of HSco1 as a thioredoxin. The similar reduction potentials of
WT-HSco1 and P174L-HSco1 also indicate that the pathogenic
mutation does not significantly affect the thermodynamic equi-
librium between reduced and oxidized HSco1. However, the
kinetic rates of disulfide bond formation and reduction are
significantly different in WT-HSco1 and P174L-HSco1 forms.
Air oxidation of cysteines in apoWT-HSco1 has an half-life time
of4 h. Oxidation of apoP174L-HSco1 is a much slower process,
because 70% of the reduced form still is present after 4 h of
air exposure (SI Fig. 9). Reduction of the disulfide bond in
oxidized apoHSco1, by 1 mMDTT, also has different rates in the
two proteins, being much faster in WT-HSco1 than in the
mutant. In the former, the reduction of the disulfide bond is
completed already after 1 min (SI Fig. 10); however, after the
same period, only 20% of oxidized apoP174L-HSco1 is reduced,
and, after 5 min, a reduction level of only 55% is reached (SI Fig.
10). In summary, P174L-HSco1 mutant has a similar redox
potential as compared with WT protein but significantly slower
reduction and oxidation rates.
Fig. 2. SolutionstructureofCu1(I)P174L-HSco1mutant. (A)Backboneatomsare
represented as a tube with variable radius, proportional to the backbone rmsd
value of each residue for Cu1(I)P174L-HSco1 and Cu1(I)WT-HSco1. The side chains
of Cys-169, Cys-173, His-260, and the copper(I) ions are shown in yellow, green,
and orange, respectively. The secondary structure elements also are indicated:
-strandsare incyanand-helices in red. (B) Side-chainpacking involvingPro-174
or Leu-174 (in yellow) and Tyr-216 and Phe-220 (in green) is shown on the WT and
P174L mean minimized solution structures. The mutant protein was copper-
saturated resulting in a 1:1 copper:protein complex.
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Fig. 3. Redox properties of WT-HSco1 and P174L-HSco1. (A) Fluorescence
emission spectra of 5 M WT-HSco1 (black) and P174L-HSco1 (blue) recorded
under native conditions of the oxidized (50 mM phosphate buffer, pH 7.0, 0.01
mM GSSG; dotted lines) and the reduced (50 mM phosphate buffer, pH 7.0, 200
mM GSH; solid lines) protein after excitation at 280 nm. (B) Redox equilibrium
of WT-HSco1 and P174L-HSco1 with different [GSH]2/GSSG ratios as followed
by measuring fluorescence emission at 327 nm. After nonlinear regression,
values of Keq  17.70  2.23 mM and of 15.66  1.86 mM (correlation
coefficient: 0.986 and 0.996) were obtained for the WT-HSco1 and P174L-
HSco1/glutathione systems, corresponding to a redox potentials of0.277
0.030 V and0.275 0.028 V, respectively, by using the glutathione standard
potential of 0.240 V at pH 7.0 and 298 K.
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Transfer of Copper from Cox17 to HSco1.After the characterization
of the structural and redox properties of the P174L-HSco1
mutant, we also addressed and analyzed the mechanism of
copper acquisition from the copper chaperone Cox17, which also
could be affected by the mutation. For this analyses, we have
used porcine Cox17, which differs from human Cox17 only in the
first four amino acid residues. Cox17 could exist in three
different oxidation states, which have different metal-binding
properties (23). In oxidative environment, a completely oxidized
form with three disulfide bonds (Cox173S-S hereafter) is present
that is unable to bind copper. In the presence of 1 mM DTT,
Cox17 is partially oxidized with two disulfide bonds (Cox172S-S)
and two reduced Cys residues, which bind one Cu(I) ion
[Cu1(I)Cox172S-S hereafter]. In more reducing conditions, Cox17
exists in the fully reduced state, which binds cooperatively four
Cu(I) ions forming a tetracopper-thiolate cluster [Cu4(I)Cox17
hereafter] (23). In principle, both metallated forms of Cox17
could transfer metals to HSco1 protein.
To test which form of Cox17 can transfer Cu(I) to WT-HSco1,
we have produced amixture of Cu4(I)Cox17 and Cu1(I)Cox172S-S
forms and mixed it to reduced apoWT-HSco1. ESI-MS data of
the Cox17 mixture showed metalation of apoWT-HSco1 with
one Cu(I) ion and the concomitant decrease of the peak of
Cu1(I)Cox172S-S, whereas that of Cu4(I)Cox17 remains unaltered
(SI Fig. 11). This finding indicates that Cu1(I)Cox172S-S prefer-
entially transfers Cu(I) to apoWT-HSco1. All of the subsequent
NMR and ESI-MS experiments thus have been performed with
the Cu1(I)Cox172S-S form.
Competition experiments for Cu(I) between the Cox172S-S
protein and the Cu(I) chelator DTT were carried out with
ESI-MS technique as described in ref. 23. From these data, it
results that Cox172S-S bind one Cu(I) ion tightly with a KD value
of 6.4  0.6  1015 M (SI Fig. 12).
When 15N-labeled apoWT-HSco1 is titrated with increasing
amounts of unlabelled Cu1(I)Cox172S-S in the presence of 1 mM
DTT, the intensity of someof itsNH signals decreases in the 1H-15N
HSQC spectra, and, concomitantly, NH signals of the Cu(I)WT-
HSco1 species appeared with increasing intensities along the titra-
tion (SI Fig. 13). No additional signals from a possible (transiently
populated) intermediate could be detected at any point of the
titration. ApoWT-HSco1 reaches 90% of its metalation upon
addition of 1 eq of Cu1(I)Cox172S-S, indicating a lower limit of the
equilibrium constant of 102. Considering the latter value and theKD
value of Cu1(I)Cox172S-S (KD  6.4  0.6  1015 M), KD of
Cu(I)WT-HSco1 is estimated to be 1017 or lower, thus WT
protein displaying a higher affinity for Cu(I) compared with the
mutant (KD 3.2 0.6 1013M).The rotational correlation time
(13.2  0.9 ns) of WT-HSco1 in the 1:1 mixture with
Cu1(I)Cox172S-S is not higher than that of isolated apo orCu(I)WT-
HSco1 (13.8  1.6 and 14.5  1.1 ns, respectively), indicating that
no complex is present at detectable concentrations. The copper(I)
transfer process is slow on the chemical-shift time scale, setting a
lower limit for the equilibration rate of102 s1 [determined by the
smallest chemical-shift difference between apoWT-HSco1 and
Cu(I)WT-HSco1 that can be detected, i.e.,0.1 ppm at 800MHz].
The comparison of the 1H-15N HSQC spectra of the Cu(I)WT-
HSco1metalated viaCu1(I)Cox172S-S with that ofCu(I)WT-HSco1
metallated via Cu(I) acetonitrile complex (SI Fig. 14) shows that a
fewNH resonances (residues 164, 243, 245, 258, and 260–262) close
to the metal-binding site are missing, broader, or having two
conformational states in the former spectrum, indicating that
Cox17 is transiently interacting with this region of WT-HSco1
producing conformational exchange processes of these NH
resonances.
ESI-MS spectrometry confirms the NMR data, showing that, by
adding an excess of apoCox172S-S, the apoWT-HSco1/Cu(I)WT-
HSco1 ratio does not change (SI Fig. 15C versus B), indicating that
Cu(I) ion is bound to WT-HSco1 with higher affinity than to
Cu1(I)Cox172S-S. According to the different metal-binding affini-
ties, from ESI-MS experiments, we also established that even 10
mM DTT cannot extract Cu(I) from Cu(I)WT-HSco1, whereas
already 5mMDTTextracts40%of copper fromCu1(I)Cox172S-S.
Therefore, Cox172S-S does not compete with WT-HSco1 for Cu(I)
ions, but vice versa, it contributes to metalation of WT-HSco1
protein as it follows from the fact that Cox172S-S shifts the meta-
lation equilibrium of HSco1 toward the Cu(I)WT-HSco1 form
more than the Cu(I)DTT complex does (SI Fig. 15A and B). These
data are in agreement with the copper content of human Sco1,
determined from the cytoplasmof yeast cells overexpressing human
Sco1 in the presence and absence of co-overexpression of human
Cox17 (9).
ESI-MS spectra also indicate that, in the absence of metal ion,
WT-HSco1 and Cox17 proteins do not form any complex.
However, in the presence of 1 eq of Cu(I) there are two minor
twin-peaks in the ESI-MS spectra (SI Fig. 15D) whose decon-
volution yields molecular masses of 26,497 and 26,562 Da, which
correspond to WT-HSco1/Cu1(I)/Cox172S-S and WT-HSco1/
Cu2(I)/Cox172S-S complexes (theoretical Mr 26,499.8 and
26,563.4 Da, respectively). These peaks have very low intensity,
indicating that these complexes are transient and not highly
populated states, in agreement with NMR results obtained at
millimolar concentration. However, the relative intensity of
these minor peaks increases at higher concentration of proteins,
indicating that an equilibrium between free proteins and protein
complexes is present. Moreover, at substoichiometric concen-
trations of Cu(I) ions, WT-HSco1/Cu1(I)/Cox172S-S is prevalent,
whereas at higher Cu(I) concentrations, the WT-HSco1/Cu2(I)/
Cox172S-S form prevails. This is another example of formation of
a metal-mediated protein–protein complex, also observed in
the case of other copper chaperones (24–26). As a whole, the
ESI-MS results indicate that WT-HSco1/Cu1(I)/Cox172S-S is
the transient intermediate involved in metal transfer from
Cu1(I)Cox172S-S to WT-HSco1. At higher metal concentrations,
WT-HSco1/Cu2(I)/Cox172S-S complex also exists, which suggests
that the WT-HSco1/Cox172S-S complex can accommodate two
Cu(I) ions.
When Cu1(I)Cox172S-S is added to apoP174L-HSco1, differently
fromwhat happens forWT-HSco1, no copper transfer occurs at 1:1
Cu1(I)Cox172S-S/P174L-HSco1 ratio, as judged by the 1H-15N
HSQC spectrum of the mixture. By increasing the Cu1(I)Cox172S-
S/P174L-HSco1 ratio up to 2:1, copper transfer occurs slowly on the
chemical-shift time scale, similarly to the WT protein, but only
20% of P174L-HSco1 is metallated, accordingly to the higher
affinity of Cox172S-S for copper(I) [KD  6.4  0.6  1015 M for
Cu1(I)Cox172S-S; KD  3.2  0.6  1013 M for Cu(I)P174L-
HSco1]. ESI-MS spectra also show that the addition ofCox172S-S up
to 3 eq does not improve the metalation of P174L-HSco1 (Fig. 1 E
versusD), which is different fromwhat occurs with theWTprotein.
Addition of Cox172S-S also does not change the charge-state dis-
tribution of Cu(I)P174L-HSco1 (SI Fig. 16), which remains similar
to that of apoP174L-HSco1 (Fig. 1E). Similarly to WT-HSco1, no
protein–protein complexes are observed in ESI-MS spectra in the
absence of metal, and a minor twin peak, corresponding to P174L-
HSco1/Cu1(I)/Cox172S-S and P174L-HSco1/Cu2(I)/Cox172S-S com-
plexes, is detected inESI-MS spectrum in presence ofCu(I) ions (SI
Fig. 16), which indicates that transient protein–protein complexes
with 1 and 2 Cu(I) ions also do exist in case of the mutant protein.
All of the data indicate that, even if Cox17 is still capable of
interacting and exchanging copper(I) with the P174L-HSco1 mu-
tant, the latter is not efficientlymetallated into a compact copper(I)
form, at variance with what occurs in WT protein.
Discussion
Copper incorporation into CcO is biologically crucial; it is,
however, an extremely complex process, which is tightly regu-
lated and requires a large array of proteins, each of them with
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a specific, in most of the cases, nonreplaceable role. The
comprehension and description of these processes are still in
their infancy, and only now knowledge about the structure and
functional role of the assisting proteins has begun to become
available. Many lines of evidence show that copper insertion into
CuA site of COXII subunit is not a simple, passive copper
transfer from Cox17 to Sco1/2 proteins and finally to COXII, but
redox reactions are interlinked with the process of copper
transfer (12, 15, 16, 27).
In this work, we have shown that the P174Lmutation in HSco1
significantly affects the redox and metal-binding properties of
this protein. Structurally, the mutation produces the lack of well
organized hydrophobic contacts and a structural heterogeneity
in the vicinity of the metal-binding region. The local structural
changes induced by the point mutation decrease the copper(I)
affinity of the mutant, thus negatively affecting the cometal-
lochaperone function of HSco1 in the CuA assembly. The
mutation also determines that the oxidation and reduction rates
of the disulphide bond of the mutant are much slower than those
of the WT protein. It is likely that introduction of the bulky
Leu-174 disturbs the mutual orientation of cysteines and slows
down the local conformational changes necessary for disulfide
bond formation and disruption. The thioredoxin role of HSco1,
proposed for maintaining the receiving CuA site in the suitable
reduced state (15, 16), therefore is significantly perturbed be-
cause the mutation could slow down the reduction of the
copper-binding cysteines in CuA site of CcO. Overall, these
alterations induced by the mutation on copper-binding and
redox properties of HSco1 can sizably decrease the efficiency of
the copper transfer from Cu(I)HSco1 to the CuA site of CcO.
Our results also provide a detailed understanding of the
metalation process of HSco1 by Cox17 and show how the
mutation at position 174 of HSco1 affects this process. ESI-MS
data demonstrate that Cu1(I)Cox172S-S, but not Cu4(I)Cox17, is
capable of transferring Cu(I) to apoWT-HSco1 and that minor
amounts of the metal-bridged species, WT-HSco1/Cu1(I)/
Cox172S-S and WT-HSco1/Cu2(I)/Cox172S-S, do occur, which are
probably the transient intermediates involved in the metal
transfer from Cu1(I)Cox172S-S to apoWT-HSco1. Such transient
interaction with Cox172S-S assists WT-HSco1 to pass from the
open to the closed state, which binds Cu(I) ions extremely
strongly (Fig. 4). The mutant P174L-HSco1 behaves differently:
the conformational disorder experienced by Cu(I)P174L-HSco1
indeed is associated with a weakly bound metal (Fig. 4), and
Cox172S-S is not able to assist the mutant P174L-HSco1 to form
the more compact state as it happens with WT-HSco1.
In conclusion, the P174L mutation in HSco1 decreases the
efficiency of both metal-binding and redox properties of HSco1,
which both are potentially involved in HSco1-mediated transfer of
the copper and electrons fromCox17 to theCuA site of COXII (16).
Methods
Protein Expression and Characterization. The pathogenic mutation
at the gene position C520T, corresponding to P174L amino acid
change, was made by using QuikChange mutagenesis kit (Strat-
agene, La Jolla, CA). WT-HSco1 protein and P174L-HSco1
pathogenic mutant were produced in E. coli BL21-Gold(DE3)
(Stratagene) following an already reported protocol (16). Por-
cine Cox17 was isolated from porcine intestine as fully oxidized
apo protein (Cox173S-S) and lyophilized (23).
The oxidation state of the cysteines of the WT- and P174L-
HSco1 proteins was evaluated through the selective reaction of
the free thiol groups with 4-acetamido-4-maleimidylstilbene-2,2-
disulfonic acid, which adds 500 Da per reactive thiol to the
total mass, thus shifting the mobility of the protein on a
SDS/PAGE denaturing gel. The metal content was determined
by inductively coupled plasma mass spectrometry. Far-UV CD
spectra (185–260 nm) were recorded on a Jasco J-810 spectropo-
larimeter on 10 M protein solutions in 20 mM phosphate
buffer, pH 7.2, at 298 K.
The melting temperatures of WT- and P174L-HSco1 proteins
in the apo state were determined through the fluorescence-
based thermal-shift assay (28). Fluorescence intensity was mea-
sured at different temperatures with excitation/emission wave-
lengths of 490 and 575 nm, respectively.
Redox equilibration between WT- or P174L-HSco1 and glu-
tathione was followed through the change of fluorescence
monitored on 5 M concentrations of protein samples previ-
ously incubated for at least 6 h under an N2 atmosphere, with
different reduced/oxidized glutathione (GSH/GSSG) ratios
(0.01 mM GSSG and varying concentrations of GSH, 0.1–200
mM) in 50 mM phosphate buffer, pH 7.2. The collection and
data analysis was performed by following a protocol previously
described for thioredoxins (29).
Preparation of Cox17, HSco1, and P174L-HSco1 Samples for MS Mea-
surements. ForMS experiments, purifiedWT- and P174L-HSco1
proteins containing one disulfide bond were brought into 50 mM
ammonium acetate, pH 7.5, by using HiPrep26/10 desalting
column (Amersham Biosciences, Uppsala, Sweden). Lyophilized
Cox173S-S was dissolved in argon-saturated 50 mM ammonium
acetate, pH 7.5, at 75 M concentration, and this stock solution
was used for further experiments. Cox172S-S was produced by
reduction of Cox173S-S with 1 mM DTT at 298 K (incubation
time 2 min), which leads to reduction of one most labile disulfide
bond in Cox173S-S. Fully reduced Cox17 was prepared by incu-
bation of Cox173S-S with 1 mM DTT at 45°C for 100 min.
MALDI-TOF and ESI-MS Protein Characterization. In MALDI-TOF
experiments, reduction of oxidized apoWT-HSco1 and
apoP174L-HSco1 (2 M protein concentration) by 1 mM DTT
was followed in 50 mM ammonium acetate buffer, pH 7.5, by
stopping the reduction with 5 mM iodoacetamide. Protein
adducts were identified by MALDI-TOF MS on a Voyager STR
instrument (Applied Biosystems, Foster City, CA).
In ESI-MS experiments, 0.8–4.8Mconcentrations of protein
samples or mixtures were infused by a syringe pump at 15 l/min
into an Ettan API ESI-TOF mass spectrometer (Amersham
Biosciences). Mass spectra were recorded during 2 to 3 min at a
capillary exit voltage of 150 V. HSco1 and P174L-HSco1 were
reduced with 1.0 mM DTT at 298 K. ESI-MS spectrum of
P174L-HSco1 also exposed two minor peaks corresponding to
incorrectly cleaved protein forms, which did not disturb mea-
surements. Reconstitution of HSco1 and Cox17 forms with
Fig. 4. The effect of the P174L-Sco1 mutation in the copper transfer with
Cox17. The pathogenic human Sco1 mutation P174L, next to the copper-
binding motif, determines a reduction of the efficiency of the copper transfer
from the mitochondrial metallochaperone Cox17 to Sco1.
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copper was conducted as follows. First, Cu(II) acetate was
dissolved at 150 M concentration in argon-saturated 50 mM
ammonium acetate, pH 7.5, and Cu(II) was reduced to Cu(I) by
addition of 1.0 mM DTT. Different equivalents of freshly
prepared Cu(I)DTT complex were added to HSco1 or Cox17
and incubated in buffer with 1.0 mM DTT, and the mixture was
incubated for additional 1 min at 25°C, and ESI-MS spectra were
recorded as described above. In Cox17/HSco1 titration experi-
ments, Cu1(I)Cox172S-S was prepared by addition of Cu(I) to
Cox172S-S, which subsequently was mixed with a sample of HSco1
protein. All buffers contained 1 mM DTT. The dissociation
constant of Cu1(I)Cox172S-S complex has been calculated as
previously reported (23).
NMR Protein Characterization. The fully copper-loaded state of the
Cu1(I)P174L-HSco1 NMR sample used for structure determi-
nation has been produced by adding 1.5 eq of
[Cu(I)(CH3CN)4]PF6 complex to reduced apo protein in 50 mM
phosphate buffer at pH 7.2 and in the absence of DTT. NMR
spectral assignment and structure determination of
Cu1(I)P174L-HSco1 were obtained through the experiments
listed in SI Table 1. The 1H, 13C, and 15N resonance assignments
of the Cu1(I)P174L-HSco1 are reported in SI Table 2. After
conversion of the NMR data in structural restraints, the struc-
ture was calculated by using the program DYANA. The relative
intensity of the split resonances was taken into account when
converting NOE volumes into distances. The best 30 conformers
of the DYANA family were subjected to restrained energy
minimization (REM) with AMBER 8.0, by using the metal force
field already applied for WT-HSco1 (16). The statistical analysis
of the REM family of Cu1(I)P174L-HSco1 structures is reported
in SI Table 3. The programs PROCHECK, PROCHECK-NMR
(30, 31), and WHATIF (32) were used in the evaluation of the
quality of the structures.More than 90% of residues were located
in the allowed regions of the Ramachandran plot.
Titrations of 15N-labeled apoHSco1 (0.1 mM) and apoP174L-
HSco1 (0.1 mM) with unlabelled Cu1(I)Cox172S-S or
[Cu(I)(CH3CN)4]PF6 were performed with NMR spectroscopy
following the 1H-15N spectral changes in HSQC spectra upon
addition of increasing amounts of the unlabelled protein partner
or copper(I) complex in the presence of 1 mM DTT. Aliquots
were added in a Coy chamber under nitrogen atmosphere at 298
K. The metalation state of WT-HSco1 and P174L-HSco1 pro-
teins was monitored along the NMR titration through a few
residues that are next to the copper(I) binding motif CXXXC
and therefore are experiencing chemical shifts sensitive to the
metalation state. In addition, their NHs are not overlapped in
the 1H-15N HSQC maps, thus they are easily integrated during
the titration steps to estimate the relative population of apo and
copper(I) loaded forms, which allows the estimation of the metal
affinity. The dissociation constant KD of Cu(I)P174L-HSco1 is
obtained according to the following scheme:
Cu(I)P174L-HScol  DTTN apoP174L-HScol
 Cu(I)DTT. [1]
The conditional dissociation constant for the Cu(I)DTT com-
plex, necessary for the above KD estimation, is 6.31  1012 M
at pH  7.4 and T  298 K (33).
R1 and R2 15N relaxation rates on 1:1 Cu1(I)Cox17/WT-HSco1
mixture were measured at 298 K on a Bruker (Billerica, MA)
Avance 500 spectrometer and then analyzed by using a standard
procedure (34). An estimate of the overall rotational correlation
time was derived from the measured R2/R1 ratio.
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Fluorescence spectral properties of W159F, W159F/Y163F and Y216F Sco1 mutants 
Fluorescence spectra (Fig. 4 of the Supplementary Material) of apoWT-HSco1 and of W159F, 
W159F/Y163F and Y216F apoHSco1 mutants (5 µM) were carried out at 298K on Cary 50 Eclipse 
Spectrophotometer supplied with a Single cell Peltier thermostatted cell holder. After excitation at 
either 280 nm and 295 nm an emission scan was recorded between 200 nm and 500 nm. The fully 
reduced protein was obtained incubating the sample for at least 6 h in the presence of 1 mM DTT 
or 200 mM GSH, while the completely oxidized protein was obtained incubating the sample for at 
least 6 h in the presence of 0.1 mM GSSG. To avoid air oxidation, the solutions were degassed and 
subsequently flushed with nitrogen and the sample were manipulated under an N2 atmosphere. 
Fluorescence spectra of oxidized and reduced HSco1 were measured in 50 mM sodium phosphate, 
pH 7.0. 
 
Determination of the Redox Potential of the Active-site Cysteines of Sco1 
The fluorescence properties of HSco1 and the reduction of its active-site disulfide by GSH were 
used to measure the equilibrium constant between HSco1 and glutathione. After excitation at 280 
nm, the fluorescence intensity at 327 nm, for WT-HSco1 and P174L-HSco1, and at 302, for 
W159F-HSco1,  (the wavelengths at which the maximal difference between the emission of 
oxidized and reduced protein was observed, see Fig. 4 of the Supplementary Material) was 
recorded for 60 second and averaged. The redox equilibrium of HSco1 with glutathione is given by 
Eq. 1 and Eq. 2. 
 
 
 
 
Oxidized HSco1 (5 µM or 20 µM) was incubated, under anaerobic conditions, in 50 mM sodium 
phosphate, pH 7.0 at 298K containing different concentrations of GSH (0.1 mM to 200 mM). 10 
 HSco1SH + GSSG                        HSco1SS +  2GSH                    (Eq. 1)
              
Keq=    [HSco1SH][GSSG] 
 [HSco1SS][GSH]2 
(Eq. 2)
uM GSSG was added to all the reaction mixtures. The relative amount of reduced HSco1 (R) at 
equilibrium was measured by the intrinsic HSco1 fluorescence (F). R was calculated according to 
Eq. 3, where F is the measured fluorescence intensity (at 327 nm or 303 nm), and Fred and Fox are 
the fluorescence intensities of completely reduced or oxidized Sco1, respectively. 
 
 
 
Fred , for the completely reduced protein, was measured  at 1 mM DTT or 200mM GSH,  and Fox 
for the completely oxidized protein was measured at 0.1 mM GSSG.  
By fitting the data shown in Fig. 4 and Fig. 4 of the Supplementary Material by non-linear 
regression, according to Eq. 4, an equilibrium constant for the reaction shown in Eq. 1 was 
determined.  
 
 
 
The standard redox potential of WT-HSco1, P174L-HSco1 and W159F-HSco1 mutants active-site 
cysteines was calculated from the Nernst equation (Eq. 5) using the glutathione standard potential 
of -0.240 V at 298K and pH 7.0. 
 
 
 
 
 F - Fox 
 Fred-Fox 
 
R=  (Eq. 3)
 
  F - Fox 
Fox - Fred 
 
R=                  =   
[GSH]2/[GSSG] 
Keq + [GSH]2/[GSSG]
(Eq. 4)
E’0(HSco1)  = E’0(GSH/GSSG) – 0.059/2 log  Keq   (Eq. 5) 
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Fig. 5. Folding and thermal stability properties of WT-HSco1 and P174L-
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Fig. 7. 1H-15N HSQC spectra optimized for the detection of 2J-NH of histidine rings, recorded on 
Cu(I)P174L-HSco1 (red) and Cu(I)WT-HSco1 (black).
The spectra were collected at 298 K and pH 7.2 on a spectrometer equipped with cryo-probe and 
operating at 500 MHz. His 260 and His 168 show the presence of two and three patterns, respectively, 
one of those matching with those of the WT protein (black straight line).
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Fig. 8. Fluorescence emission spectra of W159F, W159F/Y163F and Y216F mutants  of HSco1 
compared with that of wild-type, recorded under native conditions of the oxidized (50 mM phosphate 
buffer, pH 7.0, 0.01 mM GSSG; dotted line) and the reduced (50 mM phosphate buffer, pH 7.0, 200 
mM GSH; solid line) protein after excitation at 280 (A) and 295 nm (B). In the inset, the redox
equilibrium of W159F-HSco1 with different [GSH]2/GSSG ratios as followed by measuring 
fluorescence emission at 302 nm is shown.
No significant difference of fluorescence emission is observed in the spectra of the double W159F/Y163F mutant 
between the oxidized and reduced forms, indicating that W159 and Y163 residues are the main responsible of the 
change in fluorescence intensity upon Cys reduction. On the contrary, Y216F mutant does not show a meaningful 
contribution to the fluorescence intensity upon change of Cys redox state. The change in fluorescence intensity at 327 
nm, after excitation at 280 nm, used for measuring the reduction potentials of WT and P174L pathogenic mutant, is 
mainly due to W159 residue. The reduction potential of W159F-HSco1 measured by monitoring the emission at 303 
nm (-0.282 ± 0.030 V) is the same of that obtained for the wild-type protein measured at 327 nm, indicating that both 
W159 and Y163 are suitable to observe the same reduction process of the two cysteine residues.
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Fig. 10. Reduction of WT-H Sco1 and P174L-HSco1 mutant with DTT. MALDI-TOF mass 
spectra of WT-HSco1 (2.0 µM) and P174L-HSco1 (2.0 µM) reduced with 1 mM DTT at 25°
C in 50 mM ammonium acetate, pH 7.5. Reduction was stopped with addition of 5 mM
iodoacetamide. (A) WT-HSco1; (B) WT-HSco1 + 1.0 mM DTT incubated for 1 min; (C)
P174L-HSco1; (D) P174L-HSco1 + 1.0 mM DTT incubated for 1 min; (E) P174L-HSco1+ 
1.0 mM DTT incubated for 5 min; Numbers on the peaks denote the number of 
carboxyamidomethyl groups in the protein. 
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Fig. 11. Interaction of human WT-Sco1 with different metalloforms of Cox17. (A) ESI-TOF mass spectrum of the mixture 
of Cox173S-S, Cu1Cox172S-S, Cu4Cox17 and Cu5Cox17 (total concentration of Cox17 6.0 µM) in 50 mM ammonium acetate, 
pH 7.5, 0.5 mM DTT. (B) effect of WT-HSco1 (1.6 µM) on the mixture of Cox173S-S, Cu1Cox172S-S, Cu4Cox17 and 
Cu5Cox17 (total concentration of Cox17 6 µM) in 50 mM ammonium acetate, pH 7.5, 0.5 mM DTT. Charge state +6 ions are 
presented for Cox17 and +9 and +10 ions are presented for WT-HSco1. Numbers on the peaks denote the metal stoichiometry
of the complex
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Fig.12. Binding of Cu(I) ions to Cox17 in the presence of DTT. A. ESI mass spectra of 
Cox17 (1.2 µM) reconstituted with 4 equivalents of Cu(I) ions in the presence of various 
concentrations of DTT in 20 mM ammonium acetate, pH 7.5, 25ºC. (a) 0.2 mM DTT; (b) 0.5 
mM DTT; (c) 1.0 mM DTT; (d) 2 mM DTT; (e) 5 mM DTT. Charge state +6 ions are 
presented and numbers on the peaks denote the metal stoichiometry of the complex. B. 
Determination of the dissociation constant for Cu1Cox172S-S complex. Dependence of the 
fractional  content of Cu1Cox172S-S (Y = ICu1Cox17 / (ICox17 + ICu1Cox172S-S) from the 
concentration of free Cu(I) ions in metal competition experiment. Solid line shows the fitted 
curve for hyperbola with KCu = 6.4 x 10 -15 M.
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Fig. 14. The effect of Cu 1Cox172S-S on the WT-HSco1 metallation state. Superimposition of 1H-15N HSQC 
spectra of Cu(I)WT-HSco1 metallated via Cu(I) acetonitrile complex (black) and via Cu1Cox172S-S (red) in 
50 mM phosphate pH 7.2, 1 mM DTT at 298K.
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Fig. 15. The effect of Cox17 to the metallation of human Sco1 with Cu(I) 
ions. ESI-TOF mass spectra of WT-HSco1 reconstituted with Cu(I)DTT complex 
or Cu1(I)Cox172S-S in 50 mM ammonium acetate, pH 7.5. (A) WT-HSco1 (0.8 µM) + 1 equivalent of Cu(I) in the presence of 1.0 mM DTT; (B) WT-HSco1 (0.8 
µM) + 1 equivalent of Cu(I) + 1 equivalent of Cox172S-S in the presence of 1.0 
mM DTT; (C) WT-HSco1 (0.8 µM) + 1 equivalent of Cu(I) + 3 equivalent of 
Cox172S-S in the presence of 1.0 mM DTT; charge state +9 and +10 ions are 
presented for WT-HSco1 and +5, +6 and +7 ions for Cox172S-S and numbers on 
the peaks denote the metal stoichiometry of the complex. (D) Determination of 
protein-protein complexes in the mixture of Cox172S-S (2.4 µM) + Cu(I) (2.4 µM) 
+ WT-HSco1 (2.4 µM) in the presence of 1.0 mM DTT.
Fig. 16. Interaction of Cox17 to the metallation of human P174L-HSco1 with Cu(I) ions. 
ESI-TOF mass spectra of P174L-HSco1 in the presence of Cu(I) ions and Cox172S-S in 50 
mM ammonium acetate, pH 7.5. (A) P174L-HSco1 (1.6 µM); (B) P174L-HSco1 (7.2 µM) + 
Cu(I) (4.8 µM) + Cox172S-S (7.2 µM) in the presence of 1.0 mM DTT; charge state +9 and 
+10 ions are presented for P174L-HSco1 and +5, +6 and +7 ions for Cox172S-S and numbers 
on the peaks denote the metal stoichiometry of the complex. (C) Peaks corresponding to 
protein-protein complexes in the mixture of P174L-HSco1 (7.2 µM) + Cu(I) (4.8 µM) + 
Cox172S-S (7.2 µM) in the presence of 1.0 mM DTT. Charge state +10 and +11 ions are 
denoted for P174L-HSco1-Cox172S-S complexes and numbers on the peaks denote the metal 
stoichiometry in the complex.
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The eukaryotic copper,zinc superoxide dismutases
are remarkably stable dimeric proteins that maintain
an intrasubunit disulfide bond in the reducing environ-
ment of the cytosol and are active under a variety of
stringent denaturing conditions. The structural inter-
play of conserved disulfide bond and metal-site occu-
pancy in human copper,zinc superoxide dismutase
(hSOD1) is of increasing interest as these post-transla-
tional modifications are known to dramatically alter the
catalytic chemistry, the subcellular localization, and the
susceptibility of the protein to aggregation. Using bio-
physical methods, we find no significant change in the
gross secondary or tertiary structure of the demetal-
lated form upon reduction of the disulfide. Interest-
ingly, reduction does lead to a dramatic change in the
quaternary structure, decreasing the monomer-to-
dimer equilibrium constant by at least four orders of
magnitude. This reduced form of hSOD1 is monomeric,
even at concentrations well above the physiological
range. Either the addition of Zn(II) or the formation of
the disulfide leads to a shift in equilibrium that favors
the dimeric species, even at low protein concentrations
(i.e. micromolar range). We conclude that only the most
immature form of hSOD1, i.e. one without any post-
translational modifications, favors the monomeric state
under physiological conditions. This finding provides a
basis for understanding the selectivity of mitochondrial
SOD1 import andmay be relevant to the toxic properties
of mutant forms of hSOD1 that can cause the familial
form of amyotrophic lateral sclerosis.
Eukaryotic copper,zinc superoxide dismutase (SOD1)1 cata-
lyzes the dismutation of superoxide radical to oxygen and hy-
drogen peroxide and is a 32-kDa homodimeric enzyme found
predominantly in the cytosol (1). SOD1 is one of the most
thermally stable enzymes known in mesophilic organisms. Dis-
mutase activity declines at 80 °C with a corresponding melting
temperature, Tm, above 90 °C (2). The protein is stable in the
presence of strong denaturants, and the activity is observed in
4% SDS or 10 M urea (3). Structural properties of SOD1 that
contribute to this extreme thermochemical stability are
thought to include an eight-stranded -barrel motif, hydropho-
bic interactions associated with dimerization, coordinate cova-
lent bonds, and an intrasubunit disulfide bond between highly
conserved pair of cysteines, namely Cys57 and Cys146 in the
human form. Whereas the dimerization can contribute to the
structural stability through the reduction of its mobility (4), the
roles of the disulfide bond in the SOD1 function and/or struc-
ture are only now beginning to emerge. Inspection of the SOD1
structure reveals that the loop containing Cys57 can influence
the conformation of the catalytically important residue, Arg143,
through a hydrogen-bonding network (5). Portions of this loop
contribute to the dimer interface (6), leading to the possibility
that the disulfide bond influences the protein dimerization and
thereby the SOD1 quaternary structure.
To attain the correctly folded quaternary structure and be-
come enzymatically active, several post-translational modifica-
tions need to occur in SOD1 such as the acquisition of copper
and zinc ions, formation of the disulfide bond, and dimeriza-
tion. Whereas the mechanism by which SOD1 acquires Zn(II) is
not fully understood, several aspects of the copper insertion by
the copper chaperone for SOD1 (CCS) are well established
(7–12). More recently, Furukawa et al. (13) have shown that
the intrasubunit disulfide bond is correctly introduced in yeast
SOD1 by the copper-bound form of yeast CCS. However, given
that the cytosol is a strongly reducing environment due to the
high GSH/GSSG ratio (100:1–1000:1) (14), the disulfide forma-
tion is an unfavorable process. Those results suggest that the
immature disulfide-reduced hSOD1 is a more important spe-
cies in the cytosolic environment than previously thought.
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Field et al. (15) have also recently shown that uptake of the
SOD1 molecule into the intermembrane space of the mitochon-
dria is dependent on the status of the disulfide bond. The
reduced form of SOD1 is imported through the mitochondrial
outer membrane, but the disulfide-bonded apo-SOD1, the
Zn(II)-loaded SOD1, and the holo-form or fully mature form of
SOD1 are not readily transferred from the cytosol into the
intermembrane space of the mitochondria. The effects of disul-
fide reduction on the SOD1 structure are therefore relevant to
our understanding of the intracellular localization and stability
of the SOD1 molecule. In this study we show that, even after
removal of both copper and zinc ions from the active and
mature form of hSOD1, the dimeric state still persists; how-
ever, upon reduction of the disulfide bond, the protein can
readily dissociate to the monomer form. Zn(II) addition to the
reduced apo-hSOD1 restores the dimeric state, indicating that
only the most immature form of hSOD1 before any post-trans-
lational modifications favors the monomeric state. These re-
sults provide a molecular basis for understanding factors that
control the SOD1 monomer-dimer equilibrum in the cytosol
and have direct relevance to models for the toxic gain of func-
tion mutations in SOD1 that are associated with familial amyo-
trophic lateral sclerosis (fALS).
EXPERIMENTAL PROCEDURES
Sample Preparation—hSOD1 was expressed in the Escherichia coli
TOPP1 (Stratagene) or BL21(DE3) strain. The mutations were per-
formed using a QuikChangeTM site-directed mutagenesis kit (Strat-
agene). The 15N-labeled protein in which the non-conserved cysteine
residues, Cys6 and Cys111, were mutated to Ser was obtained by grow-
ing the cells in the M9 minimal medium with N15-NH4Cl following a
reported procedure (16), whereas LB medium was used for the non-
labeled protein. The cells were grown at 37 °C until A600  0.6 and
induced with 1.0 mM isopropyl 1-thio--D-galactopyranoside for 6 h. The
protein was isolated and purified according to previously published
protocols (16). Fully reduced and demetallated hSOD1 (E,E-hSOD1SH)
was prepared by treating the isolated protein with dithiothreitol at
37 °C for 1 h in an anaerobic chamber to reduce the disulfide bond (13).
The protein solution was then acidified using 0.4% trifluoroacetic acid,
and organic solvents (15% CH3CN, 10% CH3OH) were included to
remove the metal ions. The protein solution was purified using reverse-
phase high pressure liquid chromatography through a 300-Å C18 Ju-
piter column (Phenomenex) equilibrated with 0.1% trifluoroacetic acid
in water. The fractions containing hSOD1 were eluted with a linear
gradient of 0.1% trifluoroacetic acid in CH3CN and lyophilized. The
metal content of E,E-hSOD1 was checked by inductively coupled
plasma atomic emission spectrometry using a Thermo Jarrell Ash At-
omscan Model 25 Sequential inductively coupled spectrometer, and zinc
and copper ions were 10 nM in the 2 M protein sample. Zinc recon-
stitution was obtained as previously described (17). Protein reduction
and metallation were carried out under a nitrogen atmosphere in an
anaerobic chamber.
Thiol-Disulfide Reduction Assay—The thiol-disulfide status of puri-
fied hSOD1 was determined by chemical modification with the thiol-
specific reagent 4-acetamide-4-maleimidylstilbene-2,2-disulfonic acid
(AMS) (Molecular Probes, Inc.) (13). AMS conjugation results in a 1
kDa increase in the molecular mass of hSOD1 as visualized by non-
reducing SDS-PAGE and Coomassie Blue staining. 3 g of the SOD1
protein that is dissolved in 10 l of the buffer was mixed with 2.5 l of
100 mM AMS and 2.5 l of 10% SDS. The reaction mixture was incu-
bated at 37 °C for an hour in an anaerobic chamber, and then the
Laemmli buffer without any reducing agent was added. After boiling at
95 °C for 2 min, the sample was loaded on SDS-PAGE gel.
CD Spectroscopy—Far-UV CD spectra (185–260 nm) of hSOD1 were
recorded on JASCO J-810 spectropolarimeter. A cell with a path length
of 1 mm was used for the measurement, and the parameters were set as
follows: bandwidth, 2 nm; step resolution, 0.1 nm; scan speed, 50
nm/min; and response time: 2 s. Each spectrum was obtained as the
average of five scans. The protein concentration was typically around 20
M. Prior to the calculation of the mean residue molar ellipticity, all of
the spectra were corrected by subtracting the contributions from the
buffer. Spectra were then smoothed using adjacent averaging or Fast
Fourier transform filter. Quantitative estimations of the secondary
structure contents were made using the DICROPROT software package
(18).
NMR Spectroscopy—Data were collected on Bruker Avance 500 spec-
trometer, operating at a proton nominal frequency of 500.13 MHz. A
triple resonance Cryoprobe equipped with pulsed field gradients along
the z-axis was used. The two-dimensional 1H-15N HSQC spectra and
relaxation experiments were acquired on 0.5 mM samples of 15N-labeled
E,E- and E,Zn-hSOD1SH in 20 mM sodium phosphate buffer (pH 7.0).
The 15N backbone longitudinal and transverse relaxation rates, R1 and
R2, were measured as previously described (19). The value of reorien-
tational correlation time m was estimated from the R2/R1 ratio with the
program Quadric_diffusion (20). All of the spectra were collected at 298
K, processed using the standard Bruker software (XWINNMR). All of
the NMR samples were prepared under nitrogen atmosphere in a glove
box where they were loaded into 5-mm quartz NMR tubes capped with
latex serum caps.
Gel Filtration Chromatography—200 l of 30 M hSOD1 protein was
loaded on Superose 12 HR 10/30 (Amersham Biosciences) at 4 °C. The
column was preequilibrated with 50 mM potassium phosphate, pH 7.5,
and the flow rate was 1.0 ml/min. To prevent the possible air-oxidation
of the thiol groups, 1 mM dithiothreitol was added in the above buffer for
the gel filtration analysis of E,E- and E,Zn-hSOD1SH. For the experi-
ments using E,E-hSOD1SH/SS, 0.1 mM EDTA was included in the buffer.
The chromatogram was obtained by monitoring the absorbance at 215
nm. The calibration of the column for the estimation of molecular
weight was performed using 200 l of 0.25 g/liter immunoglobulin G,
bovine serum albumin, ovalbumin, carbonic anhydrase, horse heart
skeletal myoglobin, E. coli thioredoxin, and aprotinin as protein
standards.
RESULTS
Chemical reduction of the disulfide in hSOD1 with dithio-
threitol followed by acidification to remove bound metal ions
yields the fully reduced and demetallated E,E-hSOD1SH sam-
ple as confirmed by AMS modification and inductively coupled
plasma atomic emission spectrometry analysis. In the NMR
and CD studies, two of the four Cys residues in hSOD1 have
been mutated to Ser (i.e. C6S/C111S) to avoid the possible
oxidation of the free thiol groups and it has been reported that
these Cys residues, Cys6 and Cys111, which are not involved in
disulfide formation, have little effects on the SOD1 activity and
structure (21). When the disulfide bond is intact, previous
studies have shown that SOD1 is mainly comprised of  sheets
and has little -helical structure (19). To examine the possible
structural changes upon disulfide reduction, CD spectroscopy
was used to probe the secondary structure.
Disulfide Reduction Has a Little Effect on the SOD1 Second-
ary Structure—As seen in Fig. 1, the CD spectrum of the most
immature form, E,E-hSOD1SH, exhibits a negative peak at 207
nm, indicating that E,E-hSOD1SH is predominantly comprised
of the  sheets (22). The absence of a strong band at 222 nm in
the spectrum indicates low -helical content (22). We at-
tempted to see whether any major changes in the secondary
structure upon the disulfide formation could be detected by
using E,E-form of the monomeric hSOD1 mutant, E,E-
Q133M2SOD1SS. However, both E,E-hSOD1SH and E,E-
Q133M2SOD1SS give CD signals similar to that of the matured
form of the enzyme, Cu,Zn-hSOD1SS (Fig. 1). The fitting of CD
data (18, 23) suggests that these forms of hSOD1 have similar
secondary structure content as reported in Table I. Disulfide
reduction does not significantly alter the secondary structure,
suggesting that several features of the  barrel-folding pattern
are acquired before any post-translational modifications. We
also examined the effects of the disulfide reduction on the
tertiary and quaternary structure of hSOD1 by NMR
spectroscopy.
Disulfide Reduction and Zinc Removal Disrupt SOD1 Qua-
ternary Structure—The two-dimensional 1H-15N HSQC spec-
trum of E,E-hSOD1SH is shown in Fig. 2A (red contours). Al-
though several signals are present in a spectral region typical
of unfolded polypeptides (between 8 and 8.5 ppm in the 1H
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dimension), this spectrum is remarkably similar to that of
E,E-Q133M2SOD1SS (Fig. 2B) for which the NMR signals have
been assigned (19). This finding suggests that the tertiary
structure of E,E-hSOD1SH also is similar to that of E,E-
Q133M2SOD1SS, i.e. the  barrel structure is maintained, and
loops IV (residues 45–85) and VII (residues 121–142) are se-
verely disordered (19). Because loop IV contains three His
ligands involved in Zn(II) binding and also involves a disulfide-
bond residue, namely Cys57, it is likely that zinc removal and
disulfide reduction can destabilize and increase the structural
mobility of loop IV. Likewise, it has been reported that loop VII,
which produces an optimal electrostatic field for uptake of the
superoxide substrate, becomes well organized upon the zinc
binding (19, 24). Therefore, even after demetallation and re-
duction of the disulfide bond, most of the protein tertiary struc-
ture is retained with the exception of the disorder of some loop
regions.
However, when zinc ion is added to the E,E-hSOD1SH sam-
ple, a dramatic change in the 1H-15N HSQC spectrum is ob-
served (Fig. 2A, blue contours). Compared with the E,E state,
E,Zn-hSOD1SH shows a larger signal dispersion in the spec-
trum, which resembles that of the matured protein, Cu,Zn-
hSOD1SS (Fig. 2C). Monomeric E,Zn-Q133M2SOD1SS shows
the intermediate features in the HSQC spectrum between mo-
nomeric E,E-hSOD1SH and dimeric Cu,Zn-hSOD1SS (see Sup-
plemental Fig. S1). The 1H and 15N chemical shift differences
between the three zinc-bound forms of the protein are shown in
Fig. 3 as the weighted average chemical shift differences,
avg(HN) (i.e.{[(H)
2  (N/5)2]/2}1⁄2, where H and N are
chemical shift differences for 1H and 15N, respectively). Differ-
ences between E,Zn-hSOD1SH and E,Zn-Q133M2SOD1SS (Fig.
3A) are due to disulfide reduction and/or dimerization, differ-
ences between E,Zn-hSOD1SH and Cu,Zn-hSOD1SS (Fig. 3B)
are due to disulfide reduction and/or copper binding, and dif-
ferences between E,Zn-Q133M2SOD1SS and Cu,Zn-hSOD1SS
(Fig. 3C) are due to dimerization and/or copper binding. In all
of the cases, significant chemical shift differences are present
in loops IV and VII, whereas those for the residues at the N-
and C-terminal regions are relatively small. The disulfide for-
mation/copper binding in the zinc-bound proteins affects loops
IV and VII more significantly than the N- and C-terminal
regions, which are at the dimer interface. Cross-peaks of some
of these residues at the dimer interface, which are outside the
crowded regions and well resolved in 1H-15N HSQC spectra, are
indicated with arrows in Fig. 2, A–D.
The overall correlation time for molecular reorientation (m)
provides insights into the hSOD1 quaternary structure. The m
values were estimated from the averaged values of 15N R1 and
R2, which are obtained for 69 and 72 backbone NH resonances
of E,E- and E,Zn-hSOD1SH, respectively (Table II). The overall
correlation time is highly sensitive to the protein size (25), and
the dimerization is expected to increase m. Estimated from the
R2/R1 ratios, m is significantly larger in E,Zn-hSOD1
SH
(20.6  0.9 ns) than in E,E-hSOD1SH (10.3  0.4 ns). In
particular, the m value of E,E-hSOD1
SH is very similar to that
of monomeric E,E-Q133M2SOD1SS (10.1 ns) (19) and E,Zn-
Q133M2SOD1SS (8.4  0.3 ns) (24), whereas E,Zn-hSOD1SH
exhibits a m value similar to that found for dimeric Cu,Zn-
hSOD1SS (25.3 ns) (4). These results suggest that E,E-
hSOD1SH is monomeric and that Zn(II) addition to the reduced
protein can lead to the dimerization. This result is quite sur-
prising, because previous studies have shown that SOD1 dimer
is very stable, even after complete demetallation (26). To di-
rectly examine the effects of the disulfide reduction on the
monomer-dimer equilibrium at physiological concentrations of
protein, we employed gel filtration chromatography.
Monomer-DimerEquilibrium of E,E- andE,Zn-hSOD1SH/SS—
Fig. 4A compares the gel filtration chromatograms between the
wild-type E,E- and E,Zn-hSOD1SH proteins. The E,E-form of
reduced hSOD1(WT) favors the monomeric state at the concen-
tration of 30 M (broken curve in Fig. 4A). The physiological
concentration of SOD1 in the cell has been estimated to be 10
M in yeast by quantitative Western blot (8) and 100 M in the
cytosol of cultured hepatocytes by quantitative immunocyto-
chemistry (27). After E,E-hSOD1SH(WT) is anaerobically incu-
bated with an equimolar amount of zinc ion for an hour at 37 °C,
the resultant protein, E,Zn-hSOD1SH(WT), strongly favors the
dimeric state (solid curve in Fig. 4A). The preference for the
monomeric state in E,E-hSOD1SH(WT) can be also confirmed by
using a hSOD1 mutant in which all of the Cys residues are
changed to Ser, C6S/C57S/C111S/C146S (i.e. the C4S form). The
protein conformation of reduced hSOD1 can be modeled by this
quadruple mutant, which cannot undergo any type of thiol oxi-
dation. Consistent with the WT data, the E,E-form of this C4S
TABLE I
Secondary structure content of various forms of hSOD1 obtained from
the fitting of far-UV CD spectra by the DICROPROT software package
(18) using the least square method of Chen et al. (23)
 Helix  Sheet Random coil
%
E,E-hSOD1SH 8 50 42
E,E-Q133M2SOD1SS 4 46 50
Cu,Zn-hSOD1SS 6 43 51
FIG. 1. The CD spectra of E,E-
hSOD1SH(C6S/C111S) (broken curve),
E,E-Q133M2SOD1SS (solid curve), and
Cu,Zn-hSOD1SS(C6S/C111S) (dotted
curve) in 20 mM sodium phosphate
buffer, pH 7.0. 20 M protein was used
for the measurements.
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mutant favors the monomeric state and turns to the dimeric state
upon the addition of the zinc ion (Fig. 4B).
To investigate the effects of the conserved disulfide bond
(Cys57-Cys146) on monomer-dimer equilibrium, the non-con-
served cysteine residues, Cys6 and Cys111, were mutated to Ser.
As seen in the WT protein, the E,E-form of the C6S/C111S
mutant favors the monomeric state when the disulfide bond is
reduced and the addition of Zn ion can dimerize the protein
(Fig. 4C). These results show that the monomer-dimer equilib-
rium is not affected by the non-conserved cysteine residues. In
contrast, when the conserved Cys residues are oxidized to form
the intramolecular disulfide bond, the E,E-hSOD1SS(C6S/
C111S) form elutes at the peak position corresponding to the
dimeric state (broken curve in Fig. 4D). This result suggests
that, in the absence of any metal ions, the SOD1 monomeriza-
tion is promoted by reduction of the canonical disulfide. The
addition of Zn(II) ion to E,E-hSOD1SS(C6S/C111S) does not
further change the elution profile, and E,Zn-hSOD1SS(C6S/
C111S) still favors the dimeric state (solid curve in Fig. 4D).
Therefore, Zn(II) removal alone cannot monomerize the hSOD1
protein unless the disulfide is reduced. We conclude that the
nascent or folded form of the hSOD1 polypeptide favors the
monomer state until it undergoes the first of several post-
translational modifications in the cell.
DISCUSSION
The subunits of copper,zinc superoxide dismutase are not
linked by covalent bonds but are nonetheless unusually resist-
ant to dissociation. Strong interaction is observed under ex-
treme denaturing conditions such as 8–10 M urea, 7 M guani-
dine HCl, or SDS (3). Accordingly, it is surprising that the
E,E-hSOD1SH protein is monomeric, even without any deter-
gents present. In fact, we find that the E,E-hSOD1SH form is
dominantly monomeric even at the high concentrations (500
M) used in the NMR experiments. When we assume that
10% total 500 M E,E-hSOD1SH is in the dimeric state, the
upper limit for the association constant is estimated as Ka 
2 102 M	1. At the other extreme, E,E-hSOD1SS still favors the
dimeric state, even at the low concentrations used (30 M) in
the gel filtration experiments. Based on a conservative esti-
mate of the absorbance in the gel filtration, 10% of the total
E,E-hSOD1SS exists as the monomer in this condition, leading
to an estimate of the lower limit of Ka 
 3  10
6 M	1. Thus,
although disulfide formation does not significantly change the
secondary structure of hSOD1 (Fig. 1), it clearly favors dimer-
ization by at least four orders of magnitude. The observations
here show that the disulfide bond plays a quite significant but
not clearly exclusive role in determining the quaternary struc-
ture of the human form of SOD1.
Zinc acquisition by the E,E-hSOD1SH state seems to have as
profound effect on the monomer-dimer equilibrium as disulfide
formation, i.e. both E,E-hSOD1SS and E,Zn-hSOD1SH favor the
dimeric state, even when protein concentration is as low as 10
M. Zinc binding has been shown to reduce the mobility of the
loop IV (residues 48–85, colored with purple in Fig. 5) (19, 24),
which contains the important amino acid residues for zinc
ligation, i.e. His63, His71, and His80 (colored with green in Fig.
5). Because loop IV in SOD1 is adjacent to the interface be-
tween the subunits, such a structurization of loop IV upon the
binding of the Zn ion is also implicated to play important roles
in the SOD1 dimerization (19, 24). The results here show that,
even when the disulfide is reduced, Zn(II) binding alone is
enough to stabilize a conformation of the protein that favors
dimer formation. Likewise, it is interesting to note that loop IV
is linked to the  sheet unit via the disulfide formation between
Cys57 and Cys146. Whereas a structural determination of sev-
eral SOD1 microstates is currently in progress, reduction of the
FIG. 2. The two-dimensional 1H-15N HSQC spectra of E,E-hSOD1SH(C6S/C111S) (A, red contours) and E,Zn-hSOD1SH(C6S/C111S)
(blue contours), monomeric E,E-Q133M2SOD1SS (B), and dimeric Cu,Zn-hSOD1SS(C6S/C111S) (C). Some cross-peaks of residues at the
dimer interface and in the metal binding region are indicated by arrows and are shown in D.
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disulfide bond would release and disorder loop IV, resulting in
the increase of its conformational flexibility. Such a disordered
structure of loop IV may obstruct the interaction between the
subunits. Therefore, both disulfide formation and Zn(II) bind-
ing can add structure to the protein conformation around loop
IV, which would promote the interaction between the subunits.
Important roles of the disulfide bond in the monomer-dimer
equilibrium have also been reported in the yeast SOD1
(ySOD1) and are in accordance with this study on human
SOD1. However, Furukawa et al. (13) have found that reduc-
tion of the disulfide in E,Zn-ySOD1SS (dimer) leads to confor-
mation changes that favor the monomeric state under the same
conditions. Thus, there is an interesting difference in the be-
havior of the yeast and human proteins. The E,Zn-form of
reduced human protein favors the dimeric state, whereas the
TABLE II
Average 15N R1 and R2 values and the overall correlation time, m
Average R1 Average R2 m
s	1 ns
E,E-hSOD1SH 1.79  0.17a 13.8  2.0a 10.3  0.4
E,Zn-hSOD1SH 1.01  0.10a 29.2  3.4a 20.6  0.9
E,E-Q133M2SOD1SS 1.24  0.09b 12.6  2.7b 10.1  0.3c
E,Zn-Q133M2SOD1SS 1.36  0.29b 13.4  0.9b 8.4  0.3d
Cu,Zn-hSOD1SS 0.60  0.11b 33.9  4.1b 25.3  1.3e
a Measured at 500 MHz.
b Measured at 600 MHz.
c Ref. 19.
d Ref. 24.
e Ref. 4.
FIG. 3. 1H and 15N amide chemical shift differences between E,
Zn-hSOD1SH and E,Zn-Q133M2SOD1SS (A), between E,Zn-
hSOD1SH and Cu,Zn-hSOD1SS (B), and between E,Zn-
Q133M2SOD1SS and Cu,Zn-hSOD1SS (C). The weighted average
chemical shift differences avg(HN) are shown (see “Results”). The ex-
tents of loops IV and VII are indicated with arrows.
FIG. 4. The chromatograms of the gel filtration experiments
using hSOD1SH(WT) (A), hSOD1(C6S/C57S/C111S/C146S) (B),
hSOD1SH(C6S/C111S) (C), and hSOD1SS(C6S/C111S) (D). The solid
and broken curves represent E,Zn- and E,E-forms of each protein,
respectively. The elution profiles were obtained by using Superose 12
(Amersham Biosciences) column and monitoring the absorbance change
at 215 nm. The flow rate was 1 ml/min.
FIG. 5. The structure of E,Zn-hSOD1SS (Protein Data Bank
code 1HL4). The disulfide bond and the zinc ligands are shown as
yellow and green sticks, respectively. Copper and zinc ions are indicated
in the sphere style. Loop IV (residues 48–85) is colored purple, whereas
loop VII (residue 121–142) is colored orange.
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same state of the yeast protein favors the monomer state.
Although the structural characterization of E,Zn-ySOD1SH and
E,Zn-hSOD1SH is necessary, we speculate that this difference
may be attributed to two proline residues, Pro142 and Pro144,
near the intrasubunit disulfide bond that are present in the
yeast but not in the human protein. Culotta and co-workers
(28) have recently shown that these residues play a key role in
the CCS-independent activation pathways, which differ for the
yeast and human enzyme. The trans-configuration of these
proline residues would limit the ySOD1 conformation, espe-
cially around the disulfide bond and loop IV to reduce the
interaction between the subunits. Given that the cytosol can
provide the strongly reducing conditions (100–1000:1 of the
GSH/GSSG ratio), the monomeric form of this disulfide-re-
duced SOD1 protein appears to be more physiologically rele-
vant than has been appreciated to date.
In the yeast system, the most immature form, i.e. E,E-
ySOD1SH, is the only one that is efficiently taken up from the
cytosol into the intermembrane space of mitochondria. Mito-
chondrial retention of SOD1 is dependent upon its activation
by yeast CCS inside the intermembrane space of mitochondria
(15); however, once the Zn(II) ion is incorporated or the disul-
fide bond is introduced in E,E-ySOD1SH, mitochondrial import
of the SOD1 protein is significantly inhibited (15). This selec-
tivity for SOD1 mitochondrial import could be explained by our
current results. The completely demetallated and disulfide-
reduced form has a smaller size than any other forms. Further-
more, it is expected to be easier to unfold and thread its way
through machinery in the mitochondrial outer membrane.
Dimerization that accompanies metallation and disulfide for-
mation may prevent the SOD1 dimer from crossing the mito-
chondrial membrane.
Perturbation of the SOD1 quaternary structure by disulfide
reduction may be relevant to the etiology of fALS, which has
been associated with a number of mitochondrial pathologies in
fALS patients (29). Point mutations in the human SOD1 can
cause 20% of total fALS, which is a fatal and late-onset neuro-
degenerative disorder (30, 31). The fALS-associated mutants
do not necessarily lose the SOD1 activity but gain some new
activities to cause the disease, such as peroxidase activity or
adventitious protein aggregation (29). It has been suggested
that the apoform of the fALS mutant exhibits decreased stabil-
ity, which has some correlations with disease duration (32).
Furthermore, it has been proposed that protein monomeriza-
tion plays a role in formation of misfolded intermediates, lead-
ing to protein aggregation (33). Because the conserved disulfide
bond in SOD1 is adjacent to the dimer interface (Fig. 4) (34), we
suspect that SOD1 monomerization can increase the exposure
of these Cys residues. A thiol group in the Cys residue is in
general susceptible to the oxidative modification, which plays
an important role in the protein aggregation in some neurode-
generative disease (35). Recently, it has been shown that ex-
posed Cys residues in the SOD1 monomer can be modified by
oxidative stress, leading to disulfide-linked multimerization of
SOD1 (13). These SOD1 multimers could be involved in protein
aggregation and the pathology of amyotrophic lateral sclerosis.
Interestingly, increased susceptibility to disulfide reduction
has been observed in some fALS mutants (36); therefore, pro-
tein monomerization caused by the disulfide reduction and
demetallation might be an important process in causing the
fALS diseases.
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Abstract 
 
 It is now well established that in SOD1-related FALS disease, aberrant protein 
oligomerization of the SOD1 mutants is strongly implicated in disease pathology. Here we 
have found that, even WT SOD1 when lacking both its metal ions, forms large protein 
aggregates at physiological conditions, i.e. 37 ºC, pH 7 and 100 µM protein concentration. 
It is here  suggested that Cys 6 and Cys 111, which are reduced in the mature active form 
of SOD1, are implicated, in the absence of metal ions, in formation of disulfide bonds 
resulting in stable, soluble oligomers which reach a MW of about 800 kDa  The covalent 
nature of the oligomer is confirmed by its disruption upon addition of reducing agents 
which break the disulfide bonds thus leading to SOD1 monomers. These oligomers are 
further stabilized by interactions among beta sheets in amyloid-type aggregates. The latter 
property is evidenced by the interaction of the aggregate with ThT, an amyloid-specific 
dye and by its disruption upon addition of the chaotropic agent guanidinuim hydrochloride. 
Our results suggest a general, unifying picture of the process of SOD1 aggregation which 
can be operative when the SOD1 metalation process is altered or SOD1 fails to maintain its 
metallated state. Even if we cannot exclude that other mechanisms are operative for SOD1 
aggregation, the one here proposed has the strength of rationalize a common event, i.e. 
protein aggregation, as caused by a quite diverse and large number of SOD1 point 
mutations. If proved in vivo, it could be a starting point for designing therapeutic 
approaches to FALS and possibly to ALS.
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 Over 100 different variants of human copper-zinc superoxide dismutase 
(CuZnSOD, SOD1) have been identified and linked to the neurodegenerative disease 
familial amyotrophic lateral sclerosis (FALS) by a gain-of-function mechanism (1, 2).  
Although the exact cellular site and mechanism of the toxicity are unknown, aberrant 
SOD1 protein oligomerization has been strongly implicated in disease causation (3, 4).  
Several recent publications have presented compelling evidence that abnormal disulfide-
crosslinking of ALS-mutant SOD1 plays a role in this oligomerization, and disulfide-
linked SOD1 multimers have been detected in neural tissues of SOD1-ALS transgenic 
mice that are presumed to be components of higher molecular weight species or 
intermediates in their formation (4-7). 
 Wild type (WT) human SOD1 is an exceptionally stable protein, and, although 
some of the ALS-mutant SOD1 proteins are severely destabilized by their mutations, 
others retain much of the stability of WT SOD1 (5). Moreover, in the fully demetallated 
states, some of the ALS-mutant SOD1 proteins are actually more stable than apo WT 
SOD1 (8). Wild type human SOD1 contains 4 cysteines, Cys 6, 57, 111, and 146. In vivo, 
in the mature protein, Cys 57 and Cys 146 are normally linked by a disulfide bond, a 
characteristic that is highly unusual for an intracellular protein in the highly reducing 
environment normally encountered inside the cell. Because of the high stability of the WT 
and many of the ALS-mutant SOD1 proteins in their mature, disulfide-intact forms, it has 
generally been assumed that the abnormal disulfide crosslinks, that are associated with 
SOD1 aggregation, result from oxidative damage to the immature, disulfide-reduced forms 
of the protein in which all four cysteines are reduced and that either Cys 57, Cys 146, or 
both are involved (7, 9).  
 Abnormal protein inclusions have been observed in neural tissue of most of the 
SOD1-ALS transgenic mice and, in several cases, it has been shown that these inclusions 
are amyloid-like, based on their observed reactivities with a fluorescent dye frequently 
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used to visualize the amyloid inclusions found in Alzheimers brains (10). In experiments 
designed to mimic the conditions that might lead to such inclusions, ALS-mutant SOD1 
proteins have been induced to oligomerize in vitro to form aggregates that bind the 
amyloid-specific dye thioflavin T (ThT). However, the conditions used in each case have 
been far from physiological, i.e., either very low pH (11) or extensive metal-catalyzed 
oxidation (12), suggesting that oligomerization occurred only if the SOD1 protein was 
substantially damaged or unfolded.  
 The current study was undertaken to determine the propensity for oligomerization 
of mature, i.e., disulfide-intact, WT human SOD1 under the relatively mild conditions 
likely to be encountered by the protein in vivo and to determine the roles of metallation in 
hindering or promoting such oligomerization. We report here our finding that WT human 
SOD1 apoprotein, with its intrasubunit disulfide bond intact, forms soluble, ThT-positive, 
high molecular weight oligomeric assemblies upon incubation in solution at conditions 
very close to the physiological ones, i.e. at pH 7.0, 37 ºC, and physiological concentration; 
that these assemblies are remarkably stable, persisting in the soluble state for months; and 
that metallation with both zinc and copper or even with zinc alone totally suppresses this 
behavior. These results indicate that human SOD1 proteins, wild type or mutant, when they 
are metal-free, are highly aggregation-prone under relatively mild conditions, even when 
the intrasubunit disulfide bond is intact. These results suggest that the gain of toxic 
function of SOD1 in FALS, and possibly even in sporadic ALS (SALS), may be due to the 
inability of WT and mutant forms to achieve or to maintain the metallated state that is 
required to protect against oligomerization in vivo. 
 SOD1 has been estimated to be present in cells at concentrations of approximately 
100 µM (13-15). In order to be as close as possible to the physiological situation 
experienced by the protein in vivo, we therefore prepared 100 µM protein solutions at pH 
7.0 and incubated them at 37 ºC. Changes in secondary structure were monitored by CD 
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spectroscopy, and changes in the state of aggregation were followed by gel filtration 
chromatography and ThT fluorescence. Solutions of fully metallated Cu,Zn-SOD1 (100 
µM, pH 7.0) were found to be unchanged after incubation at 37 ºC for more than one 
month, and the same results were obtained for the copper-free derivative, E,Zn -SOD1. On 
the contrary,  the behavior of the completely metal-depleted protein (apo form) was 
dramatically different. Incubation in the presence of ThT showed a progressive increase in 
fluorescence, with a fast process in the first 230 hours of incubation which slows down 
after one months and then reaches a plateau in the following four months (Fig. 1).  No 
turbidity was detected along the entire time period. 
 
 
 
Figure 1
Time (hours)
0 50 100 150 200 250 800 850
Th
T 
Fl
uo
re
sc
en
ce
0
20
40
60
80
100
AM
S
 Fluorescence
0
100
200
300
400
500
600
Time (hours)
0 500 1000 1500 2000 2500 3000 3500 4000 4500 5000
Th
T 
Fl
uo
re
sc
en
ce
0
20
40
60
80
100
120
Fig. 1 Amyloid-like oligomer formation and free cysteines disappearance. 
Binding of thioflavin T to amyloid structures is accompanied by an increase in fluorescence.
Thioflavin T does not bind to unaggregated protein. ThT binding to fully metallated SOD1 (?);
apo SOD1 (? ), copper deprived SOD1 (?), apo AS SOD1 (?), and fully metallated AS SOD1
(?). Fluorescence of AMS bound to the free cysteines of the apo SOD1 WT sample (? ).during
its incubation at 37 ºC. Inset: ThT binding fluorescence of the apo SOD1 protein during seven
months of incubation. 
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The detection of ThT-binding fluorescence is a clear indication of the formation of 
amyloid-like oligomeric assemblies (16). The rate of ThT fluorescence enhancement was 
found to be strongly dependent on temperature; the higher the temperature the faster the 
rate of aggregation. Different conditions of pH also affected the reaction: all other things 
being equal, the rate doubled at pH 5 relative to pH 7. 
 The heterogeneous population of states of SOD1, after incubation at 37 ºC for a 
variable period of time, was fractioned through gel chromatography, and the fractions were 
analyzed by multiangle light scattering (Fig.2). The high molecular weight broad band 
originates from a mixture of species having an average molecular weight that increases as 
the time of incubation increases (Table.2 in the supplementary material).  The maximum 
molecular weight value observed for a sample incubated for seven months was estimated 
to be about 800 kDa; this value suggests that this aggregate is formed by fifty SOD1 
monomers.  
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Fig.2:Light Scattering analysis Cumulative weight fraction vs molar mass reported for 
the same sample after different periods of incubation: before incubation (a), 8 hours (b),
2.5 days (c) and 7 months (d). 
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 When apo WT SOD1 was incubated in the presence of a reducing agent, either 
(tris(2-carboxyethyl)phosphine hydrochloride (TCEP) or dithiothreitol (DTT), no enhanced 
fluorescence was observed in the presence of ThT (Fig.3A), and only the monomeric state 
was observed through gel filtration (Fig.3B), as is expected for disulfide-reduced apo 
SOD1 (17). The absence of high molecular weight species in reducing conditions, 
therefore, shows that the SOD1 oligomeric assemblies involve disulfide bonds 
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Fig.3 TCEP addition analysis (A) ThT binding to fully metallated SOD1 (? ); apo SOD1 (? ),
and apo SOD1 after the addition of TCEP 1mM (? ). (B) Gel filtration chromatogram showing
the monomer, dimer and aggregate composition of fully metallated SOD1 (a); apo SOD1 (b), and
apo SOD1 after the addition of TCEP 1mM (c) on a Superdex 75 HR 10/30 column. All samples
were analyzed about 50 hours after incubation started. 
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Freshly prepared, oxidized SOD1 contains two free cysteines (Cys 6 and Cys 111) 
per SOD1 monomer. Free cysteines content in apo SOD1 (monitored by AMS 
fluorescence on AMS-modified cysteine samples) decreased simultaneously with protein 
aggregation (monitored by ThT fluorescence) (Fig.1). The two processes have the same 
time course: aggregation and free cysteine disappearance are initially fast, successively 
reaching almost a plateau after nine/ten days. When the chaotropic agent 
guanidinium hydrochloride (GdnHCl), which disrupts hydrogen bond networks that 
stabilize secondary and tertiary structure is added to a soluble aggregate of apo WT SOD1, 
the ThT-binding fluorescence is quenched in 15 minutes.  Still, gel filtration of the 
resulting solution shows that high molecular weight species remain present.  This behavior 
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indicates that the oligomeric assemblies of apo SOD1 are both formed by covalent 
disulfide bonds probably involving the two free cysteines (Cys6 and Cys111) and 
stabilized by hydrogen bond interactions, similar to those found in amyloid.  Since 
guanidinium disrupts hydrogen bond networks, the loss of ThT-binding ability is the result 
of the disruption of the amyloid-like tertiary structure of the assemblies, but the SOD1 
oligomeric state due to the covalent S-S bonds between cysteines of the SOD1 subunits, 
persists. 
Based on all these experimental observations, we can hypothesize a process of 
aggregation where initially a fraction of apo SOD1 is in the monomeric state as a 
consequence of quaternary structure destabilitation due to lack of metal ions as already 
described in literature (15, 19).  Large molecular weight aggregates are then assembled 
through disulfide bonds formation and further stabilized by non covalent interactions 
between beta sheets (Fig. 4). 
From all these data it appears that SOD1, when lacking both its metal ions but still 
maintaining the disulfide bond intact, has a dramatic tendency to form high molecular 
weight soluble aggregates in conditions very close to the physiological ones.  This process 
occurs in vitro as well as in vivo, in E.coli cells, both for WT SOD1 and its mutants, 
provided Cys6 and Cys111 are present.  A failure to either activate and/or maintain the 
proper metallation of SOD1 makes the two free cysteines prone to be oxidized and form 
inter-disulfide bonds, therefore initiating the aggregation process. A large number of ALS-
related SOD1 mutants have a decreased metal affinity and indeed some fail even to be 
metal reconstituted in vitro (20).  Also for WT, the protein is produced in an immature 
form which then needs several steps to reach the final active form. Among the various 
posttranslational modifications SOD1 should undergo, metallation is a complex process 
which involves several processes and interactions with other proteins. Metal uptake might 
be altered by misregulation of any of these steps by external factors.  Therefore, when 
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some SOD1 is present in the immature, demetalated state, the aggregation process can start 
giving rise to amyloid-like soluble oligomers.  We have also to take into account that 
SOD1 is present in two different cell compartments, i.e. cytoplasm and mitochondria, and 
it independently acquires metal ions in the two cell compartments. These two cell 
compartments have quite different redox properties which can further modulate the 
aggregation process in vivo. This is also consistent with a recent suggestion of Wang et al. 
(4); they report that in in vivo experiments non-native intermolecular disulfide bonds help 
stabilize the aggregates and that the redox state of the cell may play a role in the 
aggregation process.  
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Fig. 4 Proposed mechanism for SOD1 aggregation. Possible mechanism for in vivo formation of 
amyloid-like oligomers which occur when the apo WT SOD1 protein is kept at 37 ºC for a period 
of time. Dimeric apo SOD1 is in equilibrium with the monomeric species which are known to be 
quite mobile. This internal dynamics could make accessible locally disordered conformations when 
the two free cysteines (Cys6 and Cys111) become solvent exposed. In this state, they are prone to 
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latters arrange in amyloid-like structures through hydrogen bonds. 
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This mechanism of SOD1 aggregation can be quite general since it does not depend 
on a specific mutation and could provide a unified picture of the general process of 
aggregation observed for SOD1 mutants, though other pathways cannot be excluded. The 
amyloid-like soluble oligomers observed under mild conditions appear to us to be likely 
candidates for the toxic species that cause SOD1-linked ALS. The knowledge of the 
factors determining SOD1 aggregation is likely to be the starting point to develop 
therapeutic strategies having the goal of finding exogenously applied agents that maximize 
the formation of the mature, fully metalated SOD1 form or interfere with the aggregation 
process. 
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Materials and Methods  
Sample Preparation— Wild type (WT) SOD1 expressed in yeast, was purified in 
the fully metallated form (1). Nα-acetylation (alanine), as expected for human SOD1, was 
confirmed by mass spectroscopy analysis. WT SOD1 was also expressed in the 
Escherichia coli BL21(DE3) strain. The protein was obtained by growing the cells in the 
LB medium. The protein was isolated by osmotic shock in a 20mM Tris, 5mM 
dithiothreitol (DTT) buffer at pH 8. After incubation for 30 minutes at 37 ºC, the protein 
was centrifuged at 40000 rpm for 20 minutes. Supernatant was purified following a 
reported procedure (2) modified by the addition of 1 mM DTT to each chromatographic 
buffer. The protein obtained with this procedure contained substoichiometric amounts of 
the metal ions (Table S1). Mutations were performed using a QuikChangeTM site-directed 
mutagenesis kit (Stratagene). 
 The demetallated (apo) protein was prepared according to previously published 
protocols (3). Zinc reconstitution was carried out as previously described (4). Metal content 
of the various forms of SOD1 was checked by inductively coupled plasma mass 
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spectrometry (ICP-MS) using a Thermo Jarrell Ash Atomscan Model 25 Sequential 
inductively coupled spectrometer (Table S1). 
Spectroscopic characterization—Protein samples were 100 µM in SOD1 
concentration (as dimer) in 20mM phosphate buffer at pH 7. The protein was incubated at 
37 °C to mimic physiological conditions. Optical and fluorescence spectroscopies, coupled 
with gel filtration chromatography, were used to monitor the formation of oligomeric 
species at these sample conditions.  
Fluorescence was followed with Thioflavin T, (ThT) probe, which specifically 
binds to amyloid-like structures (6). Free ThT has excitation and emission maxima at 350 
nm and 450, respectively. However, upon binding to amyloid-like oligomers, the excitation 
and emission λ changes to 450 and 485 nm, respectively. 54µl aliquots of sample were 
added to 646 µl of a 215 µM ThT solution in a 20 mM phosphate buffer at pH 7. The 
solution fluorescence emission was measured, over time of incubation,with a Cary 50 
Eclipse Spectrophotometer supplied with a Single cell Peltier thermostatted cell holder 
regulated at 37 ºC. The background fluorescence spectrum of the buffer was subtracted. 
The excitation wavelength was 446 nm (bandwidth 10 nm) and the emission was recorded 
at 480 nm (bandwidth 10 nm). Fluorescence intensity at 483 nm was plotted against time 
of incubation. 
Turbidity was measured at 400 nm to detect possible formation of insoluble 
precipitate. Solution turbidity was measured as apparent absorbance at 400 nm using a 
Cary UV-visible spectrophotometer. Experiments were performed by diluting 120 µl of the 
incubation SOD1 stock into 280 µl of 20mM phosphate buffer at pH 7. A 1 cm quartz 
cuvette was used. Instrumental detection limit was 0.001 at 400 nm. 
  Monitoring SOD1 Aggregation by Gel Filtration and Light Scattering—100 
µl aliquots of the incubated protein at 37 ºC were periodically taken and analyzed by gel 
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filtration on Superdex 75 HR 10/30 (Amersham Biosciences) at room temperature. The 
column was preequilibrated with 20 mM potassium phosphate, pH 7.0, and the flow rate 
was 0.6 ml/min. The chromatogram, which monitors the species formed during incubation, 
was obtained by monitoring the absorbance at 215 nm. The Superdex 75 HR 10/30 column 
was connected to a light scattering spectrometer. The online multiangle light scattering 
(MALS) detector (DAWN EOS, Wyatt Technology, Santa Barbara, CA) and differential 
refractive index (DRI) detector (Optilab DRI, Wyatt Technology) setup was used to 
measure the light scattered as a function of angle and absolute protein concentration of 
fractions eluting from the size-exclusion chromatography column. The Zimm 
approximation was used in the Astra software (Wyatt Technology) to estimate molar mass. 
Data were fit using a first-order polynomial. The analysis was performed for each one of 
the 100 µl aliquots periodically taken from the incubation batch so as to monitor the 
increase in molecular weight of the soluble species formed during aggregation. 
 Free-thiol quantification—Estimation of free thiols during aggregation was 
performed by 4-acetamido 4' maleimidylstilbene-2,2'-disulfonic acid (AMS) modification. 
This iodoacetamide derivate has high water solubility and is readily conjugated to free 
thiols. 800 µl of reaction mixture in phosphate buffer 20 mM pH 7 containing proteins 7.5 
µM, AMS 250 µM, SDS 1% was incubated for 30 minutes at 37 °C in order to complete 
the reaction. The excess of AMS was removed by dialysis. Reacted aliquots were taken 
from an apo WT SOD1 sample (100 µM) along the incubation at 37 ºC. AMS is a stilbene 
derivate, and shows a typical UV absorption at around 328 nm and emission maximum at 
408 nm. Fluorescence measurements (excitation 322 nm, emission 406 nm, 
excitation/emission slits 10) were performed in order to monitor the variation of free thiols 
during the aggregation process. The calibration curve for the free cysteine quantification 
was prepared using freshly prepared apo SOD1 WT at different concentrations as a 
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standard. MALDI analysis proved that there is a maximum of two free cysteines per apo 
SOD1 monomer. 
Aliquots taken from the incubation stock used for the AMS test, were 
simultaneously reacted with ThT, and the fluorescence of the solution was measured to 
monitor sample aggregation. 
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      Structural biology provides a detailed analysis of the structure of biological 
macromolecules at atomic level, with the ultimate goal of investigating the relationship 
between structure and function. Metalloproteins, which comprise a significant share of the 
proteome, contain biologically relevant metal ions which can have one or more accessible 
oxidation states. The investigation of  mechanisms how metals are transported and inserted 
into diverse protein locations is an emerging field in the scientific world, which is 
unravelling only in the most recent years. Therefore structural characterization of 
metalloproteins is an important aspect of post-genomic research. Out activity is integrated 
into this framework and intends to contribute to the coverage of metalloprotein structures 
and to pursue functional studies aiming to elucidate the role of metal cofactors, their redox 
properties, and implications in protein-protein interactions. 
 Intriguingly, several metalloproteins are involved in diseases, and often they contain 
copper(2). Copper is a naturally occurring redox metal essential for the activity of many 
enzymes, but it is highly reactive and toxic at high concentrations. Among the factors 
required to achieve copper ion homeostasis are the metallochaperones(3), that specifically 
traffic copper to cuproenzymes. Different copper trafficking pathways are indeed present 
in the cell, i.e. copper delivery to cytosolic superoxide dismutase, to cytochrome c oxidase 
(CcO) and to the multicopper oxidase Fet3. During the PhD course my attention was 
focused on three copper proteins (Cu,Zn SOD, Sco1 and Cox17)  belonging to the first two 
pathways. 
 
Copper incorporation into CcO is biologically crucial; it is, however, an extremely 
complex process, which is tightly regulated and which requires a large array of proteins, 
each of them with a specific, in most of the cases, non-replaceable role. The knowledge of 
these processes is still at an infant state. Therefore, to have a comprehensive description of 
proteins involved in copper delivery to CcO, we have performed a genome-wide search in 
prokaryotic organisms for sequences sharing similarity with human Cox17, Sco1/2, and 
Cox11, and we extended the analysis to genes close to the found proteins.  
We found that, while Cox11 is highly networked within the CcO assembly module and 
likely fulfills an univocal function of copper delivery to CuB, the variety of number and 
localization for Sco genes suggesting that, the related proteins, could have multifunctional 
properties and be involved in different physiological processes. In this analysis a strong 
correlation was observed for Sco genes with both red-ox and copper homeostasis. The 
structure of Sco has indeed a thioredoxin fold and a thiol-disulfide oxidoreductase function 
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has been proposed for this protein(4). Therefore, Sco might be involved, in addition to its 
well documented role in copper transfer to CuA center(5),  in the reduction of disulfide 
bonds of its protein patner Cox2 prior to copper insertion. The presence of two Sco 
paralogs in eukaryotes (i.e., Sco1 and Sco2) can be also rationalized in the light of the 
genomic-context analysis of prokaryotic paralogs: one Sco gene may preferentially interact 
with Cox2 subunit of CcO, thus favoring CcO assembly, while the second gene may assist 
the metallochaperone Cox17, which is responsible for copper recruitment in the 
intermembrane space of mitochondria. In this scenario, it is possible that the two 
eukaryotic Sco paralogs interact to promote copper insertion into CuA. Similar conclusions 
for human Sco genes were reached using an experimental approach(6). Many other  lines of 
evidence support the hypothesis  that copper insertion into CuA site of Cox2 subunit, is not 
a simple, passive copper transfer from Cox17 to Sco1/2 proteins and finally to Cox2, but 
that several redox reactions are probabily interlinked with the process of copper transfer  
The structure of the metal adducts and the protein-protein interaction analysis are 
crucial for better understanding the mechanism of Sco-mediated copper insertion into CcO. 
Therefore,  we cloned and expressed the WT-HSco1 and P174L-HSco1 pathogenic mutant. 
We have succeeded in preparing Cu(I) and Ni(II) derivatives of HSco1 and determined 
their solution structures. The solution structure of apoHSco1 has been also determined. The 
structures indicate that the metal ion is bound by two cysteines and one histidine. They also 
show the transition from a locally disordered apo protein to a compact metallated form, as 
confirmed also by ESI-MS studies. We obtained crystals of Ni(II)HSco1, and the relative 
X-ray structure  suggest the binding of the metal ion to the oxidized form of HSco1. The 
species, described from the above mentioned structure, may be represent a transition state 
of the copper transfer from HSco1 to the CuA site of Cox2. It may represent a missing link, 
which integrates the metal transfer and thioredoxin functions already proposed for this 
fascinating protein.  
The solution structure of P174L-HSco1 mutant showed that the mutation  significantly 
affects the metal binding properties of HSco1 protein. Structurally, the mutation produces 
the lack of well-organized hydrophobic contacts and a structural heterogenity in the 
vicinity of the metal binding region. The local structural changes induced by the point 
mutation decrease the copper(I) affinity of the mutant, thus negatively affecting the co-
metallochaperone function of HSco1. ESI-MS and NMR interaction studies between 
HSco1 and HCox17 demonstrate that Cu1(I)-HCox172S-S, is capable of transfering 
efficiently Cu(I) to apoWT-HSco1, but not to apoP174L-HSco1. Morever the oxidation 
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and reduction rates of the mutant disulfide bond are much slower than those of the wild-
type protein. The thioredoxin role of HSco1, proposed for maintaining the receiving CuA 
site in the suitable reduced state, is, in this case, significantly perturbed since the mutation 
could slow down the reduction of the copper binding cysteines in the CuA site of CcO. 
Overall, these alterations, induced by the mutation, on copper binding and redox properties 
of HSco1 can substantially decrease the efficiency of the copper transfer from 
Cu1(I)HSco1 to the CuA site of CcO. All these data support the multifunctional role of 
HSco1, which may act at the same time, as copper chaperone and thioredoxin in the 
process of copper insertion in the CuA site. 
The functional role of the paralog HSco2 protein is not yet defined as well as the red-
ox function of the Sco protein family. Therefore, further studies are necessary to fully 
elucidate the assembly machinery of CcO. The next step will be the investigation of 
structural and biochemical properties of HSco2. Moreover, nothing is known at the 
moment about how the two cysteines of CXXXC conserved motif of HSco1/2 are reduced 
prior to copper transfer from Cox17. Therefore interaction studies between HSco1/HSco2 
and HCox17 in both reducing and oxidizing environment will be performed. 
The structure-function paradigm claims that a specific function of a protein is 
determined by its unique and rigid three-dimensional (3D) structure. Thus, following the 
biosynthesis of a protein in  the ribosome, it should fold to be functional. This idea 
represents one of the cornerstones of modern biology. This concept is confirmed by 
numerous cases describing polypeptide chains that loose the capability of gaining a proper 
3D structure(i.e. became misfolded) due to the effect of environmental factors or because 
of genetic defects (mutations). Consequences of such misfolding are well known and 
represent loss of function, aggregation, development of conformational disorders and cell 
death.  
ALS may be classified as a “conformational” disorders. In this class of disorders, 
protein alteration, through  an abnormal folding pathway, generally results in protein 
aggregation and high-molecular weight complexes formation (Fig. 19). Our target is the 
understanding of the relationships  between structural perturbations of the ubiquitous  
SOD1 and the neurodegenerative disorder ALS.  
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Fig. 19: Example of the two possible different pathways, normal 
and aberrant, to which the immature SOD1 may be subjected.  
 
 
Over 100 different variants of human copper-zinc superoxide dismutase (CuZn-SOD1) 
have been identified and linked to the neurodegenerative disease familial amyotrophic 
lateral sclerosis (fALS).  Recent studies of a large number of ALS-mutant Cu,Zn-
superoxide dismutase (SOD1) proteins have revealed that there is great diversity in the 
biophysical properties of these proteins. Nowadays, no common denominator of SOD1 
pathogenic mutant are able to explain their aggregation propensity with respect to WT-
SOD1. Some of the ALS-mutant SOD1 proteins, in both apo and/or fully metallated form, 
are severely destabilized by their mutations, others retain much of the stability of WT 
SOD1(7,8). What is in known, is that holo-form of WT-SOD1 (Cu,Zn-SOD1) is an 
exceptionally stable protein to the extent that its melting temperature, Tm, is around 
90°C(9); however, removing a copper ion from holo-SOD1(E,Zn-SOD1) decreases the Tm 
to ~70°C, and further removal of the Zn ion from E,Zn-SOD1 (E,E-SOD1) results in 
~60°C of Tm(10). SOD1 has to undergo several post-translational modifications before 
reaching its mature form. The protein,  requires insertion of zinc and copper atoms, 
followed by the formation of a conserved S-S bond between Cys-57 and Cys-146 (human 
numbering), which makes the protein fully active. Given that these modifications generally 
increase the protein structural stability, it is well expected that most immature, the apo and 
disulfide-reduced SOD1 (E,E-SOD1SH), and the other possible intermediate forms (for 
example: E,Zn-SODSH or E,E-SODSS), are more susceptible to destabilization and  
aggregation.  
Using biophysical methods, we investigated the difference in the secondary, tertiary 
and quaternary structure of both oxidated and reduced SOD1 in all the possible different 
metallation states. From this investigation we show that, even after removal of both copper 
and zinc ions from the active and mature form of human SOD1, the dimeric state still 
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persists; however, upon reduction of the disulfide bond, the protein can readily dissociate to 
the monomer form. Zn(II) addition to the reduced apo-SOD1 restores the dimeric state, 
indicating that only the most immature form of SOD1, before any post-translational 
modifications, favors the monomeric state, even if no major changes in the secondary 
structure were detected.  
It has been proposed that protein monomerization plays a role in formation of 
misfolded intermediates, leading to protein aggregation(11).  In conclusion, the observed 
perturbation of the SOD1 quaternary structure by disulfide reduction and demetallation 
may be relevant to the etiology of  both sporadic and familiar ALS.  
In the light of this first interesting result we proceeded to determine the propensity for 
oligomerization of mature, i.e., disulfide-intact, WT human SOD1 under relatively mild 
conditions likely to be encountered in the protein “in vivo” and to determine the role of 
metallation in hindering or promoting such oligomerization.  
We found that demetallation of SOD1 induces the formation of soluble high molecular 
weight aggregates upon incubation at 37 °C, while the fully metallated WT SOD1 retains, 
under the same conditions, the dimeric state. Lack of aggregate formation for the 
metallated protein shows that the metallation state is a critical issue in the aggregation 
process.  Formation of intermolecular disulfide bonds, probably involving the Cys6 and 
Cys111, is an essential factor for aggregation, as proved by absence of aggregation under 
reducing conditions. Disulfide bonds involvement in amyloid fibrils formation has 
previously been reported for other neurodegenerative diseases(12,13). 
 The increase fluorescence intensity upon ThT binding to the apo-SOD1 suggest the 
formation of amyloid-like oligomeric assemblies. The finding of this potentially 
pathological, soluble protofibrillar structure in WT SOD1 might have relevance with 
respect to ALS, pointing at a common behaviour with many other neurodegenerative 
disorders. In fact a general pathological feature of many neurological disorders is the 
presence of inclusions bodies and other visible protein aggregates, which might represent 
the end stage of a molecular cascade of several steps.  Earlier steps in this cascade are more 
directly tied to pathogenesis than the aggregates themselves(14), and are the result of the 
pathogenic species elimination induced by the cells. The formation of the protofibrillar 
specie in apo WT SOD1 suggests a common explanation for both, familiar and sporadic 
ALS. Incorrect and/or incomplete SOD1 metallation starts the onset of pathogenic events, 
and the mutations could be only a time modulation of the disease onset and development. 
This hypothesis is consistent with the fact that most of SOD1 pathogenic mutants have a 
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decreased affinity for one or both the native metal ions(15,16). This would also explain the 
widespread of fALS mutations, with no evident correlation with structural properties.   
In conclusion our data suggest a possible general aggregation mechanism common for 
both sporadic and familiar ALS. Recently In has been shown that a significant fraction of 
the insoluble SOD1 aggregates in spinal cord of the ALS-model transgenic mice contain 
multimers cross-linked via intermolecular disulfide bonds. At this point, in order to 
validate our model, it will  be necessary to test, for the presence of disulfide-linked 
multimers, the spinal cord from of transgenic mice expressing SOD1 which lacks the two 
not conserved cysteine residues, Cys-6 and Cys-111 that we suggest to be involved in the 
aggregate formation.  
Another point to address is how SOD1 incorrect metallation can be active also in vivo. 
ALS afflicted individuals express SOD1 from birth in all tissues(17), even though the 
pathology in this disease is largely limited to motor neurons.  Neurofilaments-L (NF-L) are 
one of the most abundant proteins in motor neurons; their presence in aggregates is a 
pathologic hallmarks of both sporadic and familial ALS(18); they have a strong affinity for 
zinc(16) and form aggregates that are positive to  the thioflavin T binding assay, in the 
presence of copper and H2O2(19). Therefore, under specific conditions, they could remove 
zinc and/or copper from both WT and mutant SOD1 explaining, in this way, the restricted 
localization of SOD1 inclusions in motor neurons.  This hypothesis is supported by the fact 
that the absence of neurofilaments slows the disease onset in mice expressing a specific 
fALS mutant(20).  
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